Company Stories Q-R

Stories that earlier appeared in Nelson's News Note 1: Carl Nelson Consulting, Inc is not an investment adviser and may hold a financial interest or client relationship in companies discussed.
(Note 2: Carl Nelson Consulting does not endorse these companies or organizations or their activities.) Looking for other older stories? Visit the archives

Q32 Bio (Cambridge, MA)

Q32 Bio (Cambridge, MA; no SBIR) developing biologics to restore healthy immune regulation, announced the company's pipeline and plans to enter the clinic this year with its lead candidate. Enabled by a $46M Series A financing [is] advancing a portfolio of biologics targeting the body's innate and adaptive immune systems. The company has a robust product pipeline including a monoclonal antibody antagonist of the interleukin-7 receptor (IL-7R), and a complement therapeutics platform that has generated fusion proteins that downregulate complement activity specifically in disease-affected tissues. [company press release, May 27, 20]

Qcept Technologies (Atlanta, GA)

Qcept Technologies (Atlanta, GA; no SBIR) raised $3 million, according to [SEC] filing. ... bills itself as the only company in the world that can inspect semiconductor wafers for nonvisual defects. [Urvaksh Karkaria, Atlanta Business Chronicle, Aug 12, 14]

Qcept Technologies (Atlanta, GA; no SBIR) has rung up $3.5 million — part of a $5 million planned capital raise, according to [SEC] filing. .... plays a critical role in the development of the tiny chips that power smart phones and computers. ... backed by Imlay Investments, bills itself as the only company in the world that can inspect semiconductor wafers for nonvisual defects. ... has raised more than $40 million [Urvaksh Karkaria, Atlanta Business Chronicle, Feb 4, 14]

Qcue (Texas)

When startup FireFly LED Lighting (Austin, TX; no SBIR) was accepted into the Austin Technology Incubator two years ago, its LED bulbs were still prototypes. Since then, the company has launched its product line, signed customers including Kerbey Lane Cafe and the University of Texas and received $3.4 million from backers including the Central Texas Angel Network and the Texas Emerging Technology Fund..... Since its founding in 1989 by legendary business leader George Kozmetsky, ATI has worked with more than 200 startups, helping them raise nearly $1 billion in investment capital. [Lori Hawkins, Austin American Statesman, Jan 26, 12] Graduates: Agile Planet, Atomometrics, Axelo, Calxeda, Dorsan Biofuels, Famigo, GameSalad, Ideal Power Converters, Itzbig, Nitero, Notice Technologies, Open Algae, Qcue, RFMicron, RRE Solar, Savara Pharmaceuticals, Spredfast, Terapio ($500K SBIR), Unwired Nation, WiMax.com.

QD Vision (Watertown, MA)

Nanosys (Milpitas, CA; $4.4M SBIR) is suing -based QD Vision (Lexington, MA; $1.7M SBIR) for allegedly infringing upon 13 patents that Nanosys says it exclusively licensed from MIT and the University of California system, which are both also listed as plaintiffs in the lawsuit filed last week ... produce quantum dots—tiny semiconductor crystals that, among other things, can help deliver high-definition images on device screens, including TVs and tablets. [Jeff Engel, xconomy.com, Apr 19, 16]

QD Vision (Lexington, MA; $1.8M SBIR) a maker of optical technology for dramatically improved color quality in television sets, said it recently raised $28 million in funding from existing investors ... has developed a type of semiconductor crystal, known as quantum dot, which allows for a wider gamut of color in a displayed picture, has now raised about $101 million in total funding. [David Harris, Boston Business Journal, Jan 13, 15]

QD Vision (Lexington, MA; $1.8M SBIR), an advanced display and lighting products company, is looking to bring more realistic colors to televisions and other display screens by harnessing the power of microscopic crystals. After recently raising $20 million in financing, QD Vision is about to begin selling its optical components made of "quantum dots," or semiconductor nanocrystals, which could be used to produce displays that are even thinner than today's models, and potentially consume less power. ..... preparing to fill a major order for Sony to use its technology in TVs this year. [Wall Street Journal, Apr 9, 13]

QD Vision (Lexington, MA; $1.7M SBIR) nanomaterials company that makes Color IQ optical components for LCD applications, said Friday it closed a $20 million round of financing that will be used further expand highvolume production capacity and to fund long term company growth. [Boston Globe, Mar 29, 13]

QD Vision (Watertown, MA; $1.7M SBIR) reports it has won a $900,000 development contract from the Defense Advanced Research Projects Agency (DARPA) to make a pair of prototype devices based on its quantum dot infrared materials. ... In May QD Vision raised $22M to expand its quantum dot technology. [Rodney Brown, Mass HIgh Tech, Aug 17, 11]

QD Vision (Watertown, MA; $1.6M SBIR) has bought a patent portfolio related to using quantum dots – the QD in QD Vision – in display and lighting products from Motorola Inc., for an undisclosed amount. ... plans to ship its first products, which include display backlight units used in cell phones, laptops and TVs, in 2011 [Mass High Tech, May 24, 10]

Barely one month after reporting a $10 million venture investment, QD Vision (Watertown, MA; $1.7M SBIR) says it has taken in $3 million from DTE Energy Ventures to help expand the market for its technology for LED lighting and displays products. [Mass High Tech, Jan 21, 10]

QD Vision (Watertown, MA; $900K SBIR) landed $10 million in its latest financing round ... developer of Quantum Light, which uses quantum dots to produce high output LEDs that draw less power than traditional products [Mass High Tech, Dec 16, 09]

QD Vision (Watertown, MA; $900K SBIR) got an Army Phase 2 SBIR to continue the development of micro-displays based on the company’s quantum dot light emitting diode (QLED) technology. ... part of the firms VC backing comes from CIA's In-Q-Tel. .... technology is based on the work of Vladimir Bulovic, an associate professor of electrical engineering and computer science at MIT, and Moungi Bawendi, a professor of chemistry at MIT focused on the synthesis of nanomaterials [Mass High Tech, Jun 9, 09]

QD Vision (Watertown, MA, $900K SBIR) is promoting a new LED-based lamp that it made with Nexxus Lighting (Charlotte, NC; no SBIR). Nexxus makes a lamp designed to screw into standard sockets used in recessed ceiling lighting. It consists of an array of white-light LEDs encircled by fins that remove excess heat. QD Vision adds an optic--a plastic cover with a special coating that snaps into place over the LEDs. It's that coating that makes the difference in the quality of the light. It consists of quantum dots--tiny bits of semiconductor material just a few nanometers in diameter. When excited by a light source--in this case, the LEDs--quantum dots radiate light in a wavelength that varies according to the size of the dot. [Neil Savage, MIT Tech Review, May 13, 09]

Following its recently announced funding from In-Q-Tel, the CIA venture arm, Watertown-based QD Vision (Watertown, MA; one SBIR) has also landed $9 M of an expected $16 M round of Series C funding from private investors, according to [SEC] documents [Mass High Tech, Apr 11]

QED a.k.a. Quality Electrodynamics (Cleveland OH)

Dr. Fujita saw the need for high-performance radio frequency coils in the area of patient diagnosis so he started his work in a 300-square-foot space at Case Western Reserve University. ... spoke to [Toshiba and Siemens] about backing him as a manufacturer. They agreed to provide seed money so that Dr. Fujita's company [Quality Electrodynamics (aka QED) Cleveland OH] would remain independent. .... and $4 million in development grants, which includes [$1M] from [HHS SBIR]. ... Currently the company employs 130 and revenue has grown 3,500% since 2006, Dr. Fujita [Adrienne Selko, Industry Week, May 24, 13]

QED Therapeutics (Palo Alto, CA)

BridgeBio is snatching a recently-abandoned cancer program off Novartis’ shelves, handing the asset to a spinout [QED Therapeutics (Palo Alto, CA) with a gift of $65 million in seed money] company with unusual plans for the drug. The newly-licensed product — called infigratinib or BGJ398 — was in Phase II trials at Novartis for patients with bile duct cancer with FGFR fusions. Although the drug showed meaningful clinical activity early in the trial, Novartis decided to dump the drug last year. A chunk of that cash will go straight back out to Novartis to pay for licensing fees, although details of the deal weren’t disclosed. [Brittany Meiling, Endpoints News, Jan 31, 18]

qFuzion (Dayton, OH)

Last year, Cornerstone Research Group (Beavercreek, OH; $32M SBIR, 80 employees) took first place in the Dayton Business Journal Innovation Index Awards in the commercialization category. [Joe Cogliano, Dayton Business Journal, Feb 23, 15] recognized for its innovative approach to commercialization in providing technology commercialization services and advisory support to spin-off subsidiaries, allowing them to focus on their core business needs and move more quickly into the market. ... Spintech LLC (no SBIR) , a CRG spin-off subsidiary, has made the most profitable exit from the Accelerant fund so far (July 2013). ... qFuzion LLC (spun off 2012), With funding support from the Dayton Development Coalition's Entrepreneurial Signature Program, now leverages CRG's expertise in nanotechnology to offer capital equipment that adds nanomaterials to polymers. [company website] Since firm and its spinoffs are private firms, only the SBIR managers know the degree of economic payoff from the government handouts. And it is unlikely that they care. The only way Congress would pay much attention is if the agency failed to hand out its required minimum money.

Qioptiq (Fairport, NY)

Qioptiq (Fairport, NY; no SBIR) landed a $1.1 million contract from the U.S. government to serve as the prime contractor for a head-up displays project, the company said .... adding six jobs to its local workforce of 65 .... design and manufactures photonic products for industrial manufacturing, medical and life sciences, defense, aerospace and research and development applications. [Andrea Deckert, Rochester Business Journal, Jun 6, 11]

QM Power (Boston, MA)

QM Power (Boston, MA; $700K SBIR) is looking for $5 million to $10 million in Series B funding to commercialize its technology ... “We’re moving now from a stage where we’ve finished research and development and prototyping and going into 2010 looking to start production,” [CEO] Piper said. Piper said there is a $1 trillion installed base of products that could be improved by QM Power technology, and he estimates a market potential of about $70 billion per year. [Brendan Lynch, Mass High Tech, Jan 6, 10]

Qpex (San Diego, CA)

Qpex (San Diego, CA; no SBIR) announced the closing of a $33 million Series A financing and launch of the infectious disease company. Qpex is focused on developing new antibiotics to combat the growing threat of global antimicrobial resistance. .... Qpex management team is comprised of former executives from The Medicines Company's infectious disease business unit who were integral in the development/approval of four antibiotics in the last five years, including three products while at The Medicines Company. [company press release, Oct 22, 18]

QR Pharma (Radnor, PA)

QR Pharma (Berwyn, PA; no SBIR, founded 2008) raised $530K [John George, Philadelphia Business Journal, Mar 18, 19] total funding $8M [crunchbase.com]

Insiders pump $800K into QR Pharma (Berwyn, PA; $200K SBIR) biopharm firm [John George, Philadelphia Business Journal, Oct 27, 2016] candidate medicine Posiphen® targets early stage Parkinson’s Disease as well as Alzheimer’s Disease and may stop or slow the progression of those diseases. [company website]

QR Pharma (Berwyn, PA; $200K SBIR), developing treatment for Alzheimer’s, Parkinson’s and other neurodegenerative diseases, raised $5.7 million [Series A] in a private stock sale. ... to further develop its lead new drug candidate called Posiphen. Posiphen represents a new approach to the treatment of neurodegenerative diseases. Posiphen is a neuroprotective designed to work by inhibiting the synthesis of neurotoxic aggregating proteins — and protecting nerve cells from the toxic proteins. [John George, Philadelphia Business Journal, May 26, 15]

QR Pharma (Berwyn, PA; one SBIR) a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and acute brain injury, like traumatic brain injury (TBI) and stroke, or chronic degeneration, like Alzheimer's and Parkinson's disease and the University of California Los Angeles (UCLA) announce today that they received a US Army grant in the amount of $3,000,000 to study Posiphen® in two models of TBI. [company press release, Oct 9, 13]

QR Pharma (Radnor, PA; no SBIR), a pharmaceutical company focused on developing treatments for Alzheimer’s disease, raised $2.4 million in a seed round of investments [John George, Philadelphia Business Journal, Jun 2, 10]

QSpex (Alpharetta, GA)

lens technology firm QSpex Technologies (Alpharetta, GA; no SBIR) [has raised nearly $30 million of a planned $40 million] according to [SEC filing. ... developed a process involving a liquid plastic that, when exposed to certain wavelengths of light, is converted into a hard plastic lens. Using its technology, QSpex claims, eye-care specialists can make high-quality lenses in about 30 minutes, versus the typical three- to seven-day turnaround. [Urvaksh Karkaria, Atlanta Business Chronicle, Dec 17, 14]

QSpex (Alpharetta, GA; no SBIR) raised $15 million [Series E] ... as QSpex expands its workforce and enters new markets .... has developed a process that involves a liquid plastic that, when exposed to certain wavelengths of light, is converted into a hard plastic lens. .... Founded in 2007, QSpex is based upon technology developed by Kai Su, who spent two decades leading research and development groups at CIBA Vision, Alcon Laboratories and Bausch & Lomb. [Urvaksh Karkaria, Atlanta Business Journal, Jan 14, 14]

Qteros (Marlborough,MA)

Cellulosic ethanol company Qteros (Marlborough, MA; no SBIR) said it has raised $22 million in a Series C round and inked a partnership deal with a major Indian ethanol firm, which the company said gives it a clear path to commercialization within 18 to 24 months. [Kyle Alspach, Mass High Tech, Jan 5, 11] Just as enthusiasm for US government subsidy is waning.

Qteros (Marlborough, MA; no SBIR) and the University of Massachusetts Amherst have patented the fermentation method they use to make biofuel, a plant-based alternative to gasoline, using the so-called Q Microbe. [Erin Ailworth, Boston Globe, Mar 23, 10]

QuaDPharma (Clarence, NY)

Kinex Pharmaceuticals (Buffalo, NY; $1.1M SBIR, founded 2003) and its Korean partner Hanmi Pharmaceutica l executed an agreement whereby Kinex is leading the development of its Orascovery program [allows intravenous cancer drugs to be taken orally] in India. .... Last year, Kinex bought Newstead-based pharmaceutical manufacturer QuaDPharma (Cherry Hill, NJ; $300K SBIR) ... Kinex now has offices in Hong Kong, Taipei, New Jersey and Buffalo [David Bertola, Buffalo Business First, Apr 21, 15]

A top executive at Kinex Pharmaceuticals (Buffalo, NY; $1,.1M SBIR, 30 employees) said company officials have been eager to add a manufacturing segment in recent years. And Kinex followed through with the announcement it has acquired QuaDPharma LLC (Clarence, NY; no SBIR, 13 employees, founded 2011), a pharmaceutical manufacturer. ... Earlier this year, Kinex expanded its Asian research efforts when it entered into a new licensing agreement with Taiwan-based PharmaEssentia Corp. The agreement grants PharmaEssentia exclusive development and commercial rights in Taiwan and Singapore to Kinex drugs Oraxol and Oratecan. [David Bertola, Buffalo Business First Reporter, Sep 9, 14] To meet growing manufacturing demand for clinical testing products with an FDA seal of approval, Empire Genomics LLC (Buffalo, NY; no SBIR) has partnered with commercial contract manufacturer QuaDPharma. The companies recently completed a first batch of products for Empire Genomics customers that meet an FDA standard called “Current Good Manufacturing Practice.” [David Bertola, Buffalo Business First Reporter, Aug 29, 14]

Quadraspec

Quadraspec (Purdue Research Park - West Lafayette, IN; no SBIR) received $2.5 million from venture capital firms led by Clarian Health Ventures of Indianapolis. ... makes a machine to diagnose diseases from a blood test. The technology can detect cancer, cardiovascular disease and other serious illnesses in their early, most treatable stages. [Indianapolis Star, SEp 13, 08]

Quadra-Aerrow International (Glastonbury, CT)

Six start-up technology firms have received grants as part of the state's small-business incubator program, ... administered by the Connecticut Center for Advanced Technology ... $32,000 to $50,000 went to: AllerQuest LLC of West Hartford, Catelectric Corp. of Storrs, Hydrogen Safety of East Hartford, Quadra-Aerrow International of Glastonbury, Revegen Inc. of Farmington and the Center for Network Centric Product Support Research of East Hartford. [Hartford Courant, Dec 12, 08] no SBIR for any

Quad Technologies

North Shore InnoVentures, a technology incubator based in Beverly [MA], said that six startup companies in the clean technology and life sciences sectors have joined its program over the last few months. .... Lariat Biosciences (no SBIR), is developing a non-invasive diagnostic to detect early signs of cancer based on circulating free DNA within the bloodstream. ... Other startups recently joined include Akita InnovationsRAN BiotechnologiesQuad Technologies, and ZS Genetics, none has SBIR. .... A total of 21 companies are now in [residence]. [Chris Reidy, Boston Globe, Jun 5]

Qualcomm (San Diego, CA)

EU launches antitrust probe into Qualcomm 5G modem chipset business [ZDNet, Feb 5, 20]

Qualcomm up 12% [Apr 17, 19]

Qualcomm up 23% [Apr 16, 19] after settling Apple dispute

Amplyx (San Diego, CA) funded by over a hundred million dollars in venture investment, plus [NIH] grants , is enrolling patients in Phase 2 trials of its lead drug candidate, APX001A ... to treat life-threatening, invasive infections caused by not only strains of Candida auris, but also Aspergillis and rare molds. [xconomy.com, Apr 16, 19]

Qualcomm continues to shed workers in San Diego and elsewhere as part of a pledge to shave $1 billion in annual costs. The cellular technology giant confirmed that it was cutting 269 jobs in California and North Carolina. [San Diego Union Tribune, Dec 7, 18]

Qualcomm says NXP deal dead, despite Trump's comments that it could be revived [San Diego Union Tribune, Dec 3, 18]

Qualcomm has launched a new $100 million fund to invest in artificial intelligence startups looking to run their algorithms on devices in the field — rather than in the Internet cloud [Mike Freeman, San Diego Union Tribune, Nov 30, 18]

Qualcomm estimates damages in legal war with Apple at $7 billion [San Diego Union Tribune, Oct 29, 18]

Qualcomm to Buy Back $10 Billion of Its Shares [Wall Street Jurnal, Jul 31, 18]

Apple breaks up with Qualcomm: Will Intel chips mean slower iPhones? - Apple's break from Qualcomm, however, may mean slower iPhones compared to its Android counterparts, as phones using Qualcomm chips outperformed phones using its competitors' chips, according to a recent study. [San Jose Mercury News, Jul 27, 18]

Qualcomm announced a new $10 billion stock repurchase authorization that replaces the previous $15 billion stock repurchase program announced in March 2015, which had $1.2 billion of repurchase authority remaining. [company press release, May 9, 18]

Qualcomm, best known for its mobile chips, attempted to break into the server chip market last year, commercially shipping its Centriq 2400 ARM-based server processor in November, [as] a viable alternative to Intel in the data center. .... [now] seven months after the commercial launch of the Centriq 2400, Bloomberg is reporting that Qualcomm is planning to exit the server chip business altogether. [Timothy Green, The Motley Fool, May 10, 18]

The federal helping hand. While the current role of the federal government has captured attention, it is worth noting the contributions of federal and higher ed technology commercialization policies– themselves innovative at the time – to both companies’ origins: Qualcomm’s roots trace back to an SBIR award, while Broadcom is the result of a UCLA spinoff and generous entrepreneurial leave granted by the institution. [SSTI, Mar 13, 18] Trump won hearty approval even among some staunch San Diego Democrats when he blocked Broadcom’s hostile takeover of Qualcomm. The news was joyously received [by] Qualcomm co-founder and former CEO and board chairman Irwin Jacobs ( a vocal SBIR booster) [Diane Bell, San Diego Union Tribune, Mar 13, 18]

Qualcomm ($1.5M SBIR in 1980s) agrees $44 billion deal [to buy] Dutch chipmaker NXP [James Fontanella-Khan and Arash Massoudi, Financial Times, Feb 20, 18] How much credit should SBIR take for Qualcomm's success? Who knows, since politics, not capital economics, is first and last the basis for SBIR.

Qualcomm was slapped with a $1.23 billion antitrust fine by the European Union for illegal payments it made to Apple for exclusively using its chips in smartphones and other products [Wall Street Journl, Jan 24, 18]

The start-up Wiliot (San Diego, CA; no SBIR, founded 2017) recently backed by Qualcomm Ventures is developing battery free Bluetooth beacons that aim to push wider adoption of the micro-location technology in everything from retail to product packaging., said earlier this month that it raised $5 million from Qualcomm Ventures and M Ventures, the venture capital arm of conglomerate Merck KGaA. ... on top of a $14 million funding round that the company launched when it opened. [Mike Freeman, San Diego Union Tribune, Nov 20, 17]

Qualcomm up 13% [Nov 3, 17] Broadcom is planning an unsolicited takeover approach to rival chip maker Qualcomm, according to a person familiar with the matter. Such a deal would be enormous, given Qualcomm’s current market value of nearly $90 billion. [Wall Street Journal, Nov 3, 17]

Verizon, Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, and Novatel Wireless, an Inseego company, announced plans to collaborate on 5G New Radio (NR) millimeter wave (mmWave) technology development and over-the air field trials based on the 5G NR Release-15 specifications being developed by 3GPP – the global 5G standard. The companies plan to work together to help move the mobile ecosystem towards faster validation and commercialization of 5G NR mmWave technologies at scale, supporting a full-scale commercial network deployment before the end of the decade. [joint companies press release, Oct 17, 17]

Qualcomm lost its legal bid in South Korea to postpone implementation of changes in the way it licenses cellular patents -- moves that were called for last year by that country’s anti-monopoly regulator. [Reuters, Sep 4, 17]

Two years after setting up an artificial intelligence research laboratory with the University of Amsterdam, Qualcomm Technology has acquired one of its a spinoffs - an outfit called "Scyfer". The acquisition brings new software under Qualcomm's umbrella – a move in line with the company's strategy to use more general-purpose silicon for AI tasks. [Richard Chirgwin, theregister.co.uk, 21 Aug 2017]

The world’s dominant mobile phone chip maker, Qualcomm ran afoul of the Chinese government, getting hit in 2015 with a record $975 million fine for anticompetitive behavior. To get back in Beijing’s good graces, the company agreed to lower its prices in China, promised to shift more of its high-end manufacturing to partners in China, and pledged to upgrade the country’s technology capabilities. ... The [Chinese] government is providing land and financing to the start-up formed with Qualcomm, called Huaxintong Semiconductor. Qualcomm has provided the technology and about $140 million in initial funding. ... Robert D. Atkinson, president of the Information Technology and Innovation Foundation, a think tank focused on technology policy that has conducted studies detailing the Chinese government’s pressure on technology companies. “They have a large carrot and a large stick,” he said. “And they have a market no C.E.O. can walk away from.” [ DAVID BARBOZA, New York Times, Aug 4, 17]

Qualcomm said profit fell 40% in its latest quarter, the first in years that didn’t include patent royalties on devices from Apple. [Wall Street Journal, Jul 19, 17]

Qualcomm officially announced three brand new fingerprint sensors that work with the more demanding smartphone design of today’s market, as devices go for bezel-less designs. All three new fingerprint sensors will work on waterproof-designed handsets, with each of the new sensors also detecting heartbeats and blood flow, which will make on-screen gestures much easier. [Evan Selleck, androidandme.com, Jun 28, 17]

Qualcomm is asking a federal judge to order four companies that build Apple’s iPhones and iPads to resume paying cellular patent royalties while the two tech giants wage legal war over the value of intellectual property. [Mike Freeman, San Diego Union Tribune, May 25, 17]

Qualcomm demonstrated its vision of dynamic electric vehicle charging on a test track in France, showcasing that progress is being made toward recharging while in motion. Using its Qualcomm Halo wireless electric vehicle charging system, the San Diego company said it charged Renault Kangoo electric vehicles on a 100-meter test track at highway speeds, delivering 20 kilowatts of power along a track. ... The 100 meter test track used in last week’s demonstration costs $10.1 million, which was funded mostly by the European Commission. [Mike Freeman, San Diego Union Tribune, May 22, 17] QTI has designed, built, and tested a DEVC system capable of charging an EV dynamically at, and in excess of, 100 km/h with 20 kW. Even better, we’ve done this with not just one vehicle but two — charging them simultaneously. [Qualcomm press release. May 18, 17]

Qualcomm slashed its profit expectations Friday by as much as a third after saying that Apple is refusing to pay royalties on technology used in the iPhone. Its shares hit a low for 2017. [San Jose Mercury News, Apr 28, 17]

Qualcomm raised its dividend 8%. [Apr 13, 17]

Qualcomm said it has been ordered to pay smartphone maker BlackBerry $814.9 million in an arbitration dispute over patent royalties;after both companies entered binding arbitration in a contract disagreement over Qualcomm’s royalty caps. [San Diego Union Tribune, Apr 12, 17]

Qualcomm fired back late Monday against Apple’s legal attack on its patent licensing business -- accusing the world’s largest tech company of egging on anti-trust regulators with misleading information and meddling with Qualcomm’s long-standing patent agreements with contract manufacturers [San Diego Union Tribune, Apr 11, 17]

Qualcomm is introducing a new product designed to bring faster wireless service to basic, lower-priced cellphones in emerging markets, an attempt to bolster the chip giant’s reach among consumers who can’t afford smartphones. The new product, which starts shipping in the second quarter, includes a processor along with other hardware and software that will enable so-called feature phones to take advantage of today’s faster wireless networks, the company said [Betsy Morris, Wall Street Journal, Mar 20, 17]

Qualcomm hit another milestone in its multi-year effort to challenge Intel’s dominance in the data center semiconductor market, naming the first customer trying out its server chips. Qualcomm and Microsoft said they were teaming up to use Qualcomm’s new Centriq 2400 data center semiconductors with a Microsoft cloud-computing software platform that the Seattle company uses for its own internal data centers. [Mike Freeman, San Diego Union Tribune, Mar 8, 17]

Qualcomm introduced a number of new products prior to of next week’s Mobile World Congress (MWC) in Barcelona, Spain. These new products are part of Qualcomm’s efforts to move smartphone technology forward and push download speeds to over 1 Gbps. [Tirias Research, Forbes, Feb 21, 17]

Qualcomm spokesperson said the company’s first priority “is to provide direct support to any of our employees or their families who have been impacted by this executive order. “We recognize that inclusion and diversity are paramount to fostering innovation at Qualcomm, and we will continue to be a proponent of positive immigration policy,” the company said. [Mike Freeman, San Diego Union Tribune, Feb 8, 17]

Qualcomm down 13% [Jan23,17] as investors reacted to Apple’s $1 billion lawsuit that attacks the way the San Diego wireless giant gets paid for its patented inventions. [Mike Freeman, San Diego Union Tribune, Jan 23, 17]

Apple is suing Qualcomm alleging it demanded onerous terms for its technology and that it sought to punish Apple for cooperating in a Korean regulatory probe into Qualcomm’s licensing practices. [Wall Street Journal, Jan 20, 17]

The United States Federal Trade Commission said mobile chip giant Qualcomm forced Apple to use its modem chips by lowering its licensing fees and pushing competition out, according to a newly-unsealed antitrust suit brought against the chipmaker. ... Qualcomm is the dominant supplier of modem chips that enable phones to hook up to cellular networks, [Aaron Tilley, Forbes, Jan 17, 17]

Qualcomm views its latest smartphone chip as a “connected device” chip, a bid to outdistance rivals such as Intel Corp. in the burgeoning market for gadgets and equipment with computing and communications capabilities built in. .... unveiled its latest premium chip, Snapdragon 835, at CES 2017, a consumer-electronics show in Las Vegas. [Georgia Wells, Wall Street Journal, Jan 3, 17]

Qualcomm said it has reached a world-wide patent-licensing agreement with Chinese smartphone maker Meizu Technology, consolidating its hold on the Chinese phone market. [Wall Street Journal, Dec 29, 16]

Qualcomm: The Company Governments Love to Hate. There is scarcely a wireless device sold these days that doesn’t generate some revenue for Qualcomm. ... An added wrinkle [in South Korea's attack] is the notion that Qualcomm should be required to license its key technology to rival chip makers. The finding came with a fine of about $853 million. .... It also helps that the company is working to diversify its business with the pending acquisition of NXP Semiconductors. [Dan Gallagher, Wall Street Journal, Dec 28, 16]

A South Korean regulator said it would fine Qualcomm about $853 million for alleged antitrust violations, the highest such penalty handed to an individual company here, as the U.S. chip maker faces global scrutiny over its patent-licensing business. [Eun-Young Jeong, Wall Street Journal, Dec 27, 16]

Qualcomm is taking the wraps off its two-year effort to build computer server chips, challenging Intel’s stronghold in the fast growing datacenter market. .... said that its new server chip, called Centriq 2400, is now being tested with key customers and is expected to be commercially available in the second half of 2017. [Mike Freeman, San Diego Union Tribune, Dec 7, 16]

Gimbal, a Bluetooth beacon supplier that spun out of Qualcomm, has been acquired by mobile advertising outfit The Mobile Majority to beef up its location-based data services. The purchase price was not disclosed [Mike Freeman, San Diego Union Tribune, Dec 5, 16]

Qualcomm has a 3.3% dividend yield and has been growing its dividend by double-digit rates for several years. Qualcomm has raised its dividend 13 years in a row. [http://seekingalpha.com. Dec 4, 16]

Qualcomm agreed to buy NXP Semiconductors NV (Netherlands) for about $38 billion in the biggest-ever semiconductor industry deal, expanding the reach of its chips from phones to cars. The deal will make Qualcomm, which provides chips to Android smartphone makers and Apple Inc , the top supplier of chips to the automotive industry and help to reduce its dependence on the smartphone market. [Narottam Medhora and Supantha Mukherjee, Reuters, Oct 26, 16]

Qualcomm announced plans to deliver its first chip for the next generation of cellular networks, angling to be ready as some carriers roll out versions of 5G services by 2018. ... said it expects the forthcoming Snapdragon X50 modem chip to be available in sample quantities in the second half of 2017 and to deliver download speeds of up to 5 gigabits per second. That is roughly 100 times faster than peak speeds claimed by most networks that use the fourth-generation technology called LTE, for long-term evolution. [Don Clark, Wall Street Journal, Oct 18, 16]

Qualcomm said that it has expanded its patent infringement action against Chinese smartphone maker Meizu, including taking its case to the U.S. International Trade Commission. [Mike Freeman, San Diego Union Tribune, Oct 14, 16]

Qualcomm is teaming up with AT&T to test the operation of drones on cellular networks, which eventually could pave the way for unmanned aircraft package deliveries, remote inspection and public safety missions that require beyond line-of-sight navigation. [Mike Freeman, San Diego Union Tribune, Sep 7, 16]

A brilliant and inspirational technology business since day one may define Qualcomm ($1.3M SBIR in the 1980s) fairly. It is one of the most inventive companies ever. QCOM was always revolutionary and its technological story is a ongoing success. After dozens of acquisitions of technological companies, we can say that it's all about wireless. In fact, Qualcomm is the largest maker and creator of wireless technologies with a leading position worldwide in the mobile market. [seekingalpha.com, Aug 11, 16]

Picture This. Qualcomm created a 3D model of my face with only a tablet and a surprisingly brief amount of scan and computational time on Qualcomm’s Snadragon 820 SoC. ... potentially interactive because my digital model could be exported as an .OBJ file — an open and universal 3D geometry format — and manipulated in any number of ways. I can be animated, edited, or thrown into a video game. .... Dacuda and Qualcomm teamed up to further demonstrate how effortless 3D scanning on mobile has become. Using an off-the-shelf Samsung Galaxy S7 and Dacuda’s software-based “SLAM Scan 3D,” I watched as a bowl of vegetables was scanned into the phone within seconds [Jason Evangelho, Forbes, Aug 1, 16]

Qualcomm said that it has reached a patent-licensing agreement with up-and-coming Chinese mobile device outfit Oppo Mobile Telecommunications — the fourth largest smartphone maker globally .... has now signed patent licenses with seven of the top 10 Chinese phone makers [Mike Freeman, San Diego Union Tribune, Aug 1, 16]

Qualcomm flexes its muscles in China, sues Meizu over patent licensing problems. [Andy Boxall, Yahoo.com, Jun 24, 2016]

Qualcomm recently unveiled its new Snapdragon Wear 1100 chips at Computex 2016 in Taipei. The low-power chips are designed for "purpose-built wearables" that are designed for specific low-end uses, as opposed to more-powerful chips that power full-feature smartwatches. Qualcomm has stated that the chip will be installed in fitness trackers, kids' watches, smart headsets, and other wearable accessories. [fool.com, Jun 3, 16]

Qualcomm expects to start making some chips for the China market next year through a Chinese government-owned venture, in an example of how U.S. tech companies are localizing products as Beijing tightens control of technology within its borders. The customized chips will go into servers, the hardware for running websites, storing companies’ data and powering data centers. For Qualcomm, the world’s leading supplier of smartphone chips, servers are a new growth initiative as demand in the smartphone market softens. [Eva Dou, Wall Street Journal, May 27, 16]

Qualcomm and medical device maker Medtronic said that they would work together to develop small, inexpensive, easy-to-use continuous glucose monitors targeting people with Type 2 diabetes. ... The prescription-required devices likely will take a few years to come to market. They require [FDA] approval. And one competitor may have a head start. [Mike Freeman, San Diego Union Tribune, May 25, 16]

Qualcomm raised its dividend 10%. [Apr 11, 16]

Qualcomm said the [FAA] has authorized the big maker of wireless chips and technologies to operate drones outside its San Diego headquarters, which is within five miles of a Marine Corps air base. [Bruce Bigelow, xconomy.com, Apr 8, 16]

Qualcomm said that it has signed a patent licensing agreement with Chinese electronics maker Zhuhai Ewpe Information Technology, adding another Chinese firm to the list that has agreed to pay for using the company’s intellectual property. [Mike Freeman, San Diego Union Tribune, Apr 6, 16]

The U.S. Supreme Court declined to hear ParkerVision (Jacksonville, FL; no SBIR)’s patent infringement lawsuit against Qualcomm, putting an end to an intellectual property dispute dating back to 2011. ... the federal judge overseeing the [2013] case voided the jury verdict in 2014, saying the technical evidence didn’t support the jury’s findings. .... ParkerVision launched a 10-to-1 reverse split [Mike Freeman, San Diego Union Tribune, Mar 29, 31]

Qualcomm Ventures joined existing investors in a recent $27 million funding round for Stratoscale, an Israeli data center software company [that] makes data center management software that’s hardware agnostic. [Mike Freeman, San Diego Union Tribune, Mar 23, 16]

Qualcomm upped its dividend another 10%. [seekingalpha.com, Mar 14, 16]

Qualcomm won back the key semiconductor slot in Samsung’s latest flagship smartphones..... said that its Snapdragon 820 processor will power Samsung’s new Galaxy S7 and S7 Edge smartphones sold in select markets, such as the US.. [Mike Freeman, San Diego Union Tribune, Feb 22, 16]

A jury has determined that a man who was severely burned nearly three years ago while working around electrical equipment at Qualcomm’s headquarters should receive more than $7 million in damages. [Dana Littlefield, San Diego Union Tribune, Feb 12, 16]

Qualcomm announced a cellular chip that can transmit a billion bits of data a second, hoping to bring mobile users speed comparable to today’s most advanced wired services [Wall Street Journal, Feb 11, 16]

Qualcomm said its earnings fell 24% in the most recent quarter, the latest sign that slowing sales of high-end smartphones from Apple and others are hurting component suppliers. [Wall Street Journal, Jan 27]

Qualcomm and GlaxoSmithKline are exploring a joint venture to develop medical technologies, according to a Bloomberg report that cited unidentified sources. [Alex Lash, xconomy.com, Jan 22, 16]

Qualcomm announced that it’s working with the regional government of Guizhou Province — located in southwest China — to form a joint entity for deploying Qualcomm’s server chips in the country. The Chinese provincial government and Qualcomm together are investing $280 million into the new venture. A majority 55% will be owned by the Guizhou government, and the rest will be controlled by Qualcomm. The Chinese government is positioning the Guizhou Province to become a major cloud computing hub. [Aaron Tilley, Forbes, Jan 17, 16]

Universal Display down 10% [Jan 15, 16]

Qualcomm and Japan’s TDK are forming a jointly owned company to develop wireless components for mobile devices and other products, a deal that Qualcomm said could cost up to $3 billion over three years. [Wall Street Journal, Jan 12, 16]

Qualcomm asked a U.S. federal court to compel some of its biggest customers and competitors to hand over any documents they provided to South Korean antitrust authorities investigating the U.S. chip maker. [Don Clark,Wall Street Journal, Jan 10, 16]

Shares of Qualcomm declined by 32.8% in 2015, according to S&P Capital IQ data. Revenue and profit slumped during the year, driven by a decline in chip sales, and ongoing problems with licensing in China have stunted the company's lucrative licensing business. [Timothy Green, fool.com, Jan 8, 16]

Qualcomm ruled out splitting itself up despite pressure for change from an activist investor and scrutiny of the semiconductor companyâ€™s business by antitrust authorities. [Don Clark, Wall Street Journal, Dec 15, 15]

European trade regulators accused Qualcomm of predatory pricing and giving illegal discounts to a smartphone maker for exclusively using its semiconductors. [Mike Freeman, San Diego Union Tribune, Dec 8,15]

Qualcomm signed a licensing pact with Xiaomi Technology Co Ltd that allows the Chinese smartphone maker to use its patents to make and sell 3G and 4G devices. Xiaomi has enjoyed a rapid rise with handsets it touts as cheaper but well-designed alternatives to Apple Inc's iPhones. [Alan John Koshy, Reuters, Dec 2, 15]

Love the tech, hate the price. Qualcomm’s technology licensing practices have come under fire from another anti-monopoly regulator in Asia – South Korea. .... said that it has received a staff report from the Korea Fair Trade Commission alleging that the company’s patent licensing practices violate competition laws. .... Earlier this year, Qualcomm settled a 13-month anti-monopoly probe in China, agreeing to pay a $975 million fine and reduce its licensing royalty rate on devices sold within China’s borders. [Mike Freeman, San Diego Union Tribune, Nov 17, 15] Get the host government to attack the foreign patent monopoly without any move to compensate the developer for the huge R&D costs.

Running to stay in place. the new components of the SoC [Snapdragon 820] are new to ]30 year old] Qualcomm’s SoCs. All of this translates to a power reduction of roughly 30% on the whole SoC when compared to the previous generations of SoCs from Qualcomm, which is a big deal when you think about the Snapdragon 810. [Anshel Sag, Forbes, Nov 13, 15]

Qualcomm ended its partnership with Techstars, less than two months after graduating the inaugural class of 10 startups from the Qualcomm Robotics Accelerator, powered by Techstars. The San Diego wireless giant had indicated the program would continue for three years. [Bruce Bigelow, xconomy.com, Oct 30, 15]

Qualcomm down 22% [Nov 5, 15]

Qualcomm forecast first-quarter profit way below analysts' expectations as the chipmaker struggles against fierce competition from Chinese and Taiwanese rivals. ... is in the middle of a strategic review after hedge fund Jana Partners urged it to separate its chip unit from its highly profitable patent-licensing business. [Devika Krishna Kumar, Reuters, Nov 4, 15] Dumping a commodity chip biz worked for Intel.

Qualcomm v. Intel Qualcomm said it’s making strides in developing semiconductors for data centers – a key growth area for the San Diego firm as the smartphone market matures. While still in the early stages, Qualcomm said last week that it is delivering sample system-on-a chip products to data centers for testing. The announcement comes a year after Qualcomm revealed it aimed to make energy efficient chips for computer servers that run data centers – putting it in direct competition with Intel [Mike Freeman, San Diego Union Tribune, Oct 14, 15]

Qualcomm said it is selling its 5-year-old Vuforia augmented reality business to computer-aided-design software firm PTC (Needham, MA; no SBIR) for $65 million. ... Vuforia has been incorporated into 20,000 apps worldwide. Its annual revenue isnâ€™t enough to impact PTC financial results, the company said. [Mike Freeman, San Diego Union Tribune, Oct 12, 15]

Qualcomm CEO Mollenkopf dined twice last week with the President of China in formal gatherings including a state dinner in Washington with the POTUS. [Diane Bell , San Diego Union Tribune,Sept. 30, 2015]

Qualcomm said it has earmarked $150 million to invest in startup companies based in India though its Qualcomm Venture fund. ... said it has been investing in India’s startups since 2007. Companies funded include Yourstory, a media tech platform for entrepreneurs; Portea Medical, an in-home healthcare provider; and MapMyIndia, a digital mapping provider. [Mike Freeman, sandiegouniontribune.com, Sep 28, 15]

a new heavyweight competitor now has its sights set on the [image processing system-on-chips (SoCs)] sector. Qualcomm, the largest mobile chipmaker in the world, recently started selling SoCs for action cameras and drones as well. Could that move throttle Ambarella (Santa Clara, CA; no SBIR)'s growth in both markets? ... As for drones, Qualcomm has several advantages over Ambarella. In February, it acquired KMel Robotics (Philadelphia, PA; no SBIR), a startup which develops multi-rotor drones which can coordinate with one another in "swarms". Neither Ambarella nor Intel (which has drone ambitions of its own) owns this type of technology [The Motley Fool, Sep 26, 15]

Financial engineering. Big U.S. companies are increasingly using the bond market for the benefit of shareholders, a move that is starting to raise alarm among some debt investors.... Proceeds from some of the largest bond sales this year, including those from Microsoft, Qualcomm, and Oracle, were earmarked for share repurchases and dividends. Qualcomm floated $10B in May for stock buybacks. [Mike Cherney, Wall Street Journal, Sep 21, 15]

Qualcomm ($1M SBIR in the 1980s) slashed 1,314 full-time jobs in San Diego and hundreds of jobs elsewhere as it revamps its business in the face of slower growth in the maturing smartphone market. ... In July, Qualcomm revealed plans to trim its 31,300 global workforce by 15 percent worldwide over the next year. It aims to cut expenses by $1.4 billion annually. [Mike Freeman, sandiegouniontribune.com, Sep 17, 15] Trees don't grow to the sky.

Qualcomm said it has acquired Capsule Technologie (France), a maker of medical data collection technology, in a bid to expand the company’s footprint in the medical Internet of Things market. The purchase price was not disclosed. Capsule has more than 1,930 hospital customers in 38 countries. It will become part of Qualcomm Life – a division which offers the 2net wireless connectivity platform to medical device makers. [Mike Freeman, sandiegouniontribune.com, Sep 14, 15]

Robotics Accelerator. Qualcomm wants to bring robotics beyond factories or hobby shops and into the consumer mainstream. As part of that effort, the San Diego wireless chip firm teamed up with TechStars on the Qualcomm Robotics Accelerator. The 16-week program brought 10 startups to San Diego for mentoring and technical aid in developing their new robotic products. [Mike Freeman, sandiegouniontribune.com, Sep 14, 15]

Qualcomm executives have often said that drones are essentially flying smartphones. As part of its efforts to push mobile technology into the drone market, the San Diego wireless chip giant on Thursday introduced a new circuit board and software specifically designed to enable better aerial photography. Called the Snapdragon Flight, the circuit board aims to allow drone makers to introduce smaller, easy–to-use and inexpensive drones that would operate as flying cameras. [Mike Freeman, sandiegouniontribune.com, Sep 10, 15]

Qualcomm said it is baking additional security into its upcoming top-tier Snapdragon processors for Android smartphones – tapping machine learning technology to pinpoint hacker attacks. Called Snapdragon Smart Protect, the technology looks for and reports unusual behavior by apps and other software on a device that might signal malware threat. The technology is the first to emerge from Qualcomm’s Zeroth technology development program[Mike Freeman, San Diego Union Tribune, Aug 31, 15]

UC Berkeley’s College of Engineering is giving Bay Area companies the chance to mentor and mold the newest talent coming out of the UC system. Last week, the engineering school opened the headquarters for the new Jacobs Institute for Design Innovation in the 24,000-square-foot Jacobs Hall. The haven for "makers" and "tinkerers" has five design studios and was created to give artists and engineers from all over Berkeley’s campus a space to collaborate and innovate. ...Jacobs Hall has a price tag of just under $25 million ...The largest donation, of $20 million, was made by Dr. Paul Jacobs, executive chairman of Qualcomm [Teresa Mathew, San Francisco Business Times, Aug 28, 15]

Qualcomm completed its $2.4 billion acquisition of Internet of Things chip maker CSR (UK)– highlighting the company’s efforts to branch out beyond smartphones. Qualcomm announced plans to buy CSR last October. Lengthy regulatory reviews delayed closing of the deal. [Mike Freeman, utsandiego.com, Aug 13, 15]

Qualcomm Atheros said it has acquired Ikanos Communications for $2.75 a share in a move to round out its technology for home and central office gateways.
The acquisition of Ikanos gives Qualcomm access to A/VDSL2 and G.fast modem technology and chipsets.

A U.S. appeals court upheld a lower court's decision to clear Qualcomm in a patent lawsuit by ParkerVision (no SBIR), allowing it to escape a $173 million verdict for infringement. [Reuters, Jul 31, 15] ParkerVision has accused Qualcomm of being the chief impediment to the adoption of its wireless designs by the telecommunications industry. [Susan Decker, Bloomberg News]

Qualcomm disclosed plans to cut 15% of its workforce, reduce costs by $1.4 billion and consider changes to its corporate structure such as splitting its chip design and patent licensing businesses. .... in response to a nearly 50% drop in quarterly profit. [Don Clark, Wall Street Journal, Jul 22, 15]

Qualcomm is expected to reveal deep cost cuts that could lead to thousands of layoffs companywide. ... a 10 percent head count reduction is pretty typical,” said Tavis McCourt, an analyst. ... has 31,000 employees [utsandiego.com, Jul 21, 15]

Qualcomm retained its market share lead in supplying cellular radios that link smartphones to wireless networks, but competitors are making inroads. Qualcomm held 61 percent of the global 3G/4G cellular baseband market in the first quarter [Mike Freeman, utsandiego.com, Jul 6, 15]

Better coffee shop connections. new version of LTE is being developed and tested by mobile chip company Qualcomm and is called MuLTEfire. It encodes data in the same way as the LTE technology used by cellular networks today, but is designed to be used over the same part of the radio spectrum as Wi-Fi and has roughly the same range ... expects companies such as McDonalds that operate public Wi-Fi networks to install MuLTEfire hotspots to provide their customers faster and more reliable connections. [Tom Simonite, technologyrevieew.com, July 1, 2015]

Qualcomm Ias no plans to spin off its chips business at present, Executive Chairman Paul Jacobs said, despite recent investor pressure to do so amid intensifying industry competition. [Yahoo News, Jun 29, 15]

Qualcomm is joining a new partnership with Chinese chip maker Semiconductor Manufacturing International Corp aimed at boosting SMIC’s capability to make advanced chips. The move announced earlier this week comes after Qualcomm was hit with a $975 million fine by China’s anti-monopoly regulator this winter over its technology licensing practices. [Mike Freeman, utsandiego.com, Jun 25, 15]

Qualcomm has put a chunk of spectrum up for sale in Britain which could appeal to mobile operators grappling with the demand for Internet access. Qualcomm said it plans to sell spectrum known as L-Band which can be used to boost the downloading capacity that mobile operators provide to customers. [Reuters, Jun 7, 15]

Ten robotics companies from across the globe were selected to participate in the [Qualcomm] accelerator, where they will work on their products in 7,000 square feet of free lab space on Qualcomm’s campus. ... another example of Qualcomm’s push to get smartphone technology into adjacent markets ... participants are from [San Diego],San Francisco and New Jersey, as well as Singapore, Greece, Germany, Italy and the United Kingdom. [Mike Freeman, utsandiego, May 28, 15]

Qualcomm entered a strategic agreement with Mercedes-Benz maker Daimler AG to jointly explore wireless electric vehicle charging and other connected car technologies. The development deal – announced as part of a Formula One race in Monaco over the weekend – could help Qualcomm’s Halo wireless electric vehicle charging system gain a toehold with mainstream carmakers. [Mike Freeman, utsandiego.com, May 26, 15]

Qualcomm putting a large chunk of its $10 billion in newly issued corporate debt to work. ... is under pressure by an activist investor, said it has entered into accelerated share repurchase agreements with Goldman Sachs and Morgan Stanley to buy back $5 billion in the company’s shares. [Mike Freeman, utsandiego.com, May 21, 15] Turning from technology engine to financial engine, borrowing money for no investment purpose.

Qualcomm took on $10 billion in corporate debt to fund share buybacks and return some of its $29.5 billion cash stockpile to shareholders. ... At its annual shareholders’ meeting in March, Qualcomm committed to buying back $10 billion in stock over the next 12 months. At the time, the company said it would use available cash and debt to do it. .... A majority of Qualcomm’s cash is overseas and can’t be used to buy back shares without tax consequences. So the company is taking on debt instead. [Mike Freeman, utsandiego.com, May 13, 15]

Qualcomm has also parlayed its pioneering role in cellular technology into a patent-licensing business that generates most of its profits. Qualcomm charges a royalty on nearly every smartphone made, whether or not the device uses its chips. As a result, Qualcomm has reaped more than $50 billion in licensing revenues since 2000. ... BUT a cadre of competitors and customers hope to convince other standards groups [beyond IEEE] to change their policies in ways that could reduce royalty fees on technologies essential to ubiquitous consumer products like smartphones. [Don Clark , Wall Street Journal, Apr 13, 15]

Qualcomm is under pressure from activist investor Jana Partners LLC to consider a breakup and other options to boost the giant chip maker’s sagging stock price. Jana is asking Qualcomm to consider spinning off its chip unit from its patent-licensing business, which accounts for most of the company’s profit, according to a quarterly letter to Jana investors reviewed by The Wall Street Journal. Qualcomm itself proposed the idea 15 years ago but later called it off. [David Benoit and Don Clark, Wall Street Journal, Apr 13, 15]

Qualcomm (market cap $110B) raised its dividend by 14%

More competition. Samsung Electronics Co Ltd used more of its own chips to power the new Galaxy S6 smartphone than it did for the predecessor S5, according to an early teardown report, in a blow to U.S. chip supplier Qualcomm. Samsung is not only using its own Exynos mobile processor, as had been widely reported, but also decided to rely on its in-house semiconductor business to source other parts, including the modem and power management integrated circuit chips, Ottawa-based consultancy Chipworks said ... Qualcomm is the industry leader in LTE, the most advanced modem technology, but Samsung, Intel, MediaTek and others have developing their own offerings [Se Young Lee and Noel Randewich, Reuters, Apr 2, 15]

Qualcomm said it would buy back up to $15 billion of shares and raise its quarterly dividend. [Reuters, Mar 9, 15] returning a vast cash hoard to investors, instead of investing it in new enterprise.

Qualcomm unveiled Qualcomm Snapdragon Sense ID 3D Fingerprint Technology, which uses ultrasonic wavelengths to get a more accurate and complete, three- dimensional fingerprint scan. ... an upgrade from current technology, which uses capacitive sensors to essentially get a two-dimensional image of what’s touching it. ... It can actually see the pores in your skin to determine that it is skin” and not glue or some other material that’s trying to trick the sensor. [Mike Freeman, utsandiego.com, Mar 2, 15]

Qualcomm unveiled fourth-generation LTE modems that will enable cars to stay better-connected wirelessly to cloud-based services via the Web. Cars using the new technology should be on the market within a few years' time. [Paul Lienert, Reuters, Mar 2, 15]

Commercial drone maker 3D Robotics (Berkeley, CA; no SBIR) [ 200 employees in North America and more than 30,000 customers worldwide. ... previously raised $30 million in mid-2013] said that it has raised $50 million in additional venture capital, led by Qualcomm. [Mike Freeman, utsandiego, Feb 27, 15]

A former director of sales for Qualcomm pleaded guilty in San Diego to insider trading, officials said. [Reuters, Feb 19, 15]

KMel Robotics (Philadelphia, PA; no SBIR) has been acquired by Qualcomm Technologies. KMel's founders, two University of Pennsylvania graduates, announced the news on their company's website. ... Last month, local tech blogger Technical.ly reported that the DARPA was looking for a "tiny, speedy drone," and that it had its eyes on KMel. [Lauren Hertzler, Philadelphia Business Journal, Feb 3, 15]

Satellite Internet provider ViaSat has joined Qualcomm and Cisco as a potential investor/mentor in startups in the no-strings-attached EvoNexus incubator program. The company will examine companies admitted to EvoNexus for young firms that fit ViaSat’s interest — connected services, telecommunications technology and cyber security. It then could invest up to $250,000 in selected EvoNexus startup [Mike Freeman, utsandiego.com, Feb 12, 15]

Qualcomm said it agreed to pay China a fine of $975 million, ending a 14-month government investigation into anti-competitive practices. ... The deal also sees chip-maker Qualcomm lower its royalty rates on patents used in China, the company said in a statement. [Noel Randewich and Matthew Miller, Reuters, Feb 9, 15]

Home cooking. Qualcomm’s flagship chip won’t appear in a much-anticipated smartphone from Samsung Electronics Co. this year. But the reason may have more to do with competing technology from the South Korean company than with rumored problems with Qualcomm’s chips. [Don Clark, Wall Street Journal,Feb 1, 15]

Qualcomm down 10% [Jan 29, 15] after it cut the forecast for its yearly profit, citing shifting market share among smartphone makers. [Wall Street Journal]

Qualcomm disclosed it had awarded $95 million worth of special stock grants to its two top executives last year, citing aggressive attempts by rivals to recruit its senior managers. [Don Clark, Barron's, Jan 22, 15]

Qualcomm, the biggest supplier of chips used in smartphones, disclosed plans to compete against Intel and AMD in the market for semiconductor chips used in server systems. [Wall Street Journal, Nov 19, 14]

Qualcomm warned that an antitrust investigation and problems collecting royalties could harm its business in China next year and it also disclosed new regulatory investigations in the United States and Europe. China's expanding high-speed 4G network is driving demand for smartphones with leading-edge technology, but Qualcomm's opportunities have been clouded by an 11-month-old antitrust investigation there. [Noel Randewich, Reuters, Nov 5, 14]

Qualcomm said that it will launch a robotics accelerator aimed at funding entrepreneurs to create smart machines and robots. The win for Qualcomm is more processors sold. The robotics accelerator, which is powered by startup-mentoring program Techstars, will select 10 companies to participate. [Larry Dignan, CNET, Oct 13, 14]

Qualcomm ($1M SBIR before 1990) has pounced on U.K. connectivity chip specialist CSR PLC [formerly known as Cambridge Silicon Radio] in a £1.56 billion ($2.48 billion) takeover as the U.S. wireless-technology group seeks to expand its capabilities in the fast-growing area of Internet-connected devices. .... a near 57% premium to the U.K. company’s share price August 27. CSR rejected a takeover offer from Microchip Technology that month. [Rory Gallivan, Wall Street Journal, Oct 15, 14]

Computer graphics chip maker Nvidia said that it has filed patent infringement actions against Qualcomm and South Korea’s Samsung ... claims that Qualcomm and Samsung are using its technology in graphic processors – also known as GPUs – in smartphones and tablets, including the Galaxy S5, Galaxy Note 4 and Galaxy Tab 2, among others. .... this is Nvidia’s first attempt to assert its intellectual property in the mobile market, said Craig Berger, an analyst with Hedgeye Risk Management. [Mike Freeman, utsandiego.com, Sep 6, 14]

Qualcomm, the world's No. 1 mobile chipmaker, may face a European antitrust investigation in relation to a four-year-old complaint by a subsidiary of rival Nvidia Corp, three people familiar with the matter said [Foo Yun Chee, Reuters, Aug 26, 14].

A government newspaper says Chinese regulators have concluded Qualcomm, one of the biggest makers of chips used in mobile devices, has a monopoly. ... China's government has complained about the high cost of licenses for foreign technology [AP, Jul 25, 14] Well, the purpose of patents is to give the inventor a temporary monopoly.

Qualcomm said it has purchased startup Wilocity (Sunnyvale, CA; no SBIR), a bet that a high-speed wireless technology called WiGig will become a standard feature on smartphones and other products. Financial terms weren't disclosed. [Don Clark, Wall Street Journal, Jul 3, 14] Wilocity says it is delivering the world's first multi-gigabit wireless chipsets based on the new WiGig 60GHz and IEEE802.11ad standards for super high-speed downloads, docking, networking, and high definition video at over 10x today's typical Wi-Fi transmission rates. [company website]

A Florida federal judge has overturned a $173 million jury verdict against Qualcomm for patent infringement, saying the evidence in the highly technical case didn’t support the jury’s findings. .... ParkerVision won the jury award in the case, which centered on complex direct-down conversion transceivers. .... This may not be the final legal battle between the two companies. In May, ParkerVision filed a second patent infringement lawsuit against Qualcomm, claiming infringement of different patents than in the first case. [Mike Freeman, utsandiego.com, Jun 23, 14]

MediSafe, an Israeli company that makes a mobile medication management app for smartphones, won Qualcomm’s fourth annual global QPrize competition and $150,000 in seed investment money this week. Qualcomm established the QPrize contest to help young companies get their technologies off the ground. [Mike Freeman, utsandiago.com, Jun 11, 14]

Qualcomm will spin off its Gimbal proximity beacon unit – which has partnered with Padres and other Major League Baseball teams to power location-based services inside ballparks – into a stand-alone company. [Mike Freeman, utsandiego.com, May 1, 14]

Qualcomm’s [neuromorphic] chips won’t become available until next year at the earliest; the company will spend 2014 signing up researchers to try out the technology. But if it delivers, the project—known as the Zeroth program—would be the first large-scale commercial platform for neuromorphic computing. That’s on top of promising efforts at universities and at corporate labs such as IBM Research and HRL Laboratories, which have each developed neuromorphic chips under a $100 million project for DARPA. [Robert D. Hof, technologyreview.com, Apr 27, 14]

Qualcomm rasied its divided by 20%

Illumina the smartest. Almost 25 years after the Human Genome Project launched, and a little over a decade after it reached its goal of reading all three billion base pairs in human DNA, genome sequencing for the masses is finally arriving. It will no longer be just a research tool; reading all of your DNA (rather than looking at just certain genes) will soon be cheap enough to be used regularly for pinpointing medical problems and identifying treatments. This will be an enormous business, and one company dominates it: Illumina (San Diego, CA; $10M SBIR). ... sells everything from sequencing machines that identify each nucleotide in DNA to software and services that analyze the data. In the coming age of genomic medicine, Illumina is poised to be what Intel was to the PC era—the dominant supplier of the fundamental technology. [Eilene Zimmerman , technologyreview.com, Feb 18, 14] Other SBIR companies among 50 smartest: Cree (Durham, NC; $10M SBIR), Qualcomm (San Diego, CA; $1.5M SBIR), Arcadia Biosciences (Davis, CA, $200K SBIR).

China's anti-monopoly regulator said Qualcomm was suspected of overcharging and abusing its market position, allegations which could see the U.S. chip giant hit with record fines of more than $1 billion. [Kevin Yao and Matthew Miller, Reuters, Feb 19, 14]

Qualcomm is joining the 64-bit parade itself, with the introduction of its Snapdragon 410 processor and Long Term Evolution (LTE) modem chip set aimed at emerging markets such as China. The chip is expected to be available next year. [Mike Freeman, utsandiego.com, Dec 10, 13]

Qualcomm said it has begun selling Bluetooth proximity beacons that use the company’s Gimbal contextual awareness software to send and manage information. Shoppers must give their permission to be tracked and receive offers using the technology. The announcement comes just days after Apple rolled out its new iBeacon technology, which is being deployed in its 254 U.S. retail stores — possibly pitting Qualcomm and Apple against each other in the emerging retail beacon market. [Mike Freeman, utsandiego.com, Dec 9, 13]

Qualcomm said a Chinese government agency is investigating the chip maker under the country's antimonopoly law, a probe that comes amid rising tensions affecting U.S. companies in China. ..... the largest maker of processors and communications chips for mobile phones [Spenced Ante and Don Clark, Wall Street Journal, Nov 26, 13]

The Florida jury ordered Qualcomm to pay $173 million in damages to Jacksonville-based ParkerVision for infringing on patents related to semiconductors used in smartphones. [Mike Freeman, utsandiego.com, Oct 24, 13]

A Florida jury found that Qualcomm infringed on four patents from ParkerVision (Jacksonville, FL; no SBIR) for semiconductor chips used in smartphones. [Mke Freeman, utsandiego.com, Oct 18, 13]

The world’s largest smartphone chipmaker, Qualcomm, says it is ready to start helping partners manufacture a radically different kind of a chip—one that mimics the neural structures and processing methods found in the brain. [Dave Talbot, MIT technologyreview.com, Oct 10]

Qualcomm (San Diego, CA; $1.4M SBIR in the 1980s), the world's leading supplier of chips for cellphones, said it was raising its quarterly cash dividend by 40 percent and introduced a new $5 billion stock repurchase program. [Lianna Baker, Reuters, Mar 5, 13] ..... Irwin Jacobs, the former CEO and co-founder of Qualcomm, oversaw revolutionary innovations in wireless technology that laid the groundwork of today’s 3G mobile wireless standards. He was a professor of electrical engineering at MIT and later at the University of California at San Diego. Along with five colleagues, he commercialized Code Division Multiple Access (CDMA) technology.By figuring out how to share spectrum, their inventions have made cellular service more efficient and led to making the mobile Internet a reality. [Darrell West, Invention and the Mobile Economy, Brookings, Mar 2013] The Navy used to promote its SBIR contribution to Qualcomm without ever normalizing its contribution to something like a percentage of Qualcomm's capital investment at the time. But politics is often a rooster taking credit for the sunrise.

QualityMetric (Lincoln, RI)

QualityMetric (Lincoln, RI; $1.5M SBIR) got a $2M NIH SBIR Phase 2 to develop tools to measure the health of people with asthma [Mass High Tech, Oct 16, 07]

QualityMetric (Lincoln, RI) got two NIH SBIRs totaling $1.1M to develop uses for its computerized adaptive testing technology. ... QualityMetric executives say the company uses proprietary analytic methodologies to capture, benchmark, interpret and report on patient-based health information to use in the development of new treatments. [Mass High Tech, Nov 1,06] QM has had several Phase 1s and one prior Phase 2.

Qualtech Systems (East Hartford, CT)

Qualtech Systems [East Hartford, CT; $12M SBIR] "The first 10 years, if there were no SBIR program, there would be no Qualtech," Deb says. "If we only had product revenue, we wouldn't have a company." ... half the company's annual revenues of more than $3.5 million come from commercial licensing and commercial services. NASA is the biggest government client, at 40 percent of revenues, with the Pentagon another 10 percent. .... continued for nearly two decades, providing jobs for easily a dozen UConn engineering grads, attracting other young engineers from out of state, and retaining bright immigrants who come here to study, shows why these ideas have such appeal. [Mara Lee, Hartford Courant, Aug 10, 12] A touchy-feely story of a company dependent on government contracts with technology that has a low capital barrier to entry. What was the government thinking for two decades of "investment"? Where is the wealth-creating downstream economics for a respectable ROI? After maybe a couple of million in the first three years, why could not the company compete in its industry without government propping-up? The problem is that SBIR has too much money for its own good as the agencies feel forced to incorporate it into their mainline R&D which is too conservative for seeding disruptive innovation.

Qualtré (Marlborough, MA)

Nearly two years after it landed an $10 million round of funding, motion sensor maker Qualtre (Marlborough, MA; no SBIR) secured more funds, bringing the total amount raised to $26 million. [Patricia Resende, Boston Business Journal, May 20, 13]

Qualtré (Marlborough, MA; no SBIR) which makes solid-state silicon MEMS motion sensors, announced the closing of a $10 million round of financing to help launch products targeting both high-volume consumer and industrial applications.... Founded in 2008, the company took in $8 million in Series B financing in 2010, and $10 million last July [Don Seiffert, Mass High Tech, May 30, 12]

Qualtré (Marlborough, MA; no SBIR) an inertial sensor company has raised $10 million from venture capital backers ... after the company gave a successful demonstration of its silicon MEMS bulk-acoustic wave gyroscope, which Qualtré said it intends to commercialize, ... cheaper to make and more accurate than current sensors [Michelle Lang, Mass High Tevh, Jul 8,11]

Qualtré (Marlborough,MA; no SBIR) an inertial sensor company, has taken in $8 million in a Series B financing round ... solid-state multi-axis MEMS gyroscopes are intended for use in game controllers, mobile handsets and digital camera imaging. [Mass High Tech, Apr 22, 10]

Quantapore (Menlo Park, CA)

a $35 million investment will allow Quantapore (Menlo Park, CA; no SBIR, four employees) to prove that its experimental system indeed is better than existing technology. .... technology allows for all-important longer "reads" — DNA sequences that help researchers see how genetic material is organized — that could provide crisper views of the DNA and, as a result, give a doctor more accurate information on which to base a patient's course of treatment. [Ron Leuty, San Francisco Business Times, May 21, 14]

Quanterix (Cambridge, MA)

Quanterix (Cambridge, MA; $200K SBIR) up 29% [Sep 28, 2022]

Quanterix (Cambridge, MA; one SBIR) down 55% [Aug 9, 22]

Quanterix (Lexington, MA; one SBIR) up 23% [Nov 7, 19] reported quarterly results

The Scientist strives annually to identify the latest and greatest tools, technologies, and techniques to hit the life-science landscape. This year’s selection includes Quanterix (Lexington, MA; $200K SBIR) brought its Simoa biomarker detection technology to the lab bench, launching the compact SR-X system; Promega (Madison, WI; $5M SBIR) new protein detection system excels at measuring protein levels across the cell; and Dharmacon (Lafayette, CO; $1.6M SBIR) launched on the market in June 2017, instead provides users with an arrayed library of synthetic crRNA guides with a “one-well-per-gene” format, allowing for a much subtler assay. [The Scientist, Nov 30, 17] .

Quanterix (Lexington, MA; one SBIR) secured $46 million in Series D financing ...was working on early detection of things like cancer and neurological diseases through its single-molecule testing system that measures trace quantities of proteins in the blood. ... has since expanded into other areas such as cardiology, inflammation, immunology, and infectious diseases. [Gregory Huang, xconomy,com, Mar 23, 16]

Two companies have identified promising biomarkers and are devising and evaluating diagnostic tests to quickly diagnose concussions. A blood test that could quickly detect a brain injury and measure the damage it has done could help doctors provide better care for the millions of people suffering from such injuries. ... Quanterix (Cambrige, MA; $200K SBIR) claims its technology for detecting biomarkers in the blood requires only a single target molecule to generate a signal, whereas conventional systems need millions of molecules. ... Banyan Biomarkers (Alachua, FL; $1.1M SBIR) claims “we are in fact on the cusp of a revolution” in understanding how to noninvasively diagnose traumatic brain injury using both blood biomarkers as well as new imaging techniques. [Mike Orcutt, technology review.com, Aug 27, 15]

Quanterix (Lexington, MA; no SBIR) specializing in technology designed for the early detection of diseases, said that it has closed an $18.5 million Series C financing. .... also entered a strategic agreement with bioMerieux, a French company that plans to use Quanterix’s Simoa technology to develop specialized tests that focus on infectious diseases. ... bioMerieux has taken an initial $15 million equity stake in Quanterix. [Chris Reidy, Boston Globe, Nov 15, 12]

A molecule in a haystack. Quanterix (Cambridge, MA; one SBIR) won a [$250K] contract from the Department of Homeland Security to develop a test for the botulinum toxin that would be sensitive enough to find a single molecule in a sample. ... Founded in 2007, Quanterix has received $26 million in two rounds of financing [Rodney Brown, Mass High Tech, Dec 1, 11]

On the same day it announced a new partnership with Stratec Biomedical AG of Germany (Cambridge, MA; one SBIR) filed a federal document showing it has closed on $6 million of a new open-ended financing. ... makes an array system for molecular diagnostic tests ... will co-develop and manufacture a fully automated instrument for Quanterix’s Single Molecule Array (SiMoA) technology for both the life sciences and in vitro diagnostics (IVD) markets. [Rodney Brown, Mass High Tech, Aug 22, 11]

Drug discovery services company Quanterix (Cambridge, MA; no SBIR) closed a $10 million second tranche of a Series A funding round, according to online reports. Quanterix’s providers systems to analyze molecules and cells to find new drugs and make tests for diseases. It was spun off from Tufts University with technology developed by a chemistry professor-turned-entrepreneur, David Walt. [Mass High Tech, Aug 25]

QuantTera (Scottsdale, AZ)

QuantTera (Scottsdale, AZ; $1.4M SBIR) won [one of 18] tiny Arizona Commerce Authority grants to help develop functional cost effective nano-engineered photonic devices for telecommunications and power efficient wireless applications. ... This could entail training to compete “more effectively” for federal [SBIR/STTR] funding programs. ... The big winner Prime Solutions Group [a systems engineering and IT services company that provides consulting expertise to government and defense contractors] received AZ Fast Grant awards this year and in 2013. The company recently secured $1 million in federal funding from the U.S. Department of Defense with the help of the grant program. [Hayley Ringle, Phoenix Business Journal, Jul 10, 14] Politicals handing out money to help get bigger political money.

QuantRx Biomedical (Tualatin, OR)

QuantRx Biomedical (Tualatin, OR; no SBIR) announced its intentions to buy Global Cancer Diagnostics (Tempe, AZ; no SBIR) which produces a blood test for lung cancer. ... actually a reverse merger, which will allow Global Cancer Diagnostics to be publicly traded ... [CEO] Gartner's lung cancer test is based on similar technology he used to launch his breast cancer blood test several years ago. [Angela Gonzales, Phoenix Business Journal, Oct 5, 15]

Quanttus (Cambridge,MA )

startup Quanttus (Cambridge, MA; no SBIR) hopes to offer such insights [such as how your body is recovering from yesterday’s workout] with a smart-watch-like gadget that continuously tracks heart rate, respiration, and blood pressure, which are difficult to measure accurately with a wrist-worn device. .... in the early prototype phase, doesn’t yet have a release date, price, or even a name. [Rachel Metz ,technologyreview.com, Feb 19, 14]

Quantum Circuits (New Haven, CT)

Quantum Circuits (New Haven, CT; no SBIR needed, Yale spinout founded 2015) has raised $18M in Series A to build and sell the first practical and useful quantum computers. ... The Yale team has pioneered the field of quantum computing with superconducting circuits, introducing the transmon qubit and techniques for distributing quantum information on wires, and performing the first quantum algorithms and quantum error correction in integrated circuits. QCI is developing its computers based on a proprietary approach for error-correcting quantum bits that is hardware-efficient and requires significantly less redundancy. [company press release, Nov 13, 17] Meanwhile, Three giants of the tech world — Google, IBM, and Intel — are using a method pioneered by Mr. Schoelkopf, a Yale University professor, and a handful of other physicists as they race to build a machine ... In recent months, after grabbing a team of top researchers from the University of California, Santa Barbara, Google indicated it is on the verge of using this method to build a machine that can achieve “quantum supremacy” [Cade Metz, New York Times, Nov 14, 17] .... The firm joins startup Rigetti Computing (Berkeley, CA; no SBIR, founded 2013), which we've profiled in the past, as an underdog—but both still stand a chance of beating IBM et al. [MIT technologyreview.com, Nov 14, 17] It's the kind of opportunity too big for SBIR - yuuuge payoff if it works, big fast money needed up front, introduction to serious money and talent for fast exploitation if it works.

Diamond Technologies (Somerville, MA)

Quantum Diamond Technologies (Somerville, MA; $1.7M SBIR) reports A novel approach to testing for the presence of the virus that causes Covid-19 may lead to tests that are faster, less expensive, and potentially less prone to erroneous results than existing detection methods. Though the work, based on quantum effects, is still theoretical, these detectors could potentially be adapted to detect virtually any virus, the researchers say. [David L. Chandler, Massachusetts Institute of Technology Dec 20, 2021]

Quantum Epitaxial Designs (Bethelehem, PA)

Quantum Going Public. The DOD SBIR isn't completely dead. One firm with only $1.7M of SBIR 1991-1996, including 5 Phase 1s from BMDO, will go public this week. Quantum (Bethlehem, PA), which has only $7M in sales, up 35% from last year from several industrial customers for its compound semiconductors, is priced to raise $20M for 40% of the company

Quantum Fuel Systems Technologies Worldwide (IrvineCA)

Quantum Fuel Systems Technologies Worldwide (Lake Forest, CA; one SBIR in 2005) up 36% [Feb 9, 15] announced it has developed a technologically advanced in-house test and validation facility that is unique for testing its CNG fuel storage modules intended for over-the-road heavy-duty trucks. [company press release]

Quantum Fuel Systems Technologies Worldwide (Irvine, CA; one SBIR) down 10% after it filed to sell as much as $75 M of stock, preferred stock and warrants. [Wall Street Journal, Jul 8, 08]

A new contract helped Quantum Fuel Systems Technologies (Irvine, CA; one SBIR) gain 16% ... propulsion-systems company said its German solar partner Advanced & Automotive Solar Systems GmbH received a $17 million contract from Sunworx GmbH for silicon photovoltaic-solar modules. [Wall Street Journal, May 28, 08]

Quantum Fuel Systems Technologies Worldwide (Irvine CA; one SBIR) intends to have its first car, a four-door plug-in hybrid vehicle, on the market in the U.S. by 2009 [Wall Street Journal, Oct 29]

Quantum Logic Devices

From the Texas Emerging Technology Fund, Image Trends (Austin, TX; no SBIR) which develops image correction and enhancement products for commercial and amateur photographers will receive $1 million, and RFMicron (Austin, TX; no SBIR) $250,000 to speed development of its microchip technology [Lori Hawkins, Austin American-Statesman, Jul 14, 08] Og ten central TX companies fed from the fund, only one has failed so far: Nanocoolers (no SBIR) Tried to create a thermoelectric cooling system that would help cool semiconductors. Closed in 2007. The others: Molecular Imprints Inc. Nanotechnology company that makes advanced equipment used in producing computer chips, disk drives and other products. Monebo Technologies (no SBIR) Heart monitoring device called CardioBelt that enables users to obtain their own electrocardiogram while at home. Quantum Logic Devices ($1+M SBIR, moved from NC) Developing a system that uses single-electron devices to analyze DNA, protein and other molecular interactions. Receptor Logic Ltd. (no SBIR) Developing antibodies to improve understanding of the immune system and lead to better drugs and vaccines. Xitronix(no SBIR) Developing advanced semiconductor testing technology. XTreme Power (no SBIR) Developing electrical storage systems that are used to cut energy bills for commercial and industrial plants.

Quantum Materials (Austin, TX , from Kingston, OK)

Leading North American quantum dot manufacturer Quantum Materials (San Marcos, TX; one SBIR in 1993) announced that the company has entered into a joint venture with Guanghui Technology Group whereas GTG will invest $20 Million US for building out Quantum Materials QDX™ quantum dot production facilities and quantum dots application development in China. [company press release, Jan 27, 16]

Quantum Materials (San Marcos, TX; one SBIR, founded 2008, 14 employees) reported raising $490,000 of a planned $2 million financing. ... commercializes quantum dots used in flat-screen displays, solid-state lighting, solar and biotech manufacturing industries. [Christopher Calnan, Austin Business Journal, Apr 29, 15]

Quantum Materials (San Marcos, TX; no SBIR, founded 2008, eight employees) has bought five sets of patent families from Germany-based Bayer Technology Services GmbH. ... provide broad intellectual property protection for Quantum Materials’ advances in economical, high-volume quantum dot manufacturing, according to a company statement. [Christopher Calnan, Austin Business Journal, Aug 20, 14]

Join the industry. Quantum Materials (Kingston, OK; no SBIR, founded 2009) has chosen the greater Austin area to relocate headquarters and to establish the company's R&D labs. After considering attractive proposals from Texas, North Carolina and Florida, .. decided that Austin's "Silicon Hills" offers superior business advantages to emerging companies in both the nanotech and biotech fields.... Both [CEO] Fluke and his company’s core technical team formerly worked at Silicon Laboratories (Austin, TX; no SBIR), which formerly developed cell phone amplifiers. [company press release, Apr 22, 13]

QuantumScape (San Jose, CA)

Bill Gates's Breakthrough Energy Ventures (BEV) aims to invest $1 billion into radical energy startups capable of drastically cutting global emissions. The investees: QuantumScape (San Jose, CA; no SBIR, founded 2010, total funding $100M) building an all-solid-state battery; Commonwealth Fusion Systems (Cambridge, MA; no SBIR, founded 2017, total funding $65M) nuclear-fusion reactor that uses high-temperature superconductors and aims to be the first fusion system to produce net-positive energy ; Pivot Bio (Emeryville, CA; one SBIR, founded 2010, total funding $17M) microbial solution that can replace nitrogen fertilizers; CarbonCure (Canada, founded 2007, total funding $9M) trapping carbon dioxide in concrete blocks, while endowing them with greater strength than conventional concrete; Fervo Energy (San Francisco, CA; no SBIR) rethinking geothermal power with the help of modern computational models and horizontal-drilling; DMC Biotechnologies (Boulder, CO; $900K SBIR, founded 2017, total funding $2M) tailoring microbes to produce high-value chemicals, including biofuels; Zero Mass Water (Scottsdale, AZ; founded 2014, no SBIR) specialized panels that use solar power and batteries to pull water from the air. [Akshat Rathi, Quartz, Sep 26, 18]

QuantumScape (San Jose, CA; no SBIR), a cleantech battery maker, is expanding its operations in San Jose near the city's airport with a large new lease at a building where it could potentially employ 350 or more people. [George Avalos, Oakland Tribune, Jun 25, 13]

QuantumSphere (Santa Ana, CA)

QuantumSphere (Santa Ana, CA; one Phase 1 SBIR) is approaching nanotechnology on a broad scale by making an array of catalysts that allow batteries to operate for longer periods, electronic displays to be manufactured at lower costs and ammonia fertilizers to be produced using less energy while also generating less carbon dioxide. ... got its start with $100,000 investment from two angel investors: Jon Faiz Kayyem, a trustee of California Institute of Technology, and Marc H. Goroff, who has a doctorate from Caltech and is the founder of several companies. [James Flanigan, New York Times, Jul 16, 09]

Quantum Xchange (Bethesda, MD)

“China has a very deliberate strategy to own this [quantum conputing] technology,” said Duncan Earl, a former researcher at Oak Ridge National Laboratory who is president and chief technology officer of Qubitekk (Vista, CA; $200K SBIR, founded 2012) exploring quantum encryption. “If we think we can wait five or 10 years before jumping on this technology, it is going to be too late.” .... A second start-up, Quantum Xchange (Bethesda, MD; no SBIR, founded 2018, total funding $10M [crunchbase.com]), is building a quantum encryption network in the Northeast, hoping to serve Wall Street banks and other businesses. Researchers at Stony Brook University on Long Island are preparing a third venture. [Cade Metz and Raymond Zhong, New York Times, Dec 3, 18]

Quark Biotech (Fremont, CA)

Quark Biotech (Fremont, CA; one Phase 1 SBIR) filed for IPO.

Quark Pharmaceuticals (Fremont, CA)

Quark Pharmaceuticals (Fremont, CA; no SBIR) raised $10 million in venture funding.... working on drugs for two eye disorders: wet age-related macular degeneration and diabetic macular edema. It’s also developing a treatment for use with kidney transplantation. [Stephen EF Brown, San Francisco Business Times, Jun 17,10]

Qubitekk (Vista, CA)

QQuench Bio (Cambridge, MA)

Quench Bio (Cambridge, MA; no SBIR) leveraging new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, announced the completion of a $50 million Series A financing .... Quench Bio's lead therapeutic approach centers on inhibiting Gasdermin D, which has been recently discovered as a key target at the core of multiple inflammatory cell death pathways, including pyroptosis and NETosis. [company press release, Jan 27, 20]

Quentis Therapeutics (New York, NY)

Quentis Therapeutics (New York, NY), a biotech pursuing next-generation immuno-oncology research and drug development, debuted with the completion of a $48 million Series A financing [for] pioneering first-in-class cancer immunotherapies that modulate endoplasmic reticulum (ER) stress response pathways in the tumor microenvironment. .... born from the lab of former Weill Cornell Medicine dean and immunologist Laurie Glimcher. [company press release, Feb 27, 18]

QuEra Computing (Boston, MA)

QuEra Computing (Boston, MA; $300K SBIR) At long last, physicists from Harvard and MIT have found the killer application for quantum computing: a Mario Bros. GIF made from qubits. ... emerging from stealth, to show off the programmability of their 256-qubit quantum simulator—a special-purpose quantum computer built for solving certain types of problems. [Siobhan Roberts, MIT Tech Rvw, Nov 17, 21]

Quidel (San Diego, CA)

Quidel up 32% [May 11, 20]

Quidel (San Diego, CA; one SBIR in 2004), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received Emergency Use Authorization (EUA) from [FDA] to market its Sofia® 2 SARS Antigen FIA, a rapid point-of-care test to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid detection of SARS-CoV-2 in nasal or nasopharyngeal specimens from patients meeting the Centers for Disease Control and Prevention’s (CDC) criteria for suspected COVID-19 infection. [company press release, May 9, 20]

Quidel (San Diego, CA; no SBIR, founded 1979) said it has received regulatory clearance to sell a test to detect respiratory viruses. .....In early 2010, acquired Diagnostic Hybrids (Athens, OH, $500K SBIR) as part of a continued focus on increasing its research and development efforts to accelerate the rate of new product introductions. [Bradley Fikes, utsandiago.com, Mar 12, 13]

A day after announcing a 4 million-share stock sale, medical-testing company Quidel (San Diego, CA; one SBIR) said Thursday it will price each share at $13.15. Existing shares of Quidel fell $1.20, or 8 percent, to $13.23. The offering could raise $52.6 million for the company, which plans to spend the funds on acquisitions, debt repayment and other purposes. [Keith Darce, signonsandiego,com, Jan 6, 11]

diagnostic test maker Quidel (San Diego, CA; one SBIR) announced plans to buy the privately held Ohio diagnostics company Diagnostic Hybrids (Athens, OH; $500K SBIR) for about $130 million. [Thomas Kupper, San Diego Union Tribune, Jan 12, 10]

Quick–Med Technologies (Boca Raton, FL)

A team of UF professors and alumni, sponsored by Quick–Med Technologies (Boca Raton, FL; no SBIR), has created a new adhesive bandage that repels bacteria and promotes faster healing. The product, which received FDA approval last week, will be sold in stores come July and will aid in the creation of anti–bacterial military clothing and more effective hand gels. Known as the NIMBUS, the bandage is the first and only non–leeching, microbicidal barrier dressing. [alligator.com, Mar 5,09]

Quid (San Francisco, CA)

Artificial intelligence company Quid (San Francisco, CA; no SBIR, founded 2010) raised $39 million in Series D funding to expand its product and engineering capabilities. ... has 80 clients after launching its current platform at the beginning of 2014 [Gina Hall, Silicon Valley Business Journal, Mar 19, 15]

Quincy Bioscience (Madison, WI)

Quincy Bioscience (Madison, WI; no SBIR) that makes an anti-aging dietary supplement from jellyfish protein has raised $250,000 ... The investment brings to $1.5 million the amount has raised in a planned $3 million funding round ... markets an anti-aging dietary supplement called Prevagen at Rite-Aid stores, more than 1,000 independent health food stores, and through its own website. [Kathleen Gallagher, Milwaukee Journal Sentinel, Aug 26, 10]

Quincy Bioscience (Madison, WI; no SBIR, founded 2004) said it has received a patent on its use of a protein derived from jellyfish that it uses for products to fight the aging process. The patent covers the use of aequorin-related compounds for preventing and alleviating symptoms and disorders related to calcium imbalance [Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 8, 10]

Quintessence Biosciences (Madison, WI)

Quintessence Biosciences (Madison, WI; $0.4M SBIR) will use ($0.9M SBIR) to support development of more drugs based on its Evade Ribonuclease technology, the company said.... has similar products in pre-clinical research, the company said. [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 4, 09]

Rising Star. When Laura Strong set out in 2000 to forge a licensing agreement and raise money for a young Madison biotech company, there were no programs or networks set up to help. Strong and her colleagues at Quintessence Biosciences (no SBIR) managed to get the license and raise angel capital, ... accomplishments earned Strong one of five Rising Star awards at the Wisconsin Biotechnology and Medical Device Association.... Speakers came from state companies such as Cellectar (no SBIR), Platypus Technologies ($6M SBIR), Third Wave Technologies ($6M SBIR), and TomoTherapy ($1M SBIR) [Kathleen Gallagher, Milwaukee Journal Sentinel, Oct 19] The other companies prove that there was indeed help available for Quintessence, SBIR and the state had an active program in helping companies pursue federal funding. HHS, the natural source of SBIR for bio work, seems to have a good track record of helping young companies with markets in their eyes.

Quorum Systems (San Diego, CA)

What China can do is trade its dollars for US business capacity: Quorum Systems (San Diego, CA; no SBIR), maker of radio-frequency chips for mobile phones, has agreed to be acquired by China-based Spreadtrum Communications for $70M in cash and stock. [Mike Freeman, San Diego Union Tribune, Nov 20] Just as worried about Japan Inc in the 1980s, we can worry about China Inc now. The long term solution is to restore America's financial strength, which unfortunately requires biting too many bullets for the politicians to ask for. No, we have to tell our politicians that we want sensible management, not pandering to our illusions.

QPixel (Cupertino,CA)

Qpixel Technology, a Cupertino chip company, is the latest to benefit from excitement surrounding video sharing. It specializes in low-power digital video and audio compression, and has just raised $25 M in its second round of funding. ... One True Media is a new Silicon Valley start-up (Redwood City) that is offering video creation tools, and wants to be the next video-sharing company. There are dozens of competitors, so this is a long shot. [siliconbeat.com, Jun 16]

QurAlis (Cambridge, MA)

QurAlis (Cambridge, MA; $200K SBIR), a biotech company focused on developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurologic diseases,announnced the raise of a $42 million Series A financing, bringing the total funds raised to $50.5 million. [company press release, May 13, 20]

QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ

RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR

Radant Technologies

Radant Technologies (Stow, MA; $1.5M SBIR) landed a $14 M deal from the U.S. Navy for submarine communication antenna radomes and related engineering services [Mass High Tech, Jan 21]

Radiabeam Technologies (Santa Monica, CA)

The rest of DOE,'s Phase II list also shows a preference for SBIR experience: Euclid Labs (Solon, OH; $18M SBIR since 2004, all DOE including one $10M award), four new Phase IIs; Radiabeam Technologies (Santa Monica, CA, $10M SBIR since 2005 SBIR) three awards; Tech-x (Boulder, CO; something over $50M SBIR since 1994) three new awards Muons (Batavia, IL; $13M since 2002 SBIR, all DOE) three awards; Far-Tech (San Diego, CA;$9+M SBIR since 2003) two awards;Ridgetop Group (Tucson, AZ; $10M SBIR since 2002) two awards; Calabazas Creek Research (San Mateo, CA; $26M since 1994) two awards; Niowave (Lansing, MI; $5M since 2007 SBIR) two awards; Mesa Photonics (Santa Fe, NM; $0.8M since 2008 SBIR) two awards; Green Mountain Radio Research ( Colchester, VT; $5.7M SBIR) two awards. Of 104 awards, 33 went to multiple winners who already had collected $378M SBIR from the federal government. Is DOE over-emphasizing contractor competence at the expense of companies and technologies with brighter futures? No one knows becasue Congress shows little interest in the question, and the agency has a bias toward making itself smarter.

Radiance Technologies (Huntsville, AL)

Getting closer to the flagpole. Fresh off winning a spot on that massive U.S. Air Force[ $960 million support contract] intelligence contract late last week, Radiance Technologies (Huntsville, AL; $19M SBIR) already is looking to grow its footprint in the Dayton region. [Joe Cogliano, Dayton Business Journal, Oct 10, 14]

Radiant Photonics (Austin, TX)

Radiant Going for Broke (Nov 14) Radiant Photonics (Austin, TX) is going into bankruptcy when its second round of financing fell into the hole created by the WTC collapse. Or at least something spooked the four investors who were discussing a term sheet CEO Markwardt says that major changes to its business strategies in the works, and they are discussing its options with about seven companies and investment groups. [Austin Business Journal, Nov 12, and Fred Patterson for reporting it] Radiant was/is the spin-off of Radiant Research, a creation of Ray Chen and a winner of a fistful of BMDO Phase 2 SBIRs, all premised on the market potential. Indeed, the first round of finance proved that BMDO had done the right thing in seeding the technology at Radiant. Alas, the collapse of a second round coupled with the collapse of BMDO's market philosophy means a dark day for photonics entrepreneurs.

Radiant Gets $18M. (Sep 26) Radiant Photonics (Austin, TX) got its first round of investment, $18M to expand its production capabilities for Optical Networking. The tranche was led by Adam Smith Investment Partners and KLM Capital with Intel Capital and Ridgewood Capital. Radiant is a venture of Ray Chen's Radiant Research, a semi-academic firm that Ray started and nourished with BMDO SBIR. BMDO no doubt forced the investment issue by continuously raising the co-investment requirement for further SBIR money, which is what SBIR should be doing. BMDO would say, "either convert your past promises to real investment or stop predicting any future investment. Ray started SBIR life as the main PI at Physical Optics, a huge SBIR user. Optics is as hot as an investment topic can get, with Forbes ASAP devoting its whole August issue to it. The predictions of riches abound. With the right kind of luck, Radiant could fall into the enriching clutches of the fiber backbone competitors Lucent and Nortel as CoreTek did for $1.4B.

Radiation Monitoring Devices (Watertown, MA)

Aerodyne Research

(Billerica, MA; 199 SBIR Phase Is and something like $80M total SBIR) will receive five $1-million DOEnergy [SBIR Phase II] grants, and Radiation Monitoring Devices (Watertown, MA; 404 SBIR Phase Is and something like $150M SBIR) will receive three $1 million grants, the department said. ... Other local companies in line to receive Energy Department grants: Conispire (Boston, MA: no SBIR) , Aspen Products Group (Marlborough.MA; $5.6M SBIR), Capesym (Natick, MA; $5.3M SBIR); Nova Scientific (Sturbridge, MA; $9M SBIR); Beacon Power (Tyngsborough, MA; $1M SBIR), the department said. [Chris Reidy, Boston Globe, Jun 29, 12]

Radiation Monitoring Devices (Watertown, MA; $90M SBIR; and RMD Instruments, both photonics-related instruments companies have been acquired for $20 M by Dynasil, a photonics manufacturer for instruments, optical materials, coatings and components. [Mass High Tech, Jul 3, 08] Another SBIR mill bought for a small fraction of the SBIR "investment", and this is one company that was at least worth something after all those SBIRs. All the political bleating about how crucial small companies are to America is only half true; they are important but SBIR does nothing except shift government R&D for small companies from one list of winners to a different list of winners doing the same thing. And there is still no compelling evidence that SBIR has had any economic impact that wouldn't have happened anyway.

Loving Experience. Scientific Systems (Woburn,MA; $50M+ SBIR) won a NASA JPL Phase 2 SBIR for Distributed Formation State Estimation Algorithms Under Resource and Multi-Tasking Constraints. Creare (Hanover NH; $120M SBIR) won four NASA JPL Phase 2 SBIRs. Intelligent Automation (Rockville MD; $100M SBIR) won three NASA JPL Phase 2 SBIRs. Physical Optics (Torrance, CA; $200M SBIR) won one NASA JPL Phase 2 SBIR. Radiation Monitoring Devices (Watertown, MA; $90M SBIR) won one NASA JPL Phase 2 SBIR. Etc, etc, etc. A zillion start-ups all over America got letters saying there was not enough money to nurture their ideas.

RadioMedix (Houston, TX)

RadioMedix (Houston, TX; no SBIR) won $2.8 million from the Texas Emerging Technology Fund. [Austin American Statesman, Feb 10, 11]

Radius Health (Cambridge, MA)

Radius Health (Waltham, MA; no SBIR) announced that it’s submitted an application for U.S. approval of its drug for osteoporosis with which it hopes to take on the $1.5 billion a year drug, [Lilly's] Forteo. .... went public in June 2014 for a modest $56 million, and 12 months later it was the top performing IPO in any industry, said [CEO] Ward, who worked at AstraZeneca before coming on as CEO in late 2013. [Don Seiffert, Boston Business Journal, Mar 30, 16]

Apps are endless and IPOs dragging. The volatile market for biotechnology stocks has apparently taken a victim, with Cambridge’s Radius Health Inc. announcing it has halted its planned initial public offering. ... Founded in 2003, Radius Health has raised at least $241 million in private funding. [Kyle Alspach, betaboston,com, May 9, 14] Meanwhile app-makers had another carnival. I was walking around an expo touted as the “world’s largest startup event” last month, when I started to have flashbacks to the late 1990s. At New York TechDay, there were so many booths staffed by so many eager entrepreneurs pitching so many ideas that only needed a few million bucks and a few million users to become a real business. .... I am starting to see a lot of people leaving well-paid, white collar jobs to create mobile apps and websites. [Scott Kirsner, Boston Globe, May 9]

Radius Health (Cambridge, MA; no SBIR) has set [IPO] terms ... developer of a new treatment for bone-loss disease has filed plans showing it aims to raise up to $92 million .... to fund the clinical development of Radius Health’s advanced product candidates, which include an injection for treating the bone disease osteoporosis. ... has raised at least $241 million in funding to date [Kyle Alspach, betaboston.com, Apr 24, 14]

Radius Health (Cambridge, MA; no SBIR) biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women’s health conditions, said that it has completed a new equity financing of $43 million. [Boston Globe, Apr 25, 13]

Radius Health (Cambridge, MA; no SBIR) biotech that has raised at least $198 million in financing, filed to go public in an offering that could raise up to $86.2 million..... developing new treatments for osteoporosis and other women’s health conditions. The company is not generating revenue and had a $42.4 million net loss in 2011, according to the company’s IPO-intentions filing with the SEC. [Kyle Alspach, Boston Business Journal, Feb 7, 12]

Radius Health (Cambridge, MA; no SBIR) biotech focused on osteoporosis and women’s health, has brought in $27.65 million in closing the second tranche of a $91 million funding round announced in May. ... to support its osteoporosis therapeutics program through a Phase 3 clinical trial of its bone-building injection drug, BA058, which it plans to market in the U.S. and Europe. [Michelle Lang, Mass High Tech, Nov 23, 11]

Rafagen (Montgomery County, MD)

Montgomery County [MD, a competitor for America's richest county] will dole out $500,000 to investors in 10 life sciences companies through its coveted biotech tax credit, a fifth of which will go to backers of diagnostics company DioGenix (Gaithersburg, MD; no SBIR) ... piggybacks on the $3.5 million in tax credits from the state to those same 46 investors. The incentives are tied to a total $7 million in private biotech investments in the county last year. Also receiving the credits are backers of 20/20 GeneSystems (Rockville, MD; $4.6M SBIR, incl one of $3.3M), Alper Biotech LLC, American Gene Technologies International Inc., BeneVir Biopharm Inc., ConverGene LLC, Creatv MicroTech (Potomac, MD; $11.6M SBIR)., Rafagen Inc., Sequella (Rockville, MD; $10.3M SBIR). and SynAm Vaccine. [Bill Flook,Washington Business Journal, Feb 28, 14]

Rainbow Organic Farms

USDA has a less showy newsletter the latest issue of which notes that Diana Endicott, of Rainbow Organic Farms Co. has been a recipient of the National Agriculture Hall of Fame’s Honor Acre, the SBIR Tibbetts Award and multiple USDA SBIR awards for her work in developing new and innovative ways to bring together the resources, commitments and support for small farmers to produce and sell their products to the retail market. Which sounds like USDA SBIR funds ag marketing.

RainDance Technologies

RainDance Technologies (Billerica, MA; $1.2M SBIR) said that it doesn’t expect to be profitable until 2017, the company disclosed in federal filings ... sells genetic sequencing machines intended for research purposes, expects to raise $60 million through its [IPO] ... While sales have been promising, much of RainDance’s financial success is based on a small number of customers. Myriad Genetics (Salt Lake City, UT; $200K SBIR) molecular diagnostic company, represented 51 percent of the company’s total revenue in 2014. [Jessica Bartlett, Boston Business Journal, Mar 31, 15]

Edico Genome (La Jolla, CA; no SBIR, founded 2013) took first place [in The Scientist top ten innovation list] for its Dragen Bio-IT Processor. The add-on card accelerates the analysis of genomic data by a factor of 30, says Pieter van Rooyen, Edico's president and chief executive. .... Genome sequencers from Illumina took second and third place [Bradley Fikes, utsandiego.com, Dec 1, 14] Other winners: BioNano Genomics, RainDance Technologies (Lexington, MA; $1.1M SBIR) , Leica Microsystems, Organovo (San Diego, CA; $300K SBIR), Haplogen Genomics, Immucor, Sciencescape. [The Scientist, Dec 1, 14]

RainDance Technologies (Lexington, MA; $1.2M SBIR), a provider of microdroplet-based tools for single molecule and single cell analysis, announced that it has closed a $37.5 million Series D financing round. ... for new applications for its commercial targeted sequencing and sequence enrichment solution in the medical genetics and research markets, .. founded in 2004 by scientists from Harvard University, The Medical Research Centre in Cambridge, England, and the ESPCI in Paris [Lynette Cornell, Mass High Tech, Jan 25, 11]

drug discovery toolmaker Raindance Technologies (Lexington, MA; $400K SBIR) has raised $6 million of a proposed $12 million round, according to official documents. ... makes and sells microdroplet-based devices and related tools to accelerate human health and disease research. [Mass High Tech, May 8, 09]

RainDance Technologies (Lexington, MA; one SBIR), provider of droplet-based tools for life sciences research, reports it has formed a wholly owned subsidiary in France. [Mass High Tech, Jul 10]

RainDance Technologies (Guilford, CT; $300K SBIR) will move to Lexington. The company said its new 28,000-square-foot facility in Lexington is double the size of its current location and will employ 65 people by the end of the year. The four-year-old firm's "microdroplet" technology is used to help sequence the human genome at greater speeds. [Todd Wallack, Boston Globe, May 20]

RainStorm (Orono, ME)

Maine Technology Institute today announced four new Development Awards — conditional loans — totaling $761,348 for four Maine technology companies. The awards by MTI, a publicly financed non-profit, were matched with combined contributions over $890,047 by the recipients: Wizbe Innovations (Manchester, ME) $64,000 to develop parachute fabric for the U.S. Army with controllable and adjustable permeability. Wizbe initially began their work with a U.S. Army SBIR to develop a prototype fabric. ... Pika Energy (Gorham, ME; no SBIR) $274,291 to develop a wind turbine system that offers lower upfront costs to make it easier and less expensive for families and businesses to produce clean renewable electricity. Early stage development was supported with an MTI Seed Grant. ... Cerealus Holdings(Waterville, ME; no SBIR) $261,849 to commercialize their Cerecarb, which is designed to enable paper mills to reduce costs by substituting ash filler for expensive pulp fiber. ... RainStorm(Orono, ME; no SBIR) $161,208 to expand access to affordable education opportunities nationally by providing local adult education programs with a simple, affordable course catalog and online registration website. [Mass High Tech, Jun 27, 11

Rain Water Solutions (Raliegh, NC)

Thirteen NC companies will split $1 M from a new state fund intended to help businesses create environmentally friendly technologies. In the Triangle area: Ecocurrent of Raleigh received $100,000 to convert hog manure into electric power; Kyma Technologies of Raleigh received $60,000 to work with N.C. State University on a more efficient, cheaper electric switch.; 3F LLC of Raleigh received $100,000 to develop a natural fiber-reinforced concrete formula.; Piedmont Biofuels of Pittsboro received $75,000 to work on a reactor that more efficiently creates biodiesel.; Nextreme Thermal Solutions of Durham received $57,319 to manufacture a generator that converts waste heat into electricity.; Rain Water Solutions of Raleigh received $18,000 to develop a new rain barrel manufacturing process. [Raleigh News & Observer, Jul 1]

Raland Therapeutics (Perinton,NY)

More Buffalo subsidy. Raland Therapeutics (Perinton, NY; no SBIR), won $500,000 cash and other support Thursday in Buffalo's $5 million 43North business competition. [Rochester Democrat & Chronicle, Oct 30, 14] a biodevice company plans to create 15 new jobs [Dan Miner, Buffalo Business First, Jan 28, 15] Our proprietary technology is showcased in the CytoComm™ Living Biosensor System, an in-vivo, real time monitoring system for biological signaling and cellular responses. [company website]

Rallybio (Farmington, CT)

Rallybio (New Haven, CT; no SBIR) committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the completion of a $145 million Series B financing [to] advance Rallybio’s current portfolio of product candidates targeting devastating rare diseases, including its lead program, RLYB211. RLYB211 is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. [company press release May 19, 20]

Rallybio (Farmington, CT; no SBIR), a new, early-stage startup from Alexion Pharmaceuticals veterans, announced it raised $37 million in series A financing ... plans to develop antibodies, small molecules and engineered proteins for rare and orphan diseases. [Conor Hale, Fierce Biotech, Apr 25, 18]

RaNA Therapeutics (Cambridge, MA)

RaNA Therapeutics (Cambridge, MA; no SBIR). said it has completed a $20.7 million round of financing co-led by Atlas Venture, SR One, and Monsanto, with participation of Partners Innovation Fund. ... is developing a technology platform to enable selective activation of target genes. [Chris Reidy, Boston Globe, Jan 18, 12]

Stealthy startup RaNA Therapeutics (Cambridge, MA; no SBIR) raised $2.66 million of a planned $20.66 million initial funding, according to federal documents. [Rodney Brown, Mass High Tech, Dec 1, 11]

RAN Biotechnologies

Range Fuels (Broomfield, CO)

Range Fuels (Broomfield, CO; no SBIR), a cellulosic ethanol company backed by as much as $156 million in U.S. loans and grants from[Bush] administration, is being forced by the government to liquidate its only factory [in Soperton, GA] after failing to produce the fuel. [Mario Parker, Bloomberg News, Dec 3, 11]

The Range Fuels (Broomfield, CO) plant, to be located in southeast Georgia, could be producing ethanol as soon as next year. It's being funded [$76M to the company for the construction] by the DOE as part of the agency's effort to increase the use of biofuels. [Kevin Bullis, MIT Tech Review, Nov 15] Those logs streaming down I-16 to the Savannah port can be diverted to making cellulosic fuel that is eons away from market economics until a new killer chemistry appears. From an economy standpoint, investing in chemistry is a lot cheaper than production plants for known uneconomical chemistry. But then, they wouldn't be pouring millions of pork into Georgia.

Rapamycin Holdings (San Antonio, TX)

Rapamycin Holdings (founded 2012 as spinout from UTHealth Science Center San Antonio, San Antonio, TX; no SBIR) licensing exclusive rights to intellectual property central to several aspects of the rapamycin-related drugs [to] potentially slow the aging process — suggested in animal experiments at The University of Texas. [company website] obtains key patent approval in path to market [San Antonio Business Journal, Oct 16, 17]

Rapamycin Holdings (San Antonio, TX; no SBIR) drug development company, has secured $2.5 million in its Series A funding round. The company will use the funding primarily for manufacturing of its lead product candidate, eRapa-NP2g. ... founded in October 2012 and has now raised approximately $5 million. [W Scott Bailey, San Antonio Business Journal, Jun 8, 15]

Ra Pharmaceuticals (Boston, MA)

Ra Pharmaceuticals up 101% [Oct 10, 19] UCB (Belgium) and Ra Pharmaceuticals (Cambridge, MA; no SBIR) announced their entry into a merger agreement pursuant for which UCB will acquire Ra Pharma [in] a transaction value of approximately $2.1 billion [joint companies press release, Oct 10, 19]

Ra Pharma up 19% [Mar 8, 19]

Ra Pharma up 20% [Jan 2, 19]

Ra Pharma down 15% [Nov 20, 18]

Ra Pharma up 10% [Sep 27, 18]

Ra Pharma up 11% [Aug 8, 18]

Ra Pharma up 10% [Mar 9, 18]

Ra Pharma up 13% [Feb 20, 18]

Ra Pharma down 11% [Dec 5, 17]

Ra Pharma down 37% [Dec 4, 17] announced positive interim results from the Company's ongoing, global Phase 2 clinical program evaluating RA101495 SC for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) [company press release, Dec 4, 17]

Ra Pharmaceuticals (Cambridge, MA; SBIR) raised close to $92 million in [IPO] ... to develop an experimental drug, RA101495, that it hopes can become a threat to Alexion Pharmaceuticals’s eculizumab (Soliris). Alexion’s drug is the only approved therapy for two rare blood diseases—paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome—and brings in more than $2 billion annually. [Ben Fidler, xconomy.com, Oct 25, 16]

Paroxysmal nocturnal hemoglobinuria may be an ultra-rare blood disease, but Alexion Pharmaceuticals makes over $2 billion a year by selling the only approved drug for it, eculizumab (Soliris). Ra Pharmaceuticals (Cambridge, MA; no SBIR) is one of those developing an alternative, and filing for IPO. [xconomy.com, Oct 3, 16]

Ra Pharmaceuticals (Boston, MA; no SBIR)has pulled in $10.3 million of a planned $27.6 million equity round of financing, according to [SEC] filing. [Mass High Tech, Feb 26, 10]

Rapid Diagnostek (Hudson, WI)

Rapid Diagnostek (Hudson, WI; no SBIR) has raised $4 million of venture capital ... to develop a portable, one-step sensing device that could quickly diagnose diseases, bacteria, viruses, and spores by analyzing blood, urine and saliva. The company moved to Hudson in 2008 from Minnesota. [Kathleen Gallagher, Milwaukee Journal Sentinel, Jan 26, 10]

Aldevon (Fargo, ND; no SBIR), maker of DNA and protein products is putting a research and sales operation in [Wisconsin] .... founded by two ND State U graduates, has more than 70 employees, and provides products and services to pharmaceutical companies and diagnostic test-makers. ... also welcomed to Wisconsin: RJA Dispersions (no SBIR), VitalMedix (no SBIR) and Rapid Diagnostek (no SBIR), from Minnesota; Flex Biomedical (one SBIR) and Exact Sciences (no SBIR), from Massachusetts; NanoMedex ($1M SBIR), from Florida; and Inviragen ($2M SBIR) from Colorado. Biotechnology is the fastest-growing segment of the Wisconsin economy, with an annualized growth rate of nearly 7%, [Gov] Doyle said in a statement. The sector has 400 companies in the state with 34,000 employees.

Six start-ups will be recognized for making strides to commercialization at a biotech industry summit in October. ... part of a one-day Biotechnology Vision Summit 2009 that is being run by BioForward, an organization that represents Wisconsin's biotech industry. AquaMost LLC (Madison, WI; one SBIR) , Echometrix (Madison, WI; no SBIR), Flex Biomedical Inc(Madison, WI; one SBIR), Semba Biosciences (Madison, WI; no SBIR), Invivosciences LLC (Wauwatosa, WI; no SBIR), and Rapid Diagnostek Inc (Hudson, WI; no SBIR). [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 22, 09]

Moving for Subsidy. Lured by the state's tax credits for investments in high-growth companies, a biotech start-up said it was moving to Wisconsin. VitalMedix (Minneapolis, MN; no SBIR) is developing a drug that first responders, trauma center surgeons and military medics could use. The drug, Tamiasyn, has the potential to allow humans to endure severe blood loss and inhibit organ damage during resuscitation. .... Minnesota legislators tried to create a similar program but failed. .... The credits had lured another biotech company. Rapid Diagnostek (no SBIR) moved to Hudson last year from St. Paul to take advantage of the credits. The top executive at BioE (no apparent SBIR) a Twin Cities tech company, praised Wisconsin's embrace of tech companies and didn't rule out a move. [Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 10, 09)

Rapid Micro Biosystems (Bedford, MA)

Rapid Micro Biosystems, (Bedford, MA; no SBIR) a supplier of quality-control testing equipment for the pharmaceutical industry, has raised a $32.6 million Series B investment round. .... has developed technology that can quickly identify tiny microbes, which are serious contaminants in the drug-making process. The company raised an $18.6 million Series A round in 2009. [Curt Woodward, xconomy.com, Jun 26]

Rapid Micro Biosystems (Bedford, MA; no SBIR) has signed a deal with the Biomedical Advanced Research and Development Authority (BARDA) that could net up to $6.7 million for the microbial contamination detection firm. The contract calls for the development of rapid sterility testing for vaccines. ... raised an $18.6 million Series A round of financing in July 2009 [Mass High Tech, Sep 22, 10]

Rapid Micro Biosystems (Bedford, MA; no SBIR) microbial contamination detection firm, has landed an investment of $18.6 million in a Series A round [Mass High Tech, Jul 8, 09]

Rapiscan (Torrance, CA)

Demand for Rapiscan (Torrance, CA; one SBIR in 1993) products, which include airport metal detectors and larger machines used to scan cargo containers and trucks, is growing as governments all over the world increase their security efforts. Rapiscan's cargo scanning business has doubled annually for the past three years, said Peter Kant, the company's vice president of global government affairs. And the company has signed more contracts with government agencies. ... offices in Singapore, Malaysia and Australia. At the 30,600-square-foot Apex , NC facility, Rapiscan will build larger machines capable of checking for dangerous materials in cargo containers, trucks and other vehicles. ... 2007 revenue was $186.6 million, SEC filings from its parent company, OSI Systems, show. [Raleigh News&Observer, Mar 22]

Rapt Therapeutics (South San Francisco, CA)

RAPT Thera up 18% [Nov 27, 20]

RAPT Thera down 46% [Nov 16, 20] announced positive initial clinical data from its ongoing Phase 1/2 trial for FLX475 in multiple cancer indications.

RAPT Thera up 16% [Jun 17, 20]

stock deal. [Frank Vinluan, xconomy.com. Jan 16, 20]

RAPT Thera up 19% [Mar 4, 20]

RAPT Thera down 24% [Feb 5, 20] announced a proposed offering of common stock

RAPT Thera up 28% [Jan 16, 20]

RAPT Thera up 17% [Jan 15, 20]

RAPT Therapeutics up 15% [Dec 3, 19] is gaining a development partner and a foothold in Asia through a partnership potentially worth $118 million. The biotech is handing Hanmi Pharmaceutical the rights to its lead cancer program in South Korea and greater China in exchange for $10 million upfront and the promise of millions more in milestones. [Almira al Adrus, Fierce Biotech, Dec 4, 19]

RAPT Therapeutics up 44% [Nov 25, 19]

RAPT Thera up 19% [Nov 20, 19]

RAPT Therapeutics down 30% [Nov 11, 19]

RAPT Therapeutics up 26% [Nov 8, 19]

RAPT Therapeutics (South San Francisco, CA; no SBIR) up 48% [Nov 7, 19], a clinical-stage immunology-based biopharmaceutical focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, announced the pricing of its [IPO] to raise $36M. [company press release, Nov 7, 19]

Rapt Therapeutics (South San Francisco, CA; no SBIR) filed to raise up to $75 million IPO after postponing an earlier attempt [Fierce Biotech, Oct25, 19]

RareCyte (Seattle, WA)

RareCyte (Seattle, WA; $800K SBIR) creating liquid and tissue biopsy analysis platforms with emphasis on rare cell detection announced today the completion of a $22M financing [company press release, Dec 19, 19]

RareCyte (Seattle, WA; no SBIR, founded 2011, 30 employees) Completes $30M Private Financing [to] advance its commercial sales efforts and build companion diagnostics (CDx) programs with strategic partners. [company press release, Aug 29, 17] RareCyte was spun out of Applied Precision (no SBIR) in 2011, shortly after General Electric acquired API. [Clare McGrane, geekwire.com, Aug 29, 17]

Raser Technologies (Provo, UT)

Within six months of discovering an enormous geothermal field, a small Utah company had erected and fired up a power plant — an example of the speed with which companies are capitalizing on state mandates for alternative energy. Anticipation of new energy policies has sparked a rush on land leases as companies such as Raser Technologies (Provo, UT; no SBIR) lock up property that hold geothermal fields and potentially huge profits. [Paul Foy, AP, Dec 26]

Raydiance

THE DISRUPTION: Lasers that cut without heating surrounding material. THE DISRUPTED: The entire laser industry - medicine, aerospace and beyond. [Barry Schuler, former CEO of AOL] two-year-old startup, Raydiance, is taking aim at the $3 billion medical laser market with a technology called USP, or ultrashort pulse. Why? Because USP lasers are phenomenally accurate.... USP devices have been in the hands of researchers since 1989, but they've also been unmanageably large and notoriously difficult to operate. Schuler's company, funded to the tune of $35 M, has already shrunk its device to the size of a microwave oven. [Business 2.0] Why would medical laser capital flow so readily to an AOL founder? Because capital seeks entrepreneurs who know how to use it. Sweetness of the technology is a second consideration after a real entrepreneur puts up some of his money. The SBIR [theoretical] idea that capital- inspired commercialization will follow from government buying what government likes contradicts the real world of investing. If SBIR wants substantial economic spinoff, it has to look for entrepreneurs with new ideas, not just smart technicians. Oh sure, if you spend enough money on technicians, something will come out, but not enough to justify the government spending.

Raydiant Oximetry (Sacramento, CA)

Raydiant Oximetry (Sacramento, CA; no SBIR, founded 2016), winner of last year’s startup business competition at UC Davis, has raised a $1 million seed round and secured over $200,000 from [NIH] [ Olivia Rockeman, Sacramento Business Journal, Jul 30, 18] ] developed a better fetal monitor to improve outcomes for mothers and babies during childbirth. [company website]

Raymond (Greene, NY)

New York State Energy Research and Development Authority awarded $250K to Raymond (Greene, NY; no SBIR) to test the use of Navitas Systems’ lithium-ion batteries in its electric lift trucks to increase performance in cold environments. If the batteries demonstrate the projected improvement in run time and productivity, Raymond – a world leader in electric lift trucks with over 1,500 employees in Greene, NY – anticipates growing customer interest in extreme-duty applications [NYSERDA, Oct 27, 14]

Raze Therapeutics

Unum Therapeutics (Cambridge, MA; no SBIR) , that just came out of the woodwork today with $12 million in backing from some of the Boston area’s biggest life sciences players. Unum has hauled in a $12 million Series A round led by [including] Sanofi-Genzyme BioVentures. It’s the second Series A an biotech has secured in two weeks. Another cancer treatment developer, Raze Therapeutics (no SBIR), announced a $24 million Series A round on Oct. 14. Unum is the latest startup touting a way to essentially reprogram the immune system to seek out and attack tumors.... Unum will use the cash to get its first candidate, which hasn’t been disclosed, through clinical proof-of-concept studies. [Ben Fidler, xconomy.com, Oct 21, 14]

RE2 Robotics (Pittsburgh, PA)

Sarcos Technology and Robotics has agreed to acquire RE2 (Pittsburgh, PA; $22M SBIR), a developer of mobile robotic systems and autonomy software, for approximately $100 million in cash and stock. The two companies aim to offer a suite of technology products powered by artificial intelligence, machine learning, computer vision and autonomous technologies, according to a joint statement [govconwire.com, Mar 29, 22]

[US Navy] awarded RE2 Robotics a $9.5 million defense contract to enhance the development of RE2's Maritime Mine Neutralization System (M2NS), an autonomous underwater robotic arm and computer system capable of disabling mines or other improvised explosive devices found in deep seas or oceans. [Nate Doughty, Pittsburgh Business Jounal, September 14, 2021]

RE2 Robotics (Pittsburgh, PA; $20M prior SBIR) announced that it has received $1.1 million [Army] Phase II SBIR to develop a mobile robotic manipulation system that will allow combat medics to remotely assess and extract injured soldiers on the battlefield. The (ACE) program will utilize the Company’s dual-arm Highly Dexterous Manipulation System (HDMS) mounted to a FLIR [Systems] Kobra unmanned ground vehicle (UGV), provided by FLIR Systems,, to autonomously locate a casualty in the field. [comapny press release, Nov 1, 20]

RE2 Robotics (Pittsburgh, PA; no SBIR), a developer of human-like robotic manipulation systems, has received $2.5 million in funding from the Office of Naval Research to continue the development and commercialization of its technology under the Dexterous Maritime Manipulation System (DM2S) program. [David Edwards, Robotics & Automation, May 27 20]

RE2 Robotics (Pittsburgh PA; no SBIR says SBA database), a leading developer of robotic manipulation systems, announced that the company was awarded an [Army] Phase III SBIR grant from the Army and the U.S. Army Medical Research Acquisition Activity (USAMRAA) to continue the development of its LIFELINE system, which is designed to assist combat medics in the field. [company press release, Jun 24, 19] Note: Phase III is SBIR in name only, no SBIR money, just a competitive edge for sole-source follow-on work. Also got $2.9M AF SBIR in 2018, a Phase II Navy SBIR and a Phase II Army in 2017, $1M Phase II in 2016, a Phase II Army in 2012, and of course a Phase I SBIR contract before every Phase II [data from company website]. Warning: do not trust SBA database for accurate SBIR award info.

RE2 Robotics received $3 million from the Office of Naval Research to develop an underwater, dextrous robotic hand for use in the U.S. Navy. [Julia Mericle, Pittsurgh Business Journal, May 20, 19[

RE2 Robotics announced [it] received a $2.5 million [ONR] contract to continue development and commercialization of its Dexterous Maritime Manipulation System (DM2S). [company press release, Sep 24, 18]

RE2 Robotics (Pittsburg, PA; $17M SBIR) announced a $2.9M Phase III SBIR to develop a drop-in robotic kit, which will enable the Air Force to use existing construction ground vehicles as robotic vehicles during clean-up efforts after an airfield strike. [company press release, Apr 10, 18] Note: Phase III is not SBIR money, just a permission slip for non-competitive contracts after Phase II.

RE2 Robotics (Pittsburgh,PA; at least $10M SBIR) was awarded a $125,000 [US Navy SBIR] contract to develop robotics to handle cargo in a tactical landing zone. [company press release, Oct 18, 17] Note: SBA data way out of date with company press releases. Not surprising since Congress worries only whether the mandaterd minimum money goes every year to the SBs.

RE2 Robotics (Pittsburgh, PA; at least $4.5M SBIR) announced that the Company was selected by the Air Force SBIR to develop a drop-in robotic system to rapidly convert a variety of traditionally manned aircraft to robotically piloted, autonomous aircraft. This robotic system, named “Common Aircraft Retrofit for Novel Autonomous Control” (CARNAC), will operate the aircraft similarly to a human pilot and will not require any modifications to the aircraft. [company press release, Jun 21, 17]

RE2 Robotics (Pittsburgh, PA; $4.5M SBIR before 2011 as RE2 and at least $5M reported here) developer of robotic manipulator arms, has won a [Navy Phase II SBIR] to develop a cost-effective robotic system onto an unmanned underwater vehicle to assist divers in dismantling explosive devices on vessels, bridges and piers. [company press release, Feb 7, 17] also won a Army Phase II SBIR to develop robotic technologies to assist combat medics in the field. [company press release, Jan 9, 17] also delivered a two-arm Highly Dexterous Manipulation System (HDMS) to the U.S. Army’s under an Army SBIR Phase II extension contract. [company press release, May 13, 16] also awarded a $1 Million Army Phase II SBIR to develop the Biomechanical Exoskeleton Simulator System, a software tool to assess the impact of load carriage and body-wearable robotic devices on musculoskeletal health and performance. The simulator will allow the Army to more accurately predict musculoskeletal stress on military personnel while wearing assistive devices, such as robotic exoskeletons. [company press release, Feb 12, 16] also was awarded a $2.7 Million Navy ONR contract to develop an Underwater Dexterous Manipulation System for Explosive Ordnance Disposal (EOD) Applications (DMEA). RE2’s DMEA technology will provide EOD personnel with the ability to remotely and effectively address Waterborne Improvised Explosive Devices (WIEDs). [company press release, Aug 18, 15] also awarded additional funding by DOD to commercialize its high speed inspection robot called the ForeRunner unmanned ground vehicle (UGV) developed under an Army SBIR program and the additional funding was awarded through the Robotics Technology Consortium as a Phase III SBIR, [company press release, Oct 30, 13] Note: SBA database reports no SBIR for RE2 Robotics.

RE2 Robotics (Pittsburgh, PA; at least $2M SBIR since 2014) announced that the company was awarded a Phase II [Army] $1 million (SBIR) to develop technologies to assist combat medics in the field. [company press release, Jan 10, 17] ... announced a 3-year $3.3 million dollar subcontract with a division of Applied Research Associates Inc. (ARA) located at Tyndall AFB, Florida. RE2 will provide mobile manipulation and ground robotics expertise for the Air Force’s Rapid Airfield Damage Repair (RADR) program. [company press release, May 2016] .. awarded a $2.7 Million contract by [ONR] to develop an Underwater Dexterous Manipulation System for Explosive Ordnance Disposal [company press release, Aug 2015]

RE2 Robotics (Pittsburgh, PA; no SBIR) said it has signed a 3-year, $3.3 million contract to develop robotic systems for the U.S. Air Forceâ€™s Rapid Airfield Damage Repair program. ... The primary goal of the RADR program is to keep humans out of harmâ€™s way by rapidly and remotely assessing and mitigating [Patty Tascarella, Pittsburgh Business Times, May 24, 16]

RE2 Robotics (Pittsburgh, PA; $4.4M SBIR) announced the company has been awarded a $1 Million SBIR with the U.S. Army to develop the Biomechanical Exoskeleton Simulator System, a software tool to assess the impact of load carriage and body-wearable robotic devices on musculoskeletal health and performance. The simulator will allow the Army to more accurately predict musculoskeletal stress on military personnel while wearing assistive devices, such as robotic exoskeletons. .... won a Oct 2015 Navy Phase I SBIR Phase I Small Business Innovation Research (SBIR) grant to design Inflatable Underwater Manipulator arms .... RE2 is hiring! [company website, Feb 12, 16]

RE2 (Pittsburgh, PA; $4.4M SBIR) won a $2.7 million contract by the Office of Naval Research to develop manipulator arms for unmanned underwater vehicles. [Justine Coyne, Pittsburgh Business Times, Aug 18, 15]

Robotics firm RE2 (Pittsburgh, PA; $4.4M SBIR) said it has closed on a $2.25 million Series A funding round ... to accelerate development of its robotic manipulator arm technologies and to penetrate new markets including agriculture and health care [Patty Tascarella, Pittsburgh Business Times, Aug 18, 14]

RE2 (Pittsburgh, PA; $4.4M SBIR, 30 employees) robotics firm, has released a new product line of robots that mimic human functions to prevent injuries and to handle hazardous situations, President and CEO Jorgen Pedersen said. .... plans to expand the HDMS line into additional markets such as health care and manufacturing. The first customer was the Massachusetts Institute of Technology. [Patty Tascarella, Pittsburgh Business Times, Jul 28, 14]

RE2 (Pittsburgh, PA; $4.6M SBIR) said it supplied the manipulator arm for a new product by iRobot for the defense and securities sectors. .... includes a camera for the FirstLook robot from iRobot. FirstLook is a compact, multi-mission lightweight robot that provides immediate situational awareness, performs persistent observation and investigates dangerous and hazardous materials [Patty Tascarella, Pittsburgh Business Times, May 12, 14]

robotics firm RE2 (Lawrenceville, PA; $4.4M SBIR starting in 2005) has been working to get into new markets, broadening its reach beyond its current area of military bomb disposal. Now an Air Force SBIR to develop a robotic arm system that can be used to recoat parts of jet engines. .... a completely new use for the company’s core robotics technology. [Malia Spencer, Pittsburgh Buiness Times, Sep 11, 13] Doesn't sound like much of a startech for new technology, just another application. Ah well, the DOD loves certainty.

ReadCoor (Cambridge, MA)

biotech ReadCoor (Cambridge, MA; SBIR) raised $26.8M in equity according to an SEC filing. [Rowan Walrath, BostInno, Oct 21, 19] we envision swifter scientific discoveries, disease diagnosis and drug development from sequencing reads enhanced by panomic spatial data. [company website]

Ready Robotics (Columbus OH)

Baltimore startup Ready Robotics (Columbus OH; no SBIR) moved to Columbus to be near the VC that is putting up $15M. It's a relatively new entrant in the field of robotics-as-a-service, or RaaS — connected robotic devices equipped with a cloud computing unit. ... leases collaborative robots to manufacturers [Anna Hensel, venturebeat.com, Apr 23, 18]

ReAlta Life Sciences (Norfolk, VA: one $900K SBIR) is exploring whether RLS-0071, its treatment for a severe birth complication, can also treat patients with lung damage from Covid-19. The Norfolk-based biotech company raised a $14 million Series A round of funding in April, and in July it received clearance to begin early medical trials for Covid-19 treatments [RichmondInno] announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to RLS-0071 (also known as PIC1-dPEG24) for the treatment of neonatal encephalopathy. [compny press release, Dec 3, 20]

ReAlta Life Sciences (Norfolk,VA; $800K SBIR, founded 2008) prepares to transition into a clinical-stage organization later this year, the Norfolk-based biotech startup closed a $14 million series A2 to support this critical transition [and[ brings the total Series A to $26 million, ... building a technology platform that features a family of over 160 engineered peptides, or short strings of amino acids that are considered the building blocks of proteins. [Will Flanagan, DC Inno, May 5, 2020]

Reata Pharmaceuticals (Irving, TX)

Reata Pharmaceuticals (Plano, TX; at least one SBIR) announced that its investigational drug for those with Alport syndrome, bardoxolone methyl (bard), met the main goal of a Phase 3 clinical trial. After 48 weeks of treatment, patients in the study who received bard saw their kidney function—as measured by a blood test that estimates how much blood passes through filters in the kidneys each minute—improve compared to a placebo ... company now plans to ask the FDA to review the drug. No FDA-approved treatment for Alport syndrome currently exists. [Sarah de Crescenzo, xconomy.com, Nov 12, 19]

Reata Pharmaceuticals (Dallas, TX; one SBIR) which kicked things off Oct. 10 with the announcement that it would end its nine-year partnership with AbbVie. This move allows Reata to reclaim the exclusive rights to two drugs in late-stage clinical trials, as well as next-generation drugs that use the same mechanism. Days later, Reata surprised much of Wall Street with positive results from a pivotal clinical trial for omaveloxolone (omav) as a treatment for Friedreich's ataxia, a neuromuscular disease with no approved treatment options. The stock surged 60% following the announcement, adding roughly $1.5 billion to the company's valuation. [David Haen, Motley Fool, Oct 16, 19]

Reata Pharmaceuticals,(Irving, TX; no SBIR, founded 2002, IPO 2016), a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering expected to be $100, million ... for working capital and general corporate purposes, which include, but are not limited to, advancing the development of bardoxolone methyl through a Phase 2/3 program in CKD caused by Alport syndrome, Phase 2 programs in additional renal indications, and Phase 2 programs in PH-ILD and the development of omaveloxolone in Friedreich’s ataxia and mitochondrial myopathies. [company press release, Jul 26, 17]

Rebellion Photonics (Houston, TX)

Also for ARPA-E Rebellion Photonics (Houston, TX; no SBIR) for $4.2M leveraged existing product, a large spectral imaging camera called the gas cloud imager (GCI, see Figure 1), uses snapshot spectral imaging, which is well suited to size and cost reduction into a deployable product for methane leaks]. [arpa-e.energy.gov report, May 7, 18] Rebellion offers the only spectral imaging camera in the world that can both identify and quantify gas releases in real time, so you can detect leaks faster and more efficiently than ever before. [company website]

Rebellion Photonics (Houston, TX; no SBIR, founded 2010) was named "WSJ Startup of the Year", beating two dozen other young companies during the five-month-long documentary. .... builds cameras that can spot poisonous and potentially explosive gas leaks on oil rigs and at refineries. The cameras can detect at least 20 different gases simultaneously and in real time. [Tom Corrigan, Wall Street Journal, Nov 5, 13]

Rebellion Photonics (Houston, TX , no SBIR) Builds special chemical imaging cameras that can spot explosive gas leaks on rigs and refineries. ... is Number 8 in WSJ Startup of the Year competition. [Wall Street Journal, Jul 25]

Rebion (Boston, MA)

medical device firm Rebion (formerly known as Rebiscan, Boston, MA; $300K SBIR) raised nearly $2.2 million from investors, according to a new SEC filing. The company says it has developed eye-scanning technology for detecting lazy eyetraumatic brain injury. [Jeff Engel, xconomy.com, Aug 25, 17]

Rebiotix (Roseville, MN)

Ferring Pharmaceuticals (Switzerland) and Rebiotix (Roseville, MN; no SBIR) announce that they have agreed to the acquisition of Rebiotix by Ferring. .... share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients. The most advanced investigational microbiome treatment from Rebiotix is RBX2660, a non-antibiotic treatment currently in Phase 3 development for the prevention of recurrent CDI. [joint companies press release, Apr 5, 18]

Biotech Rebiotix (Roseville, MN; no SBIR, founded 2011 w/ $5M) is seeking $10 million in debt financing and convertible promissory notes, according to [SEC] filing. ... creating new treatments for gastrointestinal diseases that transplant healthy gut microbes into patients [ANDRE EGGERT, Twin Cities Business, Sep 6, 17] ... $25M Series B round in 2014 [company website]

Rebiotix (Roseville, MN; no SBIR) teamed with a Mayo Clinic expert on hospital-acquired infections to begin the clinical trial process for a new, orally-delivered microbe transplant therapy to combat recurrent Clostridium difficile (C. diff.) infection. Rebiotix’s “Microbiota Restoration Therapy” involves harvesting healthy, living gut microbes from donors and transplanting them into patients suffering from C. diff. infection, [Don Jacobson, Twin Cities Business, Jan 18, 17]

Rebiotix (Roseville, MN; no SBIR, founded 2011) that is developing a new category of biologic drugs, raised $25 million in its second funding round. .... said it will use the money to support clinical research to advance its lead product, called RBX2660, toward commercialization. .... to revolutionize the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome (transplants healthy fecal matter to unhealthy bowels). [NEAL ST. ANTHONY, Minneapolis Star Tribune, Aug 5, 14]

startup Rebiotix (Roseville, MN; no SBIR) that aims to fight bacterial infections with human stool is seeking $25 million in capital, according to a regulatory filing. ... targets patients who suffer from C. difficile, a bacterial infection that’s typically acquired during hospital stays. Research dating back as far as the 1950s has shown that transplanting “good” bacteria from a healthy person’s stool into a sick patient is an effective treatment. .... has already lined up $18 million in financing [Katharine Grayson, Minneapolis / St. Paul Business Journal, Jul 9, 14]

[FDA] accepted biotech startup Rebiotix's (Roseville, MN (formerly called Mikrobex); no SBIR) fecal-transplant product into its fast-track program, which could expedite the technology's approval for sale. aims to make it easier for physicians to treat patients suffering from severe bacterial infections using stool transplants. The company is targeting people who suffer from C. difficile, a bacterial infection that’s typically acquired during hospital stays. [Katherine Grayson, Minneapolis / St Paul Business Journal, Jun 24, 13]

Receptor Logic

Two Austin companies will share $3.7 million in grants from the Texas Emerging Technology Fund, which was created to spur commercialization of research in Texas. Receptor Logic Ltd. will receive $2 million to advance its work in the development of anti-bodies that can improve the understanding of the immune system and thus lead to better drugs and vaccines. Terapio Inc. will receive $1.7 million to develop a cream to treat hand-foot syndrome, a painful swelling and numbness of the hands and feet that can occur as a side effect of several chemotherapy drugs. Receptor was started in 2004 by Emergent Technologies Inc., an Austin-based life sciences venture capital firm, and Jon Weidanz, director of the Texas Tech University Center for Immunotherapeutic Research. The company, which has headquarters in Austin and a laboratory in Abilene, will use the investment to expand its commercialization efforts [Lori Hawkins, Austin American-Statesman, Jun 19] Neither had SBIR.

Receptos (San Diego, CA)

Receptos (LaJolla, CA; no SBIR) a biotech company developing therapies for immune and metabolic disorders, said it has priced its initial public offering of 5.2 million shares at $14 apiece. ....Receptos' lead drug, RPC1063, is a small molecule for autoimmune disorders, including relapsing multiple sclerosis and inflammatory bowel disease [Bradley Fikes, utsandiego.com, May 8, 13]

Receptos (San Diego, CA; no SBIR), which is using the structure of cellular G protein-coupled receptors to develop drug candidates for autoimmune therapies, has secured $10.8 million in a funding round that could be as much as $50 million, according to a recent regulatory filing. The biopharmaceutical startup raised about $25 million in a Series A round in 2009 [Bruce Bigelow, xconomy.com, Feb 23, 12]

Receptos (San Diego, CA; no SBIR) said that it will collaborate with pharmaceutical giant Eli Lilly to develop therapies that act on certain protein receptors involved in cellular response. The companies will work on discovering orally administered drug candidates and move them through preclinical testing, Receptos said. The effort will focus on G protein-coupled receptors, a major class of targets for new drugs. [Keith Darce, signonsandiego,com, Jan 6, 11]

Recodagen

things are looking better: the research-oriented startups seem poised to survive the downturn, and long-awaited clinical results could propel larger companies like Dendreon to stardom. ... despite the financial crisis, the Accelerator, a local incubator based in Seattle's Eastlake neighborhood, created three firms last year - Recodagen, GPC-Rx and Mirina (none had SBIR) ... "Seattle is really a town of development-stage biotechs," Miller said. ... Light Sciences Oncology (no SBIR), a firm that canceled its initial public offering last February, managed to raise $10 million from venture capitalists in July. Private investors provided Redmond-based Healionics (no SBIR) — which manufactures material for implants — with a $2.6 million boost in December. In a deal that could yield big results, Bothell-based Acucela (no SBIR), which is developing therapies to treat blindness, signed a partnership deal in September with Japanese firm Otsuka Pharmaceutical that could potentially bring it $258 million. [Angel Gonzalez, Seattle Times, Jan 25]

Local biotech incubator Accelerator is hatching its seventh firm — Recodagen (no SBIR), which will research therapies to arrest the spread of cancerous tumors. The technology underpinning Recodagen was licensed out of the laboratory of J. Suzanne Lindsey at Washington State University in Pullman. ... Accelerator's first technology-licensing deal with Washington State University, which in the past three years has been ramping up its efforts to get its research into the marketplace. [Angel Gonzalez, Seattle Times, Mar 14]

ReCode Therapeutics (Dallas, TX;)

ReCode Therapeutics (Dallas, TX; no SBIR) raised $80 million to advance a treatment for cystic fibrosis driven by what’re called nonsense mutations, as well as a treatment for another lung disease, primary ciliary dyskinesia (PCD). [Amirah Al Idrus, Fierce Biotech, Mar 26, 20] prior funding $2M [crunchbase.com]

Recombinetics (Minneapolis,MN)

Gene-editing startup Recombinetics (St Paul, MN; $5M SBIR, founded 2008) a pioneer in gene-editing solutions for human health and animal agriculture, announced the completion of a $34 million Series A financing [to] to accelerate commercialization of this transformative science to help find cures for human diseases, develop new regenerative medicine products and breed animals [mainly pigs] that are healthier and more productive.” [company press release, Aug 21, 18] prior funding $37M [crunchbase.com]

Recombinetics (St. Paul, MN; no SBIR) a recognized leader in the development and deployment of gene-editing technologies to advance human health and animal welfare, announced today the successful close of its recent $10 million common stock offering. ...closed at more than $11 million. To date, Recombinetics has raised over $24 million in private investments. [company press release, Nov 14, 16]

Gene editing company Recombinetics (St Paul, MN; no prior SBIR) received a [NIH $360K SBIR] grant to create a genetically accurate porcine model, or “minipig,” that will help create treatments for Alzheimer’s disease. [Sam Schaust, Twin Cities Business, Oct 6, 16]

Recombinetics (Minneapolis, MN; one STTR) that genetically engineers animals for biomedical and agricultural purposes, announced it has entered into a three-year development and license agreement with a Paris-based firm.Cellectis bioresearch will provide engineered nucleases to Recombinetics under the agreement. Recombinetics will use the nucleases to create animals with “improved genetic features,” according to a press release. Cellectis could receive up to $50 million if certain sales-based milestones are met and will receive royalties on products made through the agreement. [Wendy Lee, Minneapolis Star Tribune, Aug 26, 11]

Recombinetics (Minneapolis, MN; no SBIR), which genetically engineers animals for biomedical and agricultural purposes, said it is continuing to have discussions with Elk Run officials on having a presence at the development in Pine Island. The company said it would use the loan to pay for patent and engineering-related expenses. CEO Scott Fahrenkrug said he is continuing discussions with Elk Run’s developer on potentially building a bio-secure pig facility that may house up to 200 pigs with type 2 diabetes or cardiovascular disease. Fahrenkrug said he has also been talking with the Mayo Clinic on the possibility of him using a Rochester bio-secure facility for the pigs. [Wendy Lee, Minneapolis Star Tribune, Apr 24, 11]

ReconRobotics (Edina, MN)

Wars are over. Creditors who say ReconRobotics (Edina, MN; no SBIR) owes them $9.5 million have asked a federal court to put the robotics firm into Chapter 11 bankruptcy reorganization. ... sells its throwable scouting robots to the defense and law-enforcement markets. [Katharine Grayson, Minneapolis / St. Paul Business Journal, Apr 11, 14] In days of old, manufacturing lines for critical military hardware were put into layaway with military funding.

ReconRobotics (Edina, MN; no SBIR), whose throwable scouting robots are used in defense and law-enforcement jobs, has cut its staff by two-thirds after a deal with the U.S. Army was killed by sequester-related cuts. [Mark Reilly, Minneapolis / St Paul Business Journal, Jan 23, 14]

FBI agents who raided the home of a former suspect [since released and another suspect arrested] in the ricin-laced letter case brought along a mini throwable robot [with cameras] made by ReconRobotics (Edina, MN; no SBIR) ... Benjamin Wittes, a senior fellow at the Brookings Institution, identified the robot — seen resting on an agent’s knee in a photo [Katherine Grayson, Minneapolis / St Paul Business Journal, Apr 24, 13]

ReconRobotics (Edina, MN; no SBIR) received another multi-million contract with the Army for its micro-robot technology. ... $13.9 million to produce and deliver up to 1,000 miniature, throwable mobile robots. [Evelina Smirnitskaya, Minneapolis / St Paul Business JounrL, Jun 28, 12]

ReconRobotics (Edina, MN) specializing in microrobot technology, said its opening international headquarters in Lugano, Switzerland. [Minneapolis / St Paul Business Journal, May 30, 12]

ReconRobotics (Edina, MN; no SBIR) said it has acquired Xollai, (St. Paul, MN; no SBIR) that develops systems to help military drones land. ReconRobotics makes throwable microrobots for the military, ... a spokesman for ReconRobotics, said Xollai's St. Paul office will remain open and all nine of its employees will stay with the company. ReconRobotics now has 54 employees, Klobucar said. [Ed Stych, Minneapolis / St Paul Business Journal, Apr 4, 12]

ReconRobotics (Edina, MN; no SBIR). has sold more of its throwable robot kits to the U.S. military — this time to the Marine Corps. [Minneapolis / St Paul Business Journal, Mar 13, 12]

ReconRobotics (Edina, MN; no SBIR) recently raised $1.4 million from investors ... developing scout robots used by the U.S. military and FBI, is looking for another $2.5 million. [Thomas Lee's Patent_pending blog, Minneapolis Star Tribune, Sep 14, 09]

ReconRobotics (Edina, MN; no SBIR), which makes mini remote-control robots for military and police reconnaissance work, has raised $1.5 million in add-on financing from current investors. ... complete the company’s most recent $4 million round of equity financing. [Sam Black, Minneapolis/St Paul Business Journal, Sep 11, 09]

Recovery Engineering (Minneapolis, MN)

Celcuity (Minneapolis, MN; no SBIR, founded 2012) files to raise $15M through IPO [Katharine Grayson,Minneapolis / St. Paul Business Journal, Aug 23, 17] developing novel diagnostic tests that functionally analyze diseased live cells. Our mission is to transform care for cancer patients by providing the most biologically complete diagnosis available. CEO Brian Sullivan has over 25 years of experience founding and building successful technology companies. He was chairman and CEO of Sterilmed (Plymouth, MN, no SBIR) a medical device company, from 2003 until its sale to Johnson & Johnson for $330 million in 2011. Previously he was cofounder and CEO of Recovery Engineering (Minneapolis, MN; no SBIR), a filtration company that he took public and subsequently sold to Proctor and Gamble for $265 million in 1999.[company website]

Recro Pharma (Malvern, PA)

Recro Pharma down 40% [May 11, 20] reported financial results

Recro Pharma down 23% [Mar 4, 20]

Recro Pharma up 28% [Apr 4, 19]

Recro Pharma down 34% [Mar 25, 19] "We are extremely disappointed with the receipt of a second CRL from the FDA," said [CEO] Gerri Henwood. [company press release, Mar 22, 19]

Recro Pharma up 12% [Sep 5, 18]

Recro Pharma up 11% [Mar 1, 18]

Recro Pharma down 55% [May 24, 18] announced that FDA stated that although the outcome of the pivotal phase III trials demonstrated statistically significant outcomes on the primary endpoints, the FDA is unable to approve the application in its current form. The CRL states that data from ad hoc analyses and selective secondary endpoints suggest that the analgesic effect does not meet the expectations of the FDA. [company press reelease, May 24, 18]

Recro Pharma (Malvern. PA; no SBIR), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced the acquisition of exclusive global rights to two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent from Cornell University. [company press release, Jul 5, 17]

Recro Pharma up 11% [Mar 31, 17]

Recro Pharma up 10% [Dec 28, 16]

Recro Pharma (Malvern, PA; no SBIR) a revenue-generating, specialty pharmaceutical company primarily focused on developing innovative products for hospitals and ambulatory care settings, today announced the closing of the previously announced public offering, .... $36.9 million, to fund the NDA filing and regulatory approval process and preparatory commercial activities for IV meloxicam, its planned IV meloxicam Phase IIIB program, and for general corporate purposes. [company press release, Dec 16, 16]

Recro Pharma up 14% [Dec 2, 16]

Recro Pharma down 16% [Dec 1, 16]

Recro Pharma up 20% [Nov 28, 16]

Recro Pharma up 14% [Aug 23, 16]

Recro Pharma (Malvern, PA; no SBIR), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings, currently developing non-opioid products for the treatment of serious acute pain, announced the pricing of an underwritten public offering with expected gross proceeds to Recro of approximately $15 million. [company press release, Aug 16, 16] its IPO was March 2014

Recro Pharma up 29% [Jul 27, 16]

Recro Pharma up 10% [May 24, 16]

Recro Pharma up 17% [Apr 5, 16]

Recro Pharma initiated its second phase-III clinical study in as many weeks for its lead new pain drug candidate. [John George, Philadelphia Business Journal, Feb 1, 16]

Seeking a buyer? Chinese companies have launched a record wave of foreign acquisitions in the first few weeks of 2016 as they seek inroads into overseas markets amid China’s slowing economy and falling currency. ... has reached about $68 billion so far this year, the strongest volume ever for this period and already more than half of 2015’s record annual tally [Kathy Chu and Julie Steinberg, Wall Street Journal, Feb 3, 16]

Recro Pharma up 11% [Oct 9,15]

Recro Pharma down 15% [Sep 25,15]

Recro Pharma down 10% [Sep 21, 15]

Recro Pharma has expanded into Georgia in a move that its CEO believes will be “transformative” for the company. [Ellie Hensley, Atlanta Business Chronicle, Sep 4, 15]

Recro Pharma raised $16 million in a private stock placement. ... believes its pain medicines will avoid the side effects associated with commonly prescribed opioid therapeutics — which includes addiction, constipation and respiratory distress — while maintaining an analgesic effect [John George, Philadelphia Business Journal, Jul 8, 15]

Recro Pharma up 17% [Jun 18, 15]

Recro Pharma up 20% [Jun 8, 15]

Recro Pharma up 10% [Jun 5, 15]

Recro Pharma up 13% [May 28, 15]

Recro Pharma down 16% [Apr 20,15]

Recro Pharma up 11% [Mar 17,15]

Recro Pharma up 26% [Mar 16, 15]

Recro Pharma (no SBIR) up 21% [Mar 10, 15] signed a definitive agreement to acquire the rights to an experimental pain medicine and a contract manufacturing facility from Alkermes (Ireland) in a deal valued at up to $170 million. ... will make an upfront payment of $50 million to Alkermes could earn an additional $120 million if certain regulatory and net sales milestones are met. In return, Recro Pharma gets the worldwide rights to Alkermes' new drug candidate, IV/IM meloxicam, which is in late-stage clinical development as a potential treatment for moderate to severe acute pain. It also gets Alkermes' contract manufacturing facility and formulation business in Gainesville, Ga. ... founded in 2009, went public last year in a $30 million [John George, Philadelphia Business Journal, Mar 9, 15]

Recro Pharma (Malvern, PA; no SBIR) entered into a common stock purchase agreement with the Aspire Capital Fund that gives the a. specialty pharmaceutical company the right to sell Aspire up to $10 million in common stock over a two-year period. ... is developing non-opioid therapy to treat acute, post-operative pain. [John George, Philadelphia Business Journal, Feb 3, 15]

Recursion (Salt Lake City, UT)

Recursion Pharmaceuticals (Salt Lake City, UT; $3.5M SBIR) up 78% [Jul 13, 2023] After Nvidia Invests $50 Million for AI Drug Discovery [Barron's, Jul 13, 23]

Recursion Pharmaceuticals (Salt Lake City, UT; $3.5M SBIR) up 74% [Apr 16, 21] announced its [IPO] pricing to raise $436M [company press release, Apr 16, 21]

Recursion Pharmaceuticals (Salt Lake Ciy, UT; $3.3M SBIR, founded 2013) announced a $239 million oversubscribed Series D financing [to] apply our ever-growing integrated discovery and development technologies to the hardest problems in biology, and this fundraising round provides us with additional resources we need to continue to advance on our mission to decode biology to radically improve lives,” said [CEO] Chris Gibson. ... also announced that Bayer {Germany) and Recursion Pharmaceuticals have entered into a strategic collaboration agreement. [company press releases, Sep 9, 2020]

Atomwise (San Francisco, CA; no SBIR, founded 2012), which uses deep learning to shorten the process of discovering new drugs, has raised a $45 million Series A ... was founded in 2012, has now raised more than $51 million ... clients include four of the top 10 biggest pharmaceutical companies .... Now there is a roster of companies using artificial intelligence and machine learning to analyze molecules and fix bottlenecks in the drug discovery process, including Recursion Pharmaceuticals (Salt Lake City, UT, no SBIR, founded 2013), BenevolentAI (UK), TwoXAR (Palo Alto, CA; no SBIR, founded 2014), Cyclica (Canada), and Reverie Labs (Allston, MA; stealth mode). [Catherine Shu, TechCrunch, Mar 7, 18]

Recursion (Salt Lake City, UT; SBIR, founded 2014), a drug discovery startup announced a $60 million Series B round. .... started in 2014 on a mission to identify 100 new treatments in 10 years. ... uses machine learning to process and rapidly discover new drug treatments for diseases in a fraction of the time and cost. [Sarah Buhr, techcrunch.com, Oct 3, 17]

Redox Power Systems (Fulton, MD)

Redox Power Systems (Fulton, MD; no SBIR, founded 2012) has been awarded a $5 million federal grant to develop a high-tech fuel cell, among $33 million in grants from the Advanced Research Projects Agency-Energy. [Sarah Gantz, Baltimore Business Journal, Jun 20, 14] says that it plans to bring to market a fuel cell that is about one-tenth the size and one-tenth the cost of currently commercial fuel cells by 2014. The breakthrough solid oxide fuel cell technology is the brainchild of Eric Wachsman, the director of the University of Maryland’s Energy Research Center. ... Redox’s PowerSERG 2-80, also called “The Cube,” connects to your natural gas line and electrochemically converts methane to electricity. [William Pentland, Forbes, Aug 14, 14]

Redpin Therapeutics (New York, NY)

Redpin Therapeutics (New York, NY; no SBIR) a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today announced it has secured $15.5 million in the initial closing of its Series A financing round [to] to further progress the development of its groundbreaking ultra-potent ion channel based chemogenetics platform to address disorders associated with neural circuit dysfunction including epilepsy, neuropathic pain and Parkinson’s disease. [company press release, Mar 26, 20]

[DOE] has made a $70 million grant to Red Rock Biofuels (Fort Collins, CO; no SBIR, founded 2011) which will enable the company to produce 12 million gallons of fuel from wood biomass a year. .... to help finance a refinery in Oregon to produce jet fuel, diesel and naphtha from the wood scraps left behind by timber operations. [Denver Business Journal, Sep 23, 14] The organic matter will not be left to enrich the soil for future tree production. It will instead be converted to carbon dioxide and water in the atmosphere to grow trees in poorer soil. If the cycle continues, eventually the soil's ability to retain water will degrade tree production. But that's a problem for future generations beyond the scope of present business and political economics.

RedShift BioAnalytics (Burlington, MA)

RedShift BioAnalytics (Burlington, MA; no SBIR), which makes bioanalytical tools for the life sciences and biopharmaceutical market, raised $6M in a new round of equity financing, according to a Form D filing. [BostInno, Oct 23, 18]

Redwood Robotics (San Francisco, CA)

Over the last half-year, Google has quietly acquired seven technology companies in an effort to create a new generation of robots. .... not something aimed at consumers. Instead, the company’s expected targets are in manufacturing .... Among the companies are Schaft, a small team of Japanese roboticists who recently left Tokyo University to develop a humanoid robot, and Industrial Perception (Palo Alto, CA; no SBIR), a start-up here that has developed computer vision systems and robot arms for loading and unloading trucks. Also acquired were Meka (San Francisco, CA; no SBIR) and Redwood Robotics (San Francisco, CA; no SBIR), makers of humanoid robots and robot arms, and Bot & Dolly (San Francisco, CA; no SBIR), a maker of robotic camera systems that were recently used to create special effects in the movie “Gravity.” A related firm, Autofuss (San Francisco, CA; no SBIR), which focuses on advertising and design, and Holomni (Mountain View, CA, no SBIR) a small design firm that makes high-tech wheels. The seven companies are capable of creating technologies needed to build a mobile, dexterous robot. Mr. Rubin said he was pursuing additional acquisitions. [John Markoff, New York Times, Dec 4, 13] Note that all the US companies live around San Francisco Bay with the hotbed of innovative venture capital. And none needed SBIR to attract major investment.

RedZone Robotics (Pittsburgh, PA)

RedZone Robotics (Pittsburgh, PA; $1.6M SBIR) announced a partnership with Oracle in which it will develop tools for wastewater management companies to better manage underground systems, the companies said. [Stephanie Novak, Pittsburgh Business Times, Feb 17, 14]

Innovation Works and the Pittsburgh Life Sciences Greenhouse have spent the past decade as a tag-team source for fledgling companies — ideas even — to find the financial support needed to grow into viable, productive and profitable companies. .... Looking at the 2001-2005 period, firms funded by the two groups during this period include Aethon (no SBIR), Vivisimo ($700K SBIR), ALung Technologies (no SBIR), Plextronics ($300K SBIR), Inc., RedZone Robotics ($1.6M SBIR) and Thorley Industries (no SBIR) (4moms). Other than Vivisimo, which was bought by IBM in 2012, all of those companies are core firms in the portfolios of local venture capital firms [Ethan Lott, Pittsburgh Business Times, Jul 8, 13]

RefleXion Medical (Burlingame, CA)

RefleXion Medical (Hayward, CA; $4M SBIR) announced the initial closing of a $105M equity raise [which] will allow RefleXion to extend commercialization of its breakthrough SCINTIX® therapy for treating all stages of indicated solid tumor cancers, including metastatic disease. [company press release, Nov 15, 2023]

RefleXion (Hayward, CA; $4M SBIR) announced the [FDA] has granted the first marketing clearance for its SCINTIX™ biology-guided radiotherapy, a cutting-edge treatment applicable for early and late-stage cancers. [company press release, Feb 2, 2023]

RefleXion Medical (Hayward, CA; $3M SBIR) medical equipment company developing the first biology-guided radiotherapy system for targeted, personalized cancer treatment, announced that it has closed a $46 million Series B round of funding. [company press release, Apr 14, 16]

RefleXion Medical (Burlingame, CA; no SBIR) a company that makes a device that marks tumors for targeted radiation therapy, said today that it raised $11.6 million in Series A funding. ... said its device is the first that can target cancer for radiation therapy using a patient's specific tumor biology rather than use implanted markers to identify them. [Eric Van Susteren, Silicon Valley Business Journal, Apr 4, 14]

Refuge Biotechnologies (Menlo Park, CA)

Refuge Biotechnologies (Menlo Park, CA; no SBIR), leveraging gene engineering technologies to develop intelligent cell therapeutics programmed to make decisions inside of patients, announced the closing of a $25 million Series B investment round [to] support advancement of cell therapies developed with Refuge's receptor-dCas platform, which utilizes a mutated or dead Cas9 (dCas) as a targeting mechanism to enable precision CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi). [company press release, May 2, 18]

Regado Biosciences (Durham, NC)

Duke spinout Regado Biosciences dusts itself off after halting a clinical trial and watching its share price plunge into penny stock range ...said it would halt tests on a product, called Revolixys Kit, it hoped to market for use in heart surgeries after too many reports of serious allergic reactions ... As of June 30 it had $73 million in cash, thanks in part from the remaining money it raised during a public offering in April. [Jason deBruyn, Triangle Business Journal, Aug 26, 14]

Regado Biosciences (Morrisville, NC; one SBIR, founded 2011), a drug developer that spun out of Duke University, has seen its share price lose more than 60 percent of its value while it pauses a clinical trial to review safety data. ... The total costs for the trial are estimated at $150 million. Regado raised $60 million in April and $20 million earlier this year. [Jason deBruyn, Triangle Business Journal, Jul 7, 14]

Duke University spinout Regado Biosciences (Basking Ridge, NJ; one SBIR) priced its [IPO to] raise about $56 million [Jason deBruyn, Triangle Business Journal, Apr 11, 14]

Duke University spinoff Regado BioSciences (Basking Ridge, NJ; one SBIR) hit the public markets today and raised $43 million .... developing a system designed to stop blood from clotting [Jason deBruyn, Triangle Business Journal, Aug 22, 13]

Regado Biosciences (Basking Ridge, NJ; one SBIR) became one of the few biotechs of late to stumble into the public markets. Regado downsized its IPO and cut its offering price considerably before finally hitting the Nasdaq raising a total of roughly $43 million. [Ben Fidler, xconomy.com, Aug 23, 13]

Duke spin-off Regado BioSciences (Basking Ridge, NJ; one SBIR in 2004) secured $51 million from investors, ... a testament to the outstanding clinical results and potential game-changing therapeutic value we have demonstrated to date for REG1,” [CEO says]. [Lauren Ohnesorge, Triangle Business Journal, Dec 19, 12]

Regado Biosciences (Basking Ridge, NJ; one SBIR), a drug-development company whose technology was invented at Duke University, recently raised new funding that will see it through the bulk of next year. ... The company, which is developing several blood thinners, isn't saying how much money it raised. CEO David Mazzo said that the new funding is an extension of the $40 million round of financing it completed in December 2009. ... The company's leading experimental drug, REG1, is an anti-coagulant aimed for use during angioplasty and stent implants. [David Ranii, Raleigh News & Observer, Jul 2, 11]

Regado Biosciences (Durham, NC; one SBIR) raised $23M from VCs to continue testing a drug that promises to make heart surgery safer. [Raleigh News & Observer, Mar 27]

ReGear Life Sciences (Pittsburgh, PA)

ReGear Life Sciences (Pittsburgh, PA; no SBIR) medical-device firm, has raised $1.25 million from investors, according to [SEC] filing ... manufactures therapeutic deep heating products used to accelerate healing and reduce pain associated with injury and aging, using technology originally developed by the U.S. Navy to warm SEAL-team members and deep-sea divers. [Patty Tascarella, Pittsburgh Business Times, Dec 15, 14]

Regen Biologics (Franklin Lakes,NJ)

REGENXBIO down 20% [Oct 4, 21]

REGENXBIO up 16% [Feb 25, 19]

REGENXBIO up 10% [Aug 30, 18]

The FDA announced its intention to rescind a 510(k) medical device registration held by ReGen Biologics (Hackensack, NJ; $400K SBIR) for the company’s Menaflex collagen scaffold. The FDA granted marketing approval for the product in 2008. However, on Oct. 14, 2010, the FDA notified the company that it intended to rescind prior clearance, stating, “The FDA has now concluded that the Menaflex device is intended to be used for different purposes and is technologically dissimilar from devices already on the market” and that “these differences can affect the safety and effectiveness of the Menaflex device. For example, instead of simply repairing or reinforcing damaged tissue like predicate devices, Menaflex is intended to stimulate the growth of new tissue to replace tissue that was surgically removed. Because of these differences, the Menaflex device should not have been cleared by the agency.” [JM Garvey, Mass High Tech, Jan 18, 11]

[FDA] panel of outside experts found that there isn’t enough scientific evidence to come to a firm conclusion about the benefits of a knee device approved by the FDA in 2008. ... cited inadequate and low-quality evidence about the effectiveness of the Menaflex implant made by ReGen Biologics (Franklin Lakes, NJ; four Phase 1 SBIRs in mid 1990s), and not enough information about the device’s safety. [Alicia Mundy, Wall Street Journal, Mar 24, 10]

The FDA said that four New Jersey congressmen and its own former commissioner unduly influenced the process that led to its decision last year to approve a patch for injured knees, an approval it is now revisiting. .. The agency’s scientific reviewers repeatedly and unanimously over many years decided that the device, known as Menaflex and manufactured by ReGen Biologics (Franklin Lakes, NJ; $400K SBIR a decade ago), was unsafe because the device often failed, forcing patients to get another operation. But after receiving what an F.D.A. report described as “extreme,” “unusual” and persistent pressure from four Democrats from New Jersey ... agency managers overruled the scientists and approved the device for sale in December. [Gardiner Harris and David Halbfinger, New York Times, Sep 25, 09]

The recent approval of a new device to treat knee injuries followed a lobbying campaign that overcame repeated rejections by scientists within the FDA, agency documents show. The FDA's internal dissent over Menaflex, which targets the most-common knee injury afflicting everyone from high-school athletes to baby boomers, is straining a government agency that oversees a quarter of the U.S. economy. Some senior FDA staff members complained in documents that the handling of Menaflex, made by ReGen Biologics (Franklin Lakes, NJ; $400K SBIR)., shows how political and industry pressure can influence scientific conclusions. [Alicia Mundy, [Wall Street Journal, Mar 6]

Regenerative Medical Solutions (Chicago/Madison))

Eight Wisconsin biotech companies have been selected as winners of the BioForward 2013 Emerging Company Showcase: ABL Technologies LLC (Greenfield, WI; no SBIR); Co-D Therapeutics (Madison, WI; no SBIR); Imbed Biosciences (Madison, WI; no SBIR) medical device company developing novel and patent-pending technologies for imbedding bioactive molecules in wound dressings and surgical implants [company website]; Insert MRI (no SBIR) developing a platform technology for encapsulating workflow 'apps' to interactively guide magnetic resonance (MR) image-guided surgical procedures [company website]; Microscopy Innovations (Marshfield, WI; no SBIR) New Capsule-based System for preparing Microscopy Specimens [company website]; Regenerative Medical Solutions (Chicago/Madison; no SBIR) develop a protocol to grow healthy and resilient pancreatic stem cells [company website]; Stealth Therapeutics (Madison, WI; no SBIR) less invasive medical devices [company website]; and XenoGen Biosystems ( Madison, WI; no SBIR) Mathematical Modeling and Computing for the Life Sciences [company website]. ... represent "a cross section of emerging companies in our industry sector that we feel are going to make an impact down the road," said Bryan Renk, BioForward's executive director. [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 4, 13]

Regenerative Sciences (Broomfield, CO)

A U.S. federal court has found that a stem cell therapy offered by a Colorado clinic is a regulated drug. The ruling could spur a U.S. Food and Drug Administration (FDA) crackdown on other clinics offering untested adult stem cell treatments. Regenerative Sciences (Broomfield, CO; no SBIR) uses stem cells extracted from a patient’s own bone marrow to treat bone and joint injuries. The company calls its treatment a medical procedure. But in a 2010 suit, FDA argued that because the stem cells are more
than “minimally manipulated” and the procedure uses reagents that cross state lines, the cells are an FDA-regulated biological drug. [Science, Aug 3]

Regeneron

Regeneron and 2seventy bio (no SBIR) have revealed the candidate spearheading their CAR-T pact. Working with the bluebird bio spinout, Regeneron has selected MUC16 as the target for the first CAR-based solid tumor program. Bluebird and Regeneron began working together on oncology cell therapies in 2018. [Nick Paul Taylor, Fierce Biotech, Jan 11, 22]

Regentys (Miami Lakes, FL)

Regentys (formerly Asana Medical (Miami Lakes, FL; no SBIR, founded 2013) Former 43North (New York state) winner receives $15 million investment. [Dan Miner, Buffalo Business First, Dec 3, 18] developing a tissue engineered therapy for the treatment of Ulcerative Colitis (UC).[company website]

RegenXbio (Rockville, MD)

RegenXBio is already waving a flag to show that the Hunter syndrome gene therapy RGX-121 is headed for an accelerated approval request at the FDA. The company has been given the go-ahead from the FDA to file its biologics license application for the therapy under the accelerated review pathway, which allows drugs for conditions with an unmet need to reach patients sooner. But in this case, sooner means 2024, which is when RegenXBio plans to officially submit the application. [Fierce Biotech, Aug 4, 2022]

REGENXBIO (Rockville MD; $1.1M SBIR), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, announced the [FDA] clearance of the Investigational New Drug (IND) application to evaluate the suprachoroidal delivery of RGX-314 in patients with diabetic retinopathy (DR). The IND is active, and REGENXBIO plans to begin dosing patients in a Phase II trial, ALTITUDE, in the second half of 2020. [company press release, Aug 25, 20]

A decade after its founding, biotech RegenxBio (Rockville, MD; no SBIR, founded 2009) made three big moves in the last week to get products to market. It struck a deal with Pfizer, giving the pharma giant licensing rights to its tech platform for developing a gene therapy treatment. Then it partnered up with Swiss biopharma Neurimmune AG to develop gene therapies for neurodegenerative diseases. And to top it off, RegenxBio launched a research program surrounding treatments for hereditary angioedema, a life-threatening blood disorder. That's one hell of a week. Read more from the WBJ [subscriber content]. [Kieran McQuilkin, DCInno, Aug 2, 19] total funding $112M [crunchbase.com]

REGENXBIO (Rockville, MD) will relocate to a larger headquarters and research facility, and double its [150 employee] workforce again, within five years. ... with several gene therapy trials underway, will expand to a larger laboratory and research space ... Maryland has approved a $700,000 conditional loan. Montgomery County has approved a $100,000 conditional grant, and will help with expediting permits for the new location. [Jeff Clabaugh, WTOP news, Dec 4, 18]

RegenxBio (Rockville, MD; SBIR) locked in a new headquarters site [where[ it is receiving from Maryland and Montgomery County more than $800,000 in financing. (Washington Business Journal, Dec 5, 18)

Abeona Therapeutics and REGENXBIO announced a license agreement to REGENXBIO’s NAV AAV9 vector for the treatment of four diseases ... REGENXBIO has granted Abeona an exclusive worldwide license (subject to certain non-exclusive rights previously granted for MPS IIIA), with rights to sublicense, to REGENXBIO’s NAV AAV9 vector for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 Disease and CLN3 Disease. In return for these rights, REGENXBIO will receive a guaranteed $20 million upfront payment, $10 million of which will be paid upon signing and $10 million of which will be paid within 12 months of the effective date. In addition, REGENXBIO will receive a total of $100 million in annual fees, payable upon the second through sixth anniversaries of the agreement, $20 million of which is guaranteed. REGENXBIO is also eligible to receive potential commercial milestone payments of up to $60 million. [joint companies press release, Nov 5, 18]

REGENXBIO down 13% [Sep 17, 18]

REGENXBIO up 10% [Sep 14, 18]

Gene therapy specialist RegenXBio has added another program to its pipeline, going after Batten disease variant CLN2. [Phil Taylor,Fierce Biotech, Aug 30, 18]

REGENXBIO up 10% [Jun 20, 18]

REGENXBIO up 13% [May 9, 18]

REGENXBIO up 10% [Apr 16, 18]

REGENXBIO up 19% [Apr 10, 18]

REGENXBIO up 16% [Apr 9, 18]

REGENXBIO down 10% [Mar 12, 18]

REGENXBIO up 27% [Mar 7, 18] reported that it still has cash to burn on R&D expenses that far outstrip revenue

REGENXBIO down 21% [Jan 5, 18]

REGENXBIO up 10% [Sep 25, 17]

Dimension Therapeutics (Cambridge, MA; no SBIR) up 40% [Sep 18, 17] a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, today confirmed that it has received a non-binding, unsolicited proposal from Ultragenyx Pharmaceutical (no SBIR) to acquire Dimension for $5.50 per share in cash. But As announced on August 25, 2017, Dimension entered into a definitive merger agreement with REGENXBIO under which REGENXBIO will acquire Dimension in an all-stock transaction. [company press release, Sep 18, 17]

Dimension Therapeutics (Cambridge, MA; no SBIR) agreed to be acquired by RegenxBio (Rockville, MD; no SBIR), the gene therapy developer that originally helped form the company four years ago. RegenxBio will pay approximately $86 million. By comparison, Dimension went public at $13 per share in 2015. Dimension’s closing stock price on [Aug 24] was $1.20. [xconomy.com, Aug 25, 17]

RegenXBio down 10% [Aug 17, 17]

REGENXBIO up 12% [Mar 17, 17]

RegenXBio up 13% [Nov 10, 16]

RegenXBio up 10% [Oct 10, 16]

REGENXBIO up 15% [Aug 12, 16]

REGENXBIO down 11% [Jun 27, 16]

REGENXBIO up 10% [May 11, 16]

RegenXBio down 10% [Mar 24,16]

Starting 2015 with five people, Regenxbio (Rockville, MD; no SBIR) has grown to more than 60 employees ... by the end of 2016, intends to launch three clinical trials has had quite a year. The gene therapy company had one of the region's largest venture rounds in 2015, raising more than $100 million before going public in September, where it raised an additional $139 million.... has eight licensees, including Baxalta, which is working on a hemophilia therapy; has five programs in its own pipeline. [Tina Reed, Washington Business Journal, Mar 2, 16]

RegenXBio up 15% [Nov 6, 15]

RegenXBio down 11% [Oct 8,15]

RegenXBio up 17% [Oct 2,15]

RegenXBio down 14% [Oct 1,15]

RegenXBio up 13% [Sep 30, 15]

RegenXBio down 13% [Sep 22, 15]

RegenxBio (Rockville, MD; no SBIR) has priced shares for its initial public offering, which could raise as much as $121 million. ... for product development and general working capital. RegenxBio’s gene therapy technology introduces healthy genes into patients suffering from generic disorders. The company is initially focusing on treating diseases affecting the central nervous system and eyes. [Jeff Clabaugh, Washington Business Journal, Sep 10, 15]

Among the greatest risks noted by biotech RegenXBio (Rockville, MD; no SBIR) as it filed to go public? The future for its core technology — gene therapy — is still quite unpredictable. ... No gene therapy product has been approved in the United States and only one such product has been approved in the European Union, they disclosed. ... RegenxBio's gene therapy technology introduces healthy genes into patients suffering from genetic disorders, initially focusing on treating rare genetic diseases affecting the central nervous system and eyes. [Tina Reed, Washington Business Journal, Aug 18, 15]

Regenxbio (Washington, DC; no SBIR) raised a $30 million funding round to move its drugs into clinical trials. ... the company's gene therapy technology, which introduces healthy genes into patients suffering from genetic disorders, will initially focus on treating diseases affecting the central nervous system and eyes [Jennifer Nycz-Conner, Washington Business Journal, Jan 22, 15]

Regulus Therapeutics

Regulus Therapeutics began trading in an [IPO], posting gains. Before listing, it increased the size of its offering and reduced the price of its shares. [Wall Street Journal, Oct 5, 12]

Regulus Therapeutics (San Diego, CA; no SBIR, fiounded 2007) has filed [for IPO] ... focuses on microRNA, a biotechnology specialty area. RNA, or ribonucleic acid, was only discovered about a dozen years ago. It’s considered important because RNA can influence an entire network of genes. With diseases, RNA doesn’t act normally. So by targeting RNA strands, biotech researchers may be onto a new way to treat certain ailments.Regulus is currently working on therapies for several diseases including kidney fibrosis, hepatitis C, cancer and cardiovascular diseases. Long-time San Diego biotech entrepreneur Kleanthis Xanthopoulos is the company’s chief executive and president ... has formed some heavyweight strategic alliances with pharmaceutical giants AstraZeneca, Sanofi and GlaxoSmithKline, who have provided a combined $56.6 million in upfront research funding. Regulus, which spun out of Isis Pharmaceuticals and Alnylam Pharmaceuticals, also has raised an additional $50 million from founders and other investors. .[Mike Freeman, utsandiego.com, Aug 22, 12]

Regulus Therapeutics (Carlsbad, CA; no SBIR) landed an investment of at least $35 million for drug discovery and development from French pharmaceutical giant Sanofi-Aventis, with the initial work targeting fibrosis. The development alliance has a potential value of $750 million if certain milestones are met, making it the largest partnership in Regulus’ biotechnology specialty, known as microRNA. .... 45 employees, was founded by Isis Pharmaceuticals and Alnylam Pharmaceuticals. The companies each put about $20 million into Regulus, then stocked its staff and board with some of the leading experts in the microRNA field, Simeonidis said. [Mike Freeman, signonsandiego.com, Jun 23, 10]

Alnylam Pharmaceuticals said it was one of two firms that invested a collective total of $20 million in Regulus Therapeutics (no SBIR) ... In 2007, Alnylam and Isis Pharmaceuticals established Regulus to "focus on the discovery, development, and commercialization of microRNA-based therapeutics," the two companies said in a press release. [Boston Globe, Mar 5, 09].

Rehabtics LLC (Baltimore, MD)

Fifteen university research teams from Maryland will receive a total of $4.1 million to work with local companies to turn their research into products that could one day be sold on the commercial market. .... MIPS will contribute $1.8 million and private companies will contribute $2.8 million. The companies: A&G Pharmaceutical (Columbia, MD; no SBIR), Rehabtics LLC (Baltimore, MD; no SBIR) High Impact Environmental (Church Hill, MD; no SBIR), Birich Technologies (Towson, MD; no SBIR), Earth Networks (Germantown, MD; no SBIR), Fiberight (Halethorpe, MD; no SBIR), CoolCAD Electronics (College Park,MD $1.6M SBIR), XChanger Companies (Annapolis, MD; no SBIR), Remedium Technologies (College Park, MD; no SBIR), Pothole Pros LLC (Waldorf, MD; no SBIR), Hoopers Island Oyster Aquaculture (Fishers Creek, MD; no SBIR), Metompkin Seafood (Crisfield, MD; no SBIR) GreatGrow Maryland LLC (Rock Hall, MD; no SBIR), vCalc (Hagerstown, MD; SBIR), Shore Thing Shellfish (Tall Timbers, MD; no SBIR). ($114,094) [Sarah Gantz, Baltimore Business Journal, Feb 26, 14]

Rejuvenate Bio (Brookline, MA)

Rejuvenate Bio (Brookline, MA; $6M SBIR) claims it has used a technology called reprogramming to rejuvenate old mice and extend their lives, a result suggesting that one day older people could have their biological clocks turned back with an injection—literally becoming younger. [Antonio Regalado, MIT Tech Review, Jan 9, 2023]

Relativity Space (Los Angeles, CA)

startup Relativity Space (Los Angeles, CA; founded 2015) announced that it has closed a $140 million Series C funding round ... has ambitious plans to 3D print the entirety of its rockets, reducing workforce costs and increasing the company's ability to iterate on rocket design [Eric Berger, Ars Technica, Oct 1, 19] prior funding $46M [crunchbase.com]

Relay Terapeutics Cambridge, MA)

Relay Therapeutics (Cambridge, MA; no SBIR) focused on solid tumors, filed for a $200M IPO. [Rowan Walrath, BostInno, Jun 25, 20] total funding $520M [crunchbase.com]

Massachusetts startups raised $12B across 660 deals in 2018. Some notable ones include Cambridge Telematics (software Cambridge, MA; no SBIR) $500M, and Relay Therapeutics (Cambridge, MA; no SBIR) [at the intersection of computation and biotechnology] [company website], $400M. [Srividya (Sri) Kalyanaraman, BostInno, Jan 11, 19]

Relay Therapeutics (Cambridge, MA; no SBIR, founded 2016) dedicated to developing breakthrough medicines by leveraging insights from protein motion, announced the successful completion of a $63 million Series B financing [company press release, Dec 14, 17]

ReliantHeart (Houston, TX)

ReliantHeart (Houston, TX; no SBIR), a medical device company that is developing a ventricular assist device, has raised the first portion of what could be between a $16 million and $20 million capital raise. ... brings the total fundraising for ReliantHeart to just under $22 million, said [CEO Ford]. [Joe Martin Reporter Houston Business Journal, Nov 16, 16]

ReliefBand Technologies (Horsham, PA)

ReliefBand Technologies LLC (Horsham, PA; no SBIR) raised $3M for the launch of the next-generation of its wearable nausea-relief device [John George, Philadelphia Business Journal, Nov 9, 17]

Relievant Medsystems (Redwood City, CA)

medical device startup Relievant Medsystems (Redwood City, CA; no SBIR) raised a $36 million Series D round [Luke Stangel, Silicon Valley Business Journal, Oct 12, 16] .... pioneering the therapy of nerve ablation within vertebral bodies for the treatment of chronic low back pain [company website]

Relypsa (Redwood City, CA)

Relypsa (Redwood City, CA; no SBIR) up 59% [Jul 21, 16] Galenica AG, the owner of Switzerland’s biggest pharmacy network, agreed to buy Relypsa for about $1.53 billion [cash] to gain a new medicine and a commercial network in the U.S. ... The transaction gives Galenica’s business unit Vifor Pharma a U.S. commercial network and global rights to Relypsa’s drug Veltassa, which was the first new medicine in 50 years to be approved in the U.S. for hyperkalemia, a condition in which there is too much potassium in the blood. [Marthe Fourcade and Caroline Chen, bloomberg.com, Jul 21, 16]

Relypsa up 10% [Jun 28, 16]

[FDA]rejected a drug from AstraZeneca called ZS-9 for the kidney disease hyperkalemia, citing manufacturing issues. That’s positive news for Relypsa (Redwood City, CA; no SBIR), which has a rival hyperkalemia drug on the market—Relypsa shares soared 37 percent Friday morning—and a setback for the British drugmaker, which acquired ZS-9 when it paid $2.7 billion for Coppell, TX-based ZS Pharma in November. [Ben Fidler, xconomy.com, May 27, 16]

Relypsa down 19% [May 4, 16] Net loss for the first quarter 2016 was $54.8 million compared to $29.7 million for the comparable period in 2015. [company press release, May 4, 16]

Relypsa down 16% [Apr 15, 16]

Relypsa up 68% [Apr 7, 16]

Relypsa up 12% [Mar 17,16]

Relypsa down 10% [Mar 15,16]

Relypsa down 15% [Feb 25, 16]

Relypsa up 31% [Dec 4, 15]

Relypsa up 10% [Nov 18, 15]

Relypsa (Redwood City,CA; no SBIR) won its first drug approval as the [FDA] approved its treatment for potentially fatal levels of potassium in chronic kidney disease patients. ... set for a quick launch of the drug — called patiromer and branded under the name Veltassa — that would give it a six-month or greater lead on its closest competition, ZS Pharma (San Mateo, CA; no SBIR). [Ron Leuty San Francisco Business Times, Oct 21, 15]

Relypsa up 10% [Nov 2, 15]

Relypsa up 13% [Oct 28, 15]

Relypsa up10% [Oct 26,15]

Relypsa up 17% [Oct 23,15]

Relypsa down 27% [Oct 22,15]

Relypsa up 14% [Oct 15,15]

Relypsa up 11% [Jun 4, 14]

Relypsa up 16% [May 22, 14]

Relypsa down 10% [Apr 3, 14]

Relypsa down 19% [Mar 26, 14]

Relypsa up 12% [Mar 25, 14]

Relypsa up 19% [Feb 11, 14]

biotech Relypsa (Redwood City, CA; no SBIR) raised $75 million last week by offering 6.9 million shares at $11, below the company’s expected price. [Bruce Bigelow, xconomy.com, Nov 22, 13]

Relypsa (Redwood City, CA; no SBIR), a 6-year-old drug developer with an experimental drug in a late-stage trial, will seek up to $126.5 million in an [IPO] ..... scored $62.4 million in venture funding a year ago, will use the money to validate the manufacturing process used to make its lead drug, patiromer, as well as to actually make the powder. [Ron Leuty, San Francisco Business Times, Sep 30, 13]

Remedium Technologies (College Park, MD)

The BioMaryland Center has awarded nearly $1 million in grants to five life sciences firms. The companies received up to $200,000 each and will use the funding for research. ... part of the Maryland Department of Business and Economic Development. The recipients:

    Animalgesic Labs (Baltimore, MD; no SBIR) manufacturing its first batch of FDA authorized pain medication
    Cardiosolv (Baltimore, MD; one SBIR) undertaking a study to create a less-invasive treatment for tachycardia patients.
    Adlyfe (Rockville, MD; $1.7M SBIR) commercializing technologies for the early detection of Alzheimer’s disease;
    CrispTek   (Columbia, MD; no SBIR) developing and marketing three new certified gluten and allergen-free baking mixes
    Remedium Technologies (College Park, MD; no SBIR) advancing its Hemogrip TM, a proprietary lifesaving technology to stop traumatic bleeding.   [Ryan Sharrow, Baltimore Business Journal, Jun 4, 13]

Remedy Plan Therapeutics (Rockville, MD)

Remedy Plan Therapeutics (Rockville, MD; no SBIR, founded 2011) developing cancer drugs kicks off $13M round with pitch contest win [Morgan Eichensehr, Baltimore Business Journal, Sep 21, 18]

A company that designs surveillance cameras for the military has moved from the suburbs of Boston to Putnam, winning $1 million in venture funding from Connecticut Innovations, the state's quasi-public authority that invests in technology firms.RemoteReality (Westborough, MA; $2.7M SBIR) also received venture capital from a private VC firm, Kuwait Holdings and an individual investor. RemoteReality, which has received more than $10 million from the Pentagon to advance its technology, is looking to hire engineers. [Mara Lee, Hartford Courant, Dec 22, 11]

Rempex Pharmaceuticals (San Diego, CA)

In its second round of venture funding, Rempex Pharmaceuticals (San Diego, CA; no SBIR) raised $67.5 million. ... has raised a total of $76 million since it was started this summer, seeks treatments aimed at antibiotic resistant bacteria. [SEF Brown, San Francisco Business Times, Nov 9, 11]

Renaissance Services (Springfield, OH)

Renaissance Services (Springfield, OH; $900K SBIR) won a two-year $2.9 million U.S. Air Force contract to study and improve the manufacturing process for tooling used to produce investment cast jet engine turbine blades. [Joe Cogliano, Dayton Business Journal, Sep 23, 13]

Renaissance Services (Springfield, OH; $900K SBIR, founded 2003) was awarded [a $2.9M] two-year contract to study and improve the manufacturing process for tooling used to produce investment cast jet engine turbine blades. .... under a Rapid Innovation Fund program, which is designed to resolve operational challenges “characterized by the national security areas of particular interest to the Air Force and Department of Defense.” [Joe Cogliano, Dayton Business Journal, Sep 27, 13]

Renegade Materials (Springboro, OH)

Renegade Materials (Springboro, OH; $1.7M SBIR) high-tech manufacturer may be gearing up for another expansion. ... considering a 10,000-square foot addition to its 22,500-square building ... could be a signal the company has signed a deal for high-rate production of carbon composite materials for aircraft structures [Joe Cogliano, Dayton Business Journal, Jul 6, 15]

Renegade Materials (Springboro, OH; $1.8M SBIR, 22 employees) is gearing up for an expansion. Company officials confirmed it will use a nearby 40,000-square-foot facility for high-rate production of carbon composite materials for aircraft structures. [Joe Cogliano, Dayton Business Journal, Oct 18, 13]

Renegade Materials (Springboro, OH; $1.6M SBIR) is ready for a boom. The 22-employee company already has selected equipment and blueprints to more than quadruple its 26,000-square-foot footprint in Springboro, should deals in the works come through [Joe Cogliano, Dayton Business Journal, Jun 1, 12]

Reneo Pharmaceuticals (San Diego, CA)

Reneo Pharmaceuticals (San Diego, CA and UK; no SBIR) a clinical stage pharmaceutical company, announced that it has completed a $50 million Series A financing to develop therapies for diseases associated with deficits in cellular metabolism and energy production. [company press release, May 20, 19]

Vtv Therapeutics (High Point, NC; no SBIR) announced that it has entered into a global licensing agreement [for its diabetes therapies to be developed and commercialized in China and other Pacific Rim countries] with Reneo Pharmaceuticals (San Diego, CA; no SBIR), focused on developing treatments for orphan diseases. ... grants Reneo Pharmaceuticals exclusive worldwide rights to research, develop and commercialize vTv Therapeutics’ selective peroxisome proliferator-activated receptor delta (PPAR-delta) program. [company press release, Dec 21, 17]

Renerva (Pittsburgh, PA )

Renerva LLC (Pittsburgh, PA; no SBIR), developing innovative technology for peripheral nerve injuries, announced $2.4 million in nondilutive financing from the [DOD] through a Medical Technology Enterprise Consortium (MTEC) Award [company press release, Dec 14, 18]

ReNeuroGen (Elm Grove, WI)

ReNeuroGen LLC (Elm Grove, WI; some SBIR, founded 2016) drug could reverse effects of stroke, MS; working to raise a $1.75 million seed round, expected to close by the first quarter of 2019 [Molly Dill, Milwaukee Business News, Oct 1, 18]

Renewable Alternatives

Too Much Transfer. Mere months ago, the University of Missouri routinely touted chemical engineering professor Galen Suppes for his innovative research into renewable energy. Now the school considers him a renegade scientist trying to keep the university from getting its fair share of profits from his inventions. Missouri is suing the professor in federal court. ... In 2003, they formed a spin-off company, Renewable Alternatives ($1M SBIR), to develop dozens of inventions related to fuel cell technology, nontoxic diesel fuel additives and an eco-friendly antifreeze. [AP, Feb 9, 09]

Renewable Energy Group

after nine years and $81 million, the owners of LS9 (San Francisco, CA; no SBIR) sold the company last month to biodiesel maker Renewable Energy Group for $40 million in cash and stock, with an additional $21.5 million promised if technology and production milestones are met. LS9 had hoped to be selling diesel to refineries at least two years ago [Martin LaMonica, technologyreview.com, Feb 5, 14] Sweet technology, too expensive.

Renmatix (King of Prussia, PA)

Virent announced another step toward production of a key chemical needed by Coca-Cola to make plastic bottles entirely from plants. [Milwaukee Journal Sentinel, Dec 6, 13].... Renmatix (King of Prussia, PA; no SBIR) and Virent announced a strategic collaboration to convert affordable cellulosic sugars to renewable chemicals and bio-based packaging materials. Under the terms of the multi-phase development project, Renmatix’s Plantrose™ platform will be evaluated and potentially optimized to provide an affordable sugar stream for Virent’s Bioforming® process for the large-scale production of bio-based paraxylene. Paraxylene is a basic raw material used in the manufacture of purified terephthalic acid (PTA), an important chemical in the production of plastic bottles and fibers made from polyethylene terephthalate (PET) .... The development of Virent’s BioForming® technology platform is supported through strategic partners including Cargill, The Coca-Cola Company, Honda and Shell, as well as 80 employees [Virent press release, Dec 6]

Renovacor (Philadelphia, PA)

Renovacor (Philadelphia, PA; no SBIR), a preclinical-stage biopharmaceutical [Temple University spinoff] company focused on developing transformative gene therapy-based treatments for cardiovascular disease, today announced the successful completion of an $11 million Series A financing [to] advance the Company’s first-of-its-kind gene replacement therapy through filing of an IND in preparation to initiate human clinical trials in DCM patients who have mutations in their BAG3 gene. [company press release, Aug 14, 19]

Renovia (Boston, MA)

Renovia (Boston, MA; no SBIR, founded 2016) dedicated to discovering and delivering first-line digital therapeutic and diagnostic devices for women with pelvic floor disorders, announced the close of $42.3 million in financing, including $32.3 million in Series B equity and $10 million in venture debt. Proceeds from the funding will be used to support Renovia’s clinical trials, product development pipeline, corporate development and future commercial launches. [company press release, Aug 21, 18] total funding $50M [crunchbase.com]

Renovion (Durham, NC)

Renovion (Chapel Hill, NC; $1.8M SBIR) announced that the first patient has been enrolled in a Phase 3 clinical study evaluating ARINA-1, an investigational nebulized therapy to prevent the progression of bronchiolitis obliterans syndrome (BOS) progression in individuals with a bilateral lung transplant. [company press release, Apr 20, 2023] .... landed a $15 million raise to advance multiple clinical programs focused on pulmonary diseases. announced that [FDA] has granted Fast Track designation to ARINA-1 for the prevention of bronchiolitis obliterans syndrome (BOS) progression in adults with a bilateral lung transplant. [company press release, Apr 3, 2023]

Renovion (Durham, NC; no SBIR, funded 2013), an early stage drug development company targeting the treatment of lung transplant and other chronic inflammatory respiratory diseases, announced that the FDA Office of Orphan Products has granted Orphan Designation in the US to the Company's nebulized therapy Arina-1 for the treatment of lung dysfunction following lung transplant. ... has raised over $1 million to support the development. [company press release, Jan 6, 17]

Renovis (S San Francisco, CA)

With Exelixis (no SBIR)and Renovis (South San Francisco, CA; $500K SBIR) already under his belt, the longtime Bay Area biotech entrepreneur's newest venture, Labrys Biologics(no SBIR), has acquired a Phase II-ready experimental migraine treatment from Pfizer and snagged $31 million in a Series A financing round. ... Labrys' new drug, called RN-307, was discovered and developed by South San Francisco's Rinat Pharmaceuticals (South San Francisco, CA; no SBIR) which Pfizer bought in 2006 [Ron Leuty, San Francisco Business Times, Jan 3,13]

Renovis (S San Francisco, CA; one Phase 2 SBIR) up 20% on news that German pharmaceutical company Evotec AG will buy it for $150 M in stock to expand its research into treatments for inflammatory diseases. [AP, Sep 19,07]

RenovoDerm (Columbus, OH; no SBIR)

A tissue engineering company developing materials to heal wounds and grow new blood vessels has raised $4.1 million in a round led by a "startup nursery." ParaGen Technologies LLC (Columbus, OH; no SBIR) is a parent company for medical device subsidiaries that use its core microfilament technology for specific applications. The first four are for healing skin, treating sports injuries, growing blood vessels and repairing hernias. company is a joint venture of Nanofiber Solutions LLC ($150K SBIR), which invented the technology, and Ikove Capital Partners. [Carrie Ghose, Columbus Business Journal, Dec 15, 17] three subsidiary companies are RenovoDerm, Atreon Orthopedics, and Vascular Genesis. [ParaGen website]

Rentech (Los Angeles, CA)

A Punter with Pounds. A British Virgin Islands-based investor offered $372M for Rentech (Los Angeles, CA; no SBIR) an alternative energy company building a $50M fuels plant in metro Denver, ... attempting to commercialize a process to make diesel and aviation fuel from coal, natural gas, petroleum byproducts and biomass such as wood chips. [Denver Post, Dec 19, 07]

Repare Therapeutics (Cambridge, MA and Canada)

Repare Therapeutics (Cambridge, MA and Canada; no SBIR) up 54% [Jun 19, 20], a leading precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics, announced the pricing of its upsized [IPO] to raise $220.0 million. [company press release, Jun 18, 20]

Repare Therapeutics (Cambridge, MA and Canada; no SBIR) raised an $82.5 million series B round to take synthetic lethality drugs into humans. [company press release, Sep 4, 19]

Replidyne

Repligen

Repligen up 20% [Apr 26, 19]

Repligen up 17% [Nov 1, 18] reported quarterly results

Repligen down 14% [Sep 26, 17]

Repligen up 10% [Jun 23,17]

Repligen up 12% [Jan 20, 16]

Repligen down 17% [Nov 6, 15]

Repligen up 10% [Oct 16,15]

Repligen up 11% [Oct 15,15]

Repligen up 23% [Jan 8, 15]

Replidyne up 16% [Jan 16, 08]

Repligen

Repligen down 10% [Oct 6,15]

Repligen down 12% [Sep 29,15]

Repligen up 17% [May 7, 15]

Repligen up 17% [Mar 13, 15]

Repligen down 10% [Dec 15, 14]

BioMarin Pharmaceutical (San Rafael, CA; $300K SBIR) orphan drug specialist will spend $2 million upfront — with the potential to pay $160 million in milestones — to Repligen ($1.7M SBIR) for a portfolio of experimental neurological drugs. [Ron Leuty, San Francisco Business Times, Jan 21, 14]

Repligen up 10% [Jan 30, 14]

Repligen up 10% [Apr 4, 13]

Repligen up 10% [Nov 8, 12]

Repligen up 12% [Sep 10, 12]

Repligen up 16% [Aug 2, 12]

Repligen down 10% [Jun 22, 12] said federal regulators have requested additional clinical trial data for their proposed imaging agent that is designed to improve detection of pancreas problems.[Boston Globe]

>Repligen down 40% [Apr 26, 12] said it expects U.S. health regulators to reject its imaging agent to detect structural abnormalities in the pancreas [Reuters]

Repligen up 11% [Jan 25, 12]

Repligen said it has completed the acquisition of the business of Novozymes Biopharma Sweden AB, the Swedish unit of Novozymes Biopharma. The all-cash transaction, which was announced in October, had Repligen making an upfront payment of $22.7 million.
[Chris Reidy, Boston Globe, Dec 21, 11]

Repligen said that it has a definitive agreement to buy the biopharma business of Novozymes A/S (Sweden) in a cash transaction of 17 million euros ($22.7 million) and future potential milestone payments of 4 million euros ($5.6 million) .... includes a 45,000-square-foot protein factory that will double Repligen’s manufacturing capacity and established product lines with long-term customers. The products include various forms of Protein A, which is fundamental to the production of monoclonal antibodies and growth factor products used in the large-scale fermentation of cells. [Mass High Tech, Oct 28, 11]

Repligen said today that the[FDA] has granted Fast Track status to its potential treatment for spinal muscular atrophy [Boston Globe, Jun 23, 11]

Repligen down 28% [Mar 7, 11] after it said Monday that a midstage clinical trial showed that one of its drug candidates was no more effective than a placebo in treating bipolar depression. [AP, Mar 7]

Repligen has taken in $1.4 million in Muscular Dystrophy Association (MDA) funding to aid research in a treatment for Spinal Muscular Atrophy (SMA). [Mass High Tech, Dec 15, 10]

Repligen has received three grants, totalling in excess of $6 million, to apply to its HDAC inhibitor research for neurodegenerative diseases like Friedreich’s Ataxia and Huntington’s Disease. [Mass High Tech, Aug 3, 10]

Repligen up 10% [May 27, 10]

Repligen said that the FDA has granted orphan drug designation to RG2833, the company's investigational drug to treat Friedreich's ataxia. [Boston Globe, May 24, 10]

Repilgen up 14% [Mar 31, 10]

Repligen said today that it extended its long-term deal to supply recombinant protein A to General Electric's GE Healthcare unit. [AP, Jan 28, 10]

Repligen won a $731,000 Muscular Dystrophy Association research grant to development treatment for Friedreich’s ataxia, a rare neurodegenerative disease. The grant is the second such funding from the MDA for the disease. [Mass High Tech, Dec 15, 09]

Replegen down 16% [Dec 9, 09] said that its pancreas imaging agent RG1068 did not meet its main goal in a late-stage clinical study. [Boston Globe, Dec 9]

Repligen down 10% [Dec 1, 08] On a stock bloodbath day

Repligen up 13% [Oct 16, 08]

Repligen down 16% [Oct 15, 08]

Repligen up 18% [Oct 10, 08]

Biopharmaceutical Repligen got $1.125 million in research grants to develop tools to help create new treatments for the rare neurodegenerative disease Friedreich’s ataxia. The Muscular Dystrophy Association awarded Waltham-based Repligen (Nasdaq: RGEN) $1 million and the Friedreich’s Ataxia Research Foundation and the National Ataxia Foundation combined to give $125,000, according to Repligen officials. Repligen will use the funds to develop and prepare drug candidates for clinical trials and also develop biomarkers to monitor the effect of the drugs. [Mass High Tech, Sep 4, 08]

Repligen up 14% after it reached a settlement in its lawsuit alleging patent infringement against large-cap Bristol-Myers Squibb's rheumatoid-arthritis treatment Orencia. [Wall Street Journal, Apr 9, 08]

Repligen up 11% [Apr 4, 08]

Repligen said it has started a Phase 3 clinical trial to evaluate an imaging agent that would help MRI tests better detect abnormalities in the ducts of the pancreas. ... about 150,000 pancreatic MRI's are conducted in the United States each year. [Boston Globe, Mar 27, 08]

Repligen down 12% [Feb 25, 08]

Repligen down 12% [Jan 4, 08]

Repligen got a $65 M settlement from ImClone Systems on a patent infringement lawsuit . [Mass High Tech, Sep 11]

Repligen jumped 25% on a favorable patent-suit ruling. [Jul 31, 06]

Repligen took a huge dive (42%) when it announced that its experimental treatment for autism flunked late-stage clinical trial, second-quarter revenue of $1.4 million, sells several drugs which it did not develop itself.

Replimune Group (Woburn, MA)

Replimune up 18% [Jun 25, 20]

Replimune up 16% [Jun 4, 20]

Replimune up 21% [Apr 30, 20]

Replimmune up 17% [Sep 20, 19]

Replimmune down 20% [Dec 27, 18]

Replimune up 17% [Oct 12, 18]

Replimmune down 11% [Oct 9, 18]

Replimune Group up 15% [Sep 4, 18]

Replimune Group (Woburn, MA; no SBIR) focused on developing next generation oncolytic immunotherapies, announced the completion of a $55 million Series B financing. The proceeds of the financing will primarily be used to generate human proof of concept data for its lead product, RP1, in multiple tumor types. The financing will also allow the Company to advance further product candidates from its Immulytic™ platform. [company press release, Sep 8, 17]

Smart Glass One company seems to have solved the problem of making smart windows that shut out sunlight on command. DOD has poured a lot of SBIR money into small companies who always seem to need another award. Research Frontiers Inc (Woodbury, NY) seems to have succeeded without any SBIR help. A Wall Street Journal story (Sep 19) tells how. It went public in 1986 to raise the money (investors will speculate) for the suspended particle technology. Says CEO Robert Saxe, it wasn't an overnight technology . Which should partially explain why SBIR wasn't the route. SBIR was not intended for such long slogs (although no Congressman would object to a long slog by a company in his district and all Congress would like to avoid answering such questions). Oh, the technology seemed to work but on closer examination of the economics, it was unstable, the crystals clumped, and the windows bulged. One materialist estimates that it would cost $15/sqft more than drapes and curtains which translates to a ten-year recovery period. How many landlords accept ten-year payback periods? (Actually, the lower the prevailing interest rate, the longer the max acceptable payback period.) So, government agencies, keep believing in smart window technology, but don't blindly believe the company's story about commercialization.

Reprieve Cardiovascular (Milford, MA)

medical device maker Reprieve Cardiovascular (Milford, MA: no SBIR) raised $15M in equity, according to an SEC filing. [Rowan Walrath, BostInno, Aug 7, 20]

Research Innovations

Future Army contracts. The Army revealed a new roster of industry partners under a potential $37.4B contract that covers knowledge-based professional engineering support services to command, control, communications, computers, intelligence, surveillance and reconnaissance programs. SBIR companies: Artel (now big, $300K); Dynetics (now big, 31 awards); Macaulay-Brown (now big, 23 awards); NetCentric (now big, $900K); Scientific Research (Now big, $16M); Array Information Technology (one SBIR); Bennett Aerospace (21 SBIR awards); Envistacom (one SBIR); Fibertek (127 SBIRs); Future Technologies ($1M); Fulcrum ($1.2M); LinQuest ($1M); Manufacturing Techniques (One SBIR); Navmar Applied Sciences (68 awards); Peerless Technologies ($2.6M); Research Innovations (one SBIR); Sonalysts (128 awards); SURVICE Engineering (50 awards); Truestone (one SBIR).[GovConWire, Oct 19, 18]

ReShape LifeSciences (San Clemente, CA)

ReShape Lifesciences (San Clemente CA; $300K SBIR) down 59% [Feb 6, 2023] announced the pricing of its upsized underwritten public offering of $8.00 per share [company press release, Feb 6, 2023]

ReShape Lifesciences (San Clemente, CA, formerly St Paul, MN; $500K SBIR) down 43% [Jan 4, 2023]

ReShape Lifesciences (San Clemente, CA, formerly St Paul, MN; $500K SBIR) up 132% [Jan 3, 2023]

ReShape Medical

ReShape Lifesciences (San Clemente CA; $300K SBIR) up 170% [Feb 3, 2023]

EnteroMedics (St Paul, MN), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, announced that it has acquired ReShape Medical (no SBIR) medical technology company that develops, manufactures and markets the ReShape Dual Weight Loss Balloon®, an FDA-approved, minimally invasive intragastric balloon designed to treat obesity patients with a body mass index (BMI) between 30 and 40, with one or more related comorbid conditions. [company press release, Oct 2, 17]

Resolve Therapeutics (Seattle, WA)

Resolve Therapeutics (Seattle, WA; no SBIR) said it's made a deal with Takeda Pharmaceutical Company Limited of Japan to commercialize Resolve's lupus treatment compounds under development in a deal that could be worth more than $250 million. [Puget Sound Business Journal, Feb 28, 13]

Resolve Therapeutics (Seattle, WA; no SBIR) biotech targeting lupus patients, said it's raised $5.8 million in a second round of financing. [Puget Sound Business Journal, Nov 1, 12]

Resolvyx Pharmaceuticals (Bedford, MA)

Resolvyx Pharmaceuticals (Bedford, MA; no SBIR) said it has initiated a clinical trial to evaluate a drug candidate for dry-eye syndrome, which affects an estimated 25 million to 35 million Americans. [Chris Reidy, Boston Globe, Dec 18]

Resolvyx Pharmaceuticals (Bedford, MA; no SBIR) hopes to use recent scientific research on how omega-3 fatty acids work to develop a powerful new class of drugs to treat inflammatory diseases, ranging from asthma to cardiovascular problems. ... is expected to say it has raised $25 M in a second round of venture capital ..in addition to an earlier round of $17M. [Todd Wallack, Boston Globe, Apr 22]

Resonetics (Nashua, NH)

Resonetics (Nashua, NH) announced it would break into the Minnesota medtech scene with a 9,000-square-foot facility in Plymouth. ... believes its Lightspeed Application Development Lab will carry a unique value for Minnesota medical startups looking to bring products to market. Using a range of lasers, Resonetics can cut prototypes of potential medical devices out of metal, polymer or glass. ... will also offer full production capabilities, according to Resonetics, which includes welding, cutting and ablating machinery, and a Class 8 cleanroom. [Sam Schaust, Twin Cities Business, Sep 12, 16]

Respicardia (Minnetonka, MN)

Respicardia (Minnetonka, MN; no SBIR) announced that it has raised $58.5 million, two months after receiving FDA approval for a new product meant to treat sleep apnea in patients with heart failure. ... ZOLL Medical Corporation, a medical device and software firm owned by the Japanese chemical company Asahi Kasei, lead the funding round [Jared Goyette, Twin Cities Business, Dec 18, 17]

FDA cleared Respicardia (Hopkins, MN; no SBIR, founded 2006)’s neurostimulation implant for the treatment of sleep apnea. The Remede system stimulates a nerve in the chest that prompts the diaphragm to restore breathing. ... A number of devicemakers are working on alternatives to bulky CPAP machines, including the Belgian-Israeli Nyxoah, which picked up $20 million last year to develop a neurostimulation-based treatment for sleep apnea. NightBalance, based in the Netherlands, raised nearly $14 million for its sleep position trainer, which vibrates when a patient rolls onto his or her back, prompting a position change and reducing apnea. [Amirah Al Idrus, FierceBiotech, Oct 9, 17]

Respicardia (Minnetonka, MN, no SBIR, founded 2006) raised at least $5.1 million in a private debt placement after publishing positive results in a pivotal trial for its implantable, pacemaker-like device to treat sleep apnea. ... had earlier raised $17 million from venture capital backers [Don Jacobson, Twin Cities Business, Jul 5, 17]

Italian med-tech company has invested $20 million in Respicardia (Minnetonka, MN; no SBIR) startup developing an implantable device for central sleep apnea. .... plans to begin selling its system in Europe next year. The company is seeking [FDA] approval to begin a key U.S. clinical trial. ... led by former Medtronic Inc. executive Bonnie Labosky, was previously backed by several venture capital firms. [Katharine Grayson, Minneapolis / St. Paul Business Journal, Oct 21, 14]

Med-tech startup Respicardia (Minnetonka, MN; no SBIR) has lined up $6 million in debt financing that it will use to fund ongoing and future clinical trials. .... developing an implantable device that treats heart failure patients who also suffer from central sleep apnea, a condition that causes people to stop breathing for brief periods of time during the night.[Katharine Grayson, Minneapolis / St Paul Business Journal, Aug 10, 12]

Respira Therapeutics (Albuquerque, NM)

The BioScicence Center has recruited Respira Therapeutics (Albuquerque, NM; no SBIR, founded 2010) .... Respira also announced that it has closed on a venture capital deal [terms undislcosed] for development. ... founded in 2010 and is designing a new inhaler that could help with respiratory diseases and other diseases. [Dan Mayfield, Albuquerque Business First, Dec 18 13]

Response Genetics (Los Angeles, CA)

Cancer Genetics (Rutherford, NJ; $1.9M SBIR) up 18% [Oct 28, 15] Receives Third Patent for Proprietary Genomic FHACT(R) Test, Further Advancing the Detection and Treatment of Cervical and Other HPV-Associated Cancers [company press release]

Cancer Genetics (Rutherford, NJ; $1.9M SBIR) up 12% [Aug 11, 15] strong quarterly and announced it has entered into an agreement in principle to acquire substantially all the assets and operations of Los Angeles based Response Genetics (Los Angeles, CA; no SBIR). As part of the transaction, Response Genetics has filed chapter 11 Bankruptcy. [company press release]

Response Genetics (Los Angeles, CA; no SBIR, 40 employees) signed a nonexclusive license agreement with GlaxoSmithKline, which grants the pharmaceutical company some rights to Response Genetics's technology that assess gene mutations in tumor samples. [Wall Street Journal, May 12]

resTORbio

Novartis spinout resTORbio (Boston, MA; no SBIR) reverse merges with T cell biotech Adicet (Menlo Park, CA; no SBIR, total funding $146M [crunchbase.com]) after big PhIII failure [Jason Mast, Endpoints News, Apr 29, 20]

resTORbio (Boston, MA; no SBIR) down 86% [Nov 15, 19] announced that top line data from the PROTECTOR 1 Phase 3 study, evaluating the safety and efficacy of RTB101 in preventing clinically symptomatic respiratory illness (CSRI) in adults age 65 and older, did not meet its primary endpoint, and that it has stopped the development of RTB101 in this indication. RTB101 is an oral, selective, and potent TORC1 inhibitor. [company press release, Nov 15, 19]

resTORbio down23% [Mar 19, 19]

resTORbio up 13% [Sep 4, 18]

resTORbio down 14% [Aug 1, 18]

resTORbio up 13% [Jul 27, 18]

resTORbio (Boston, MA; no SBIR) nearly doubled based on positive results the company released from a Phase 2b trial of its drug for respiratory tract infections. The drug, RTB101, is a pill that blocks an enzyme called TORC1. The company says the drug works by boosting immune function, along with other benefits. ResTORbio licensed the drug from Novartis last year. [xconomy.com, Jul 26, 18] total funding $65M [crunchbase.com]

Restoration Robotics

Restoration Robotics down 11% [Jul 6, 18]

Restoration Robotics down 10% [Jun 25, 18]

Restoration Robotics up 33% [Jun 22, 18]

Restoration Robotics down 14% [May 15, 18]

Restoration Robotics up 14% [May 14, 18]

Restoration Robotics down 11% [Apr 9, 18]

Restoration Robotics (Mountain View, CA; no SBIR, founded 2012) disclosed it has raised $45 million for its treatment for baldness that uses robots. ... uses image-guided robotics to help doctors dissect hair follicles thousands of times in a single session. [Cromwell Schubarth, Silicon Valley Business Journal, Nov 10, 14]

Dr. Frederic H. Moll, 56, is a soft-spoken man who can look uncomfortable on stage. Yet his role in founding Intuitive Surgical ($2.5M SBIR), the company that now dominates the field, and his current involvement with three other robotics companies, has kept him in the sights of investors, health care providers and fellow entrepreneurs. ... He took the idea to his employer, Guidant, a medical device company. Guidant decided that robotic surgery was too futuristic and too risky, so Dr. Moll rounded up backers, resigned, and in 1995, founded Intuitive Surgical. [which] earned $144M last year on sales of $600M .... He’s now best known as chief executive of Hansen Medical (no SBIR), a publicly traded robotics company focused on minimally invasive cardiac care. But he’s also an investor in and a board member of Mako Surgical (no SBIR), an orthopedics robotics company that recently went public, and he is a co-founder and chairman of Restoration Robotics (no SBIR), a start-up company focused on cosmetic surgery. [Barnaby Feder, New York Times, May 4]

Restore Medical

Medtronic agreed to acquire Restore Medical (Roseville,MN; one SBIR) for $29 million, a deal that rescues the cash-starved company from possible insolvency from cash management problems. [Minneapolis Star Tribune, Apr 23, 08]

Restore Medical took a 12% sleeping aid [Mar 1, 07] as it reported a big loss and got a brokerage downgrade.

Retectix (St Louis, MO)

Retectix (St Louis, MO; no SBIR) CEO MacEwan told the St. Louis Business Journal last November that he was raising up to $5 million to fund Retectix through its [FDA] application and commercial release of its first product [proprietary, resorbable, non-woven surgical meshes], expected by late 2013 or early 2014. [Amir Kurtovich, St Louis Business Journal, Mar 19,13]

Retek

a troubling trend: The best new Minnesota tech companies keep leaving the state. ... SmartThings’ core is moving 2,000 miles away, to a new headquarters in Silicon Valley where the company is already advertising job openings. By selling to Samsung, SmartThings joins a roster of Minnesota start-ups including Retek, Compellent and Stellent that ultimately became part of distant tech empires. [Adam Belz, Minneapolis Star Tribune, Sep 6]

Rethink Robotics

Rethink Robotics, one of New England’s best-funded robotics companies, has shut down, according to reports by The Robot Report and The Boston Globe. Rethink, which developed collaborative factory robots, had raised more than $130 million (no SBIR) in venture funding since it was started in 2008. [Jeff Engel, xconomy.com, Oct 4, 18]

Rethink Robotics raised $18 million from investors, part of a funding roundannounced last December that now totals $36 million, according to SEC filings. That brings Rethink’s total venture capital haul to at least $148 million. The company makes robots that can collaborate with factory workers on tasks like assembly and testing. [Jeff Engel, xconomy.com, Aug 25, 17]

Rethink Robotics (Boston, MA; no SBIR) maker of robots for the manufacturing industry, announced it has officially closed its Series D funding round at $40 million. ... to fuel the company's "rapid growth and global expansion" and drive product innovations, according to a release. [Sara Castellanos, Boston Business Journal, Apr 17, 15]

I do believe that more flexible robots such as those from Universal Robots, Unbounded Robotics and Baxter from Rethink Robotics will have a major impact on the workplace. Estimating the global manufacturing labor costs at $6 trillion annually, McKinsey forecast that advanced robotics could have an economic impact on the manufacturing sector of between $720 billion to $1.45 trillion annually. [Colin Lewis, http://robotenomics.com, Apr 23] No SBIR in those three.

Rethink Robotics (Boston, MA; no SBIR) laid off more than 20 employees [of its 85 in July] last week .... has raised $73.5 million in funding since its founding [in 2008]. [Sara Castellanos, Boston Business Journal, Dec 16, 13]

Rethink Robotics (Boston, MA; no SBIR) maker of the humanoid robot Baxter, raised $11.5 million in new funding, the company confirmed [Boston Business Journal, Nov 1, 13]

Rethink Robotics’ Baxter robot now has a new friend. ... has launched the Baxter Research Robot, a humanoid robot with two seven-axis arms, a 360-degree sonar and front camera for sensing applications, sensors and direct programming access. [Patricia Boston Journal, Apr 26, 13]

Martin Buehler, iRobot’s former director of research - “Robot Guy” - touted the disruption that robotics companies in New England have made, such as Rethink Robotics (no SBIR), iRobot ($8M SBIR), Harvest Automation (no SBIR), Kiva Systems (no SBIR; acquired by Amazon.com), Symbotic (no SBIR) and, of course, his company, Vecna Technologies (Greenbelt, MD; $8.5M SBIR). Buehler showed how iRobot’s devices are used in defenseapplications as well as cleaning floors, pools and gutters. He also showed how Harvest’s robots are used in labor-intensive agriculture applications. The audience was amazed by Kiva’s robots driving efficiency, and how the robots have replaced the “runners” who fill product orders. [Patircia Resende, Boston Business Journal, Mar 7, 13]

Baxter is having quite a week. The three-foot robot (six when atop his pedestal), with a video-screen face and versatile arms, made by privately funded Rethink Robotics (Boston, MA; no SBIR) played a starring role on 60 Minutes last Sunday, albeit in a downbeat report on workshop jobs lost to technology. [Jack Hough, Barron's, Jan 21, 13]

Shake hands with Baxter, the first product of Rethink Robotics, an ambitious start-up company in a revived manufacturing district here [Boston, MA], is a significant bet that robots in the future will work directly with humans in the workplace. .... The company is betting it can broaden the market for robots by selling an inexpensive machine that can collaborate with human workers, the way the computer industry took off in the 1980s when the prices of PCs fell sharply and people without programming experience could start using them right out of the box. [John Markoff, New York Times, Sep 18, 12]

Rethink Robotics (no SBIR), founded by Rodney Brooks, one of the few rock stars in the world of robotics, is due to unveil its first robots Tuesday,with promises to bring automation to a much broader array of manufacturers. Most robot users today are large companies, such as car and semiconductor makers, able to afford machines that can cost hundreds of thousands of dollars and require highly trained technicians. Dr. Brooks's Inc., which has raised $57 million in venture capital so far, has vowed to offer inexpensive machines that are easier to operate. ..... Dr. Brooks also promised to manufacture Rethink's robots in the U.S., which would allow it to quickly respond to customers and protect its intellectual property. [James Hagerty, Wall Street Journal, Sep 14, 12]

Rethink Robotics, formerly Heartland Robotics, has received a $30 million Series C round of funding, the company announced ... focused on building robots that drive efficiency in manufacturing [Patricia Resende, Mass High Tech, Jun 19, 12]

Retia Medical (Valhalla, NY)

Retia Medical (Valhalla, NY; at keast one SBIR, founded 2011) focused on advancing the quality and clinical use of hemodynamic monitoring, announced that its Argos Cardiac Output (CO) Monitor has received [FDA]clearance and is now available for [US] sale [company press release, Dec 17, 18] prior funding $7M [crunchbase.com]

Retriever Technology (Santa Fe, NM)

Los Alamos National Laboratory has approved $250,000 in new funding for four companies from its Venture Acceleration Fund [which] provides investments of up to $100,000 to regional entrepreneurs, companies, investors or strategic partners who use LANL technology or expertise to create or grow regional businesses. Award recipients are chosen based on potential for regional impact, team composition, technical feasibility, market opportunity, and the availability of matching funds or in-kind contributions. Retriever Technology (Santa Fe, NM; no SBIR) will receive $25,000 to upgrade a low-light imaging camera for advanced digital imaging into a more user-friendly and functional form for customer demonstration and evaluation. Elemetric Instruments (Los Alamos, NM; no SBIR) will get $100,000 to further develop a prototype of an instrument that immediately detects elements in liquids and gases with continuous online, real-time processing. The device, called an element presence detector, is based on LANL technology with potential markets among food and pharmaceutical makers. STAR Cryoelectronics (Santa Fe, NM; $2M SBIR) will get $75,000 to accelerate development of a high-resolution alpha particle spectrometer to be used in nuclear forensics and nuclear nonproliferation work. Veezyon (somewhere, NM; no SBIR) will receive $50,000 to improve the technical capabilities of its Veezyon.com Web site — a knowledge-based online video site focusing on shared interest user collaboration. Since the venture fund was launched in fall 2006, LANL has awarded about $600,000 to six companies, not including the new grants, [New Mexico Business Weekly, Jan 7, 09]

Retrophin (San Diego, CA)

Retrophin (San Diego, CA; no SBIR) down 22% [Aug 22, 19] announced that the Phase 3 FORT Study evaluating the safety and efficacy of fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration (PKAN) did not meet its primary endpoint and did not demonstrate a difference between treatment groups. The study also did not meet its secondary endpoint. [company press release, Aug 22, 19]

RetroSense Therapeutics (Ann Arbor, MI)

biopharmaceutical startup RetroSense Therapeutics (Ann Arbor, MI; no SBIR) announced it has raised $6 million in a Series B round to get clinical trials up and running for RST-001, an orphan drug that treats the progressive eye disease retinitis pigmentosa.. ... has raised a total of $13 million since it licensed its lead technology from Wayne State University in 2011. [Sarah Schmid, xconomy.com, Nov 17, 15]

Revacom
The U.S. Air Force has tentatively selected over 500 companies for contracts worth $550M combined as part of an initiative launched with its AFWERX innovation arm and [SBIR]. The service said the AFVentures effort includes a strategic financing initiative where the firms will get a total of over $200M in government funding as well as $350M in private funds. [Brenda Marie Rivers, govconwire, Mar 16, 20] almost half going to the following 21 companies: Aerial Applications, Analytical Space ($3M prior SBIR), Anduril (one prior SBIR) , Applied Minds ($8M prior SBIR), Elroy Air, Sentient ($3.2M prior SBIR) , Icon, Enview ($700K prior SBIR), Edgybees ($700K prior SBIR) , Falkonry (one prior SBIR), Swarm Technologies ($1M prior SBIR) , Orbital Insight (one prior SBIR), Orbital Sidekick ($800K prior SBIR), Virtualitics (one prior SBIR) , Wickr (one prior SBIR), Tectus Corp (one prior SBIR), Valulytics, Shift.org, Pison ($1M prior SBIR), Revacomm. One other company hasn’t been named yet. These “big bet” companies are slated to receive four-year, fixed-price contracts worth a combined $550+ million through AFVentures’ Strategic Financing (STRATFI) program. This amount includes $100+ million in SBIR funds, $100+ million in Air Force funding and $350+ million in private investment. Roper said he believes future rounds of funding will be bigger. [AF Press release

Reva Medical (San Diego, CA)

Reva Medical (San Diego, CA; one SBIR) says its stock is expected to begin trading tomorrow on the Australian Securities Exchange after the medical device company raised almost $85 million in its IPO .... will use the proceeds to continue development of its absorbable ReZolve stent, including clinical trials. [Bruce Bigelow, signonsandiego.com, Dec 22, 10]

Reva Medical (San Diego, CA; one SBIR) which is developing bioabsorbable stents for treating arterial disease, has filed for a $63 million IPO on the Australian Stock Exchange, according to PE Hub. Inteq Ltd., a boutique investment bank in Sydney, is serving as the lead underwriter. The company has raised about $57 million in venture capital funding [Bruce Bigelow, signonsandiego.com, Sep 8, 10]

Reva Medical (San Diego, CA; one SBIR) plans to raise $63 million through an IPO to fund tests of its experimental coronary stent that is absorbed by the body over time. [Keith Darcé, San Diego Union Tribune, Aug 19, 10]

Revance Therapeutics Pharmaceutical (Newark, CA)

Wrinkle-smoothing drug developer Revance Therapeutics Pharmaceutical (Newark, CA; no SBIR) and rare drug company Ultragenyx (Novato, CA; no SBIR) raised a combined $225 million with IPOs over the past couple of weeks [Cromwell Schubarth, Silicon Valley Business Journal, Feb 19, 14]

Revegen (Farmington, CT)

Six start-up technology firms have received grants as part of the state's small-business incubator program, ... administered by the Connecticut Center for Advanced Technology ... $32,000 to $50,000 went to: AllerQuest LLC of West Hartford, Catelectric Corp. of >Storrs, Hydrogen Safety of East Hartford, Quadra-Aerrow International of Glastonbury, Revegen Inc. of Farmington and the Center for Network Centric Product Support Research of East Hartford. [Hartford Courant, Dec 12, 08] no SBIR for any

Reverie Labs (Allston, MA)

ReVision Optics (Lake Forest, CA)

Domain Associates, the life sciences venture firm based in San Diego and Princeton, NJ, and Rusnano Mednvest, a subsidiary of the Russian state technology developer Rusnano, joined with other venture investors to sink $55 million in ReVision Optics Lake Forest, CA; no SBIR) ophthalmic company. [Bruce Bigelow, xconomy,com, Aug 1, 13]

ReVision Therapeutics (San Diego, CA)

ReVision Therapeutics (San Diego, CA) biopharmaceutical startup, formed just five months ago to resume development of a compound for treating age-related macular degeneration, has reported encouraging results from a two-year, mid-stage clinical trial of the compound, known as fenretinide. ... The deal to acquire the compound and start ReVision means fenretinide has come full circle. It was initially under development as a potential treatment for macular degeneration by Sytera (San Diego, CA; no SBIR) founded in 2004. But development of the drug moved to Sirion Therapeutics (Tampa, FL; no SBIR), an ophthalmic-focused biopharmaceutical that acquired fenretinide through its 2006 merger with Sytera. Sirion conducted the mid-stage clinical trials at a number of sites throughout Florida, and Lichter says the last patient left the trial in April. [Bruce Bigelow, signonsandiego.com, Sep 18, 10]

Revitope Oncology (San Francisco, CA)

Revitope Oncology (San Francisco, CA; no SBIR), developing cancer immunotherapy technology initiated by Mark Cobbold in the United Kingdom in 2010, said it has raised $8.5 million to advance its approach to treating solid tumors and blood cancers. Revitope’s technology aims to make the immune system recognize cancer cells as viruses, which triggers an immune response. [Bruce Bigelow, xconomy.com, Feb 12,16]

ReVivo Medical (Albany, NY)

medical device startup ReVivo Medical (Schenectady, NY; one SBIR) said it has raised $2 million over the past year. The company’s two titanium alloy implants, which were developed in the Albany Medical Center Biomedical Acceleration and Commercialization Center, are used together to hold vertebrae in place following spinal surgeries. [Justin Dawes, October 11, 2021, Albany Inno]

ReVivo Medical (Albany, NY; $200K SBIR) startup developing a titanium alloy vertebrae implant has closed on an equity offering of over $550,000. .... will enable the startup to kick off the early stages of a clinical trial, necessary for overcoming the next hurdle of FDA market clearance for its products. [Justin Dawes, Albany Business Review, Jan 12,21]

Biomedical startup ReVivo Medical LLC (Albany, NY; no prior SBIR) secured a [$225K NIH SBIR] grant to help develop the spinal surgery device the company plans to get to market in 2017. Gary Mittleman, who was a Plug Power founder, is CEO ... was created by three local researchers. ... to conduct efficacy testing of the device on animals. The device, which is a new type of plate to hold spinal vertebrae in place after a surgery for the healing process, must get U.S. Food and Drug Administration approval before it becomes available commercially. [Marie J. French, Albany Business Review, Oct 28, 15]

RevMedx (Wilsonville, OR)

About three months after RevMedx (Wilsonville, OR; no SBIR) gained approval to expand into the civilian market, the medical device maker has raised $3.5 million. .... The US Army gave RevMedX $5 million in grants to develop the product that shoots expandible sponges into a wound to block bleeding. [Elizabeth Hayes, Portland Business Journal, Mar 28, 16]

RevMedx (Wilsonville, OR; no SBIR) announced FDA clearance for its XSTAT 30 [military] wound dressing, which is used to treat severe bleeding in the groin area. ...From 30 to 40 percent of civilian deaths by traumatic injury are the result of hemorrhaging and up to 56 percent occur before the patient reaches an emergency care facility. The U.S. Army gave RevMedx $5 million in grants to develop a solution to the problem of hemorrhaging wounds. [Elizabeth Hayes, Portland Business Journal, Dec 14, 15]

The U.S. Army gave RevMedx (Wilsonville, OR; no SBIR) $5 million in grants to develop the XStat hemorrhage control device, since uncontrolled external bleeding is the leading cause of death on the battlefield. Now the Army is the first customer. The company announced its first shipment of the XStat hemorrhage control device, which stops internal bleeding on the battlefield using injectable sponges. [Elizabeth Hayes, Portland Business Journal, Apr 17, 15]

startup RevMedx (Wilsonville, OR; no SBIR, founded 2009) a small group of veterans, scientists, and engineers who were working on a better way to stop bleeding. ... asked FDA to approve a pocket-size invention: a modified syringe that injects specially coated sponges into wounds. Called XStat, the device could boost survival and spare injured soldiers from additional pain by plugging wounds faster and more efficiently than gauze. .... After seeing early prototypes, the U.S. Army [Combat Casualty Care Research Program]gave the team $5 million to develop a finished product [started with the United States Special Operations Command] .... Last summer, RevMedx and Oregon Health and Science University won a seed grant, sponsored by The Bill & Melinda Gates Foundation, to develop a version of XStat to stop postpartum bleeding. [Rose Pastore, Popular Science, Feb 3, 14] The military has the means to respond quickly to opportunity in wartime, but SBIR is not the best vehicle because of its limitations on schedule, amounts, and procedures.

ReVolt Tech

ARPA-E Awards. The administration announced $106M in ARPA-E stimulus awards. Small biz winners: Ginkgo BioWorks (Boston, MA; one SBIR) $6M primary; OPX Biotech (no SBIR) $6M primary; Logos Tech (Arlington, VA; $2M SBIR) secondary; Sion Power (Tucson, AZ; $250K SBIR) $5M primary; ReVolt Tech (no SBIR) $5M primary; PolyPlus Battery (Berkeley, CA; one SBIR) $5M; Pellion Tech (no SBIR) $3.2M primary; A123 Systems secondary, twice; Planar Energy Devices (no SBIR) $4M; Maxpower (Harleysville, PA; $9M SBIR) secondary; NanoLab (Newton, MA; $5M SBIR) secondary; Codexis (no SBIR) $4.6M; Nexant (no SBIR) secondary.

Revolution Medicines (Redwood City,CA)

REVOLUTION Medicines (Redwood City, CA; no SBIR) is acquiring Warp Drive Bio (Cambridge, MA; $800K SBIR) ... will combine the companies’ complementary drug discovery technologies and precision oncology programs directed toward frontier oncology targets – elusive drivers of notorious cancer-promoting pathways. [joint companies press release, Oct 16, 18]

Revolution Medicines (Redwood City, CA; no SBIR) a drug discovery and development company focused on frontier cancer targets, announced it has raised $56 million in a Series B financing to support its ongoing R&D programs and general business activities. [company press release, Apr 24, 18]

REVOLUTION Medicines (Redwood City, CA; no SBIR) focused on frontier cancer targets and drug discovery inspired by nature’s lessons, announced that it has raised $25 million in a Series A extension. .... deploys an innovative toolkit including REVBLOCKS™, an integrated suite of modular synthesis methodologies applied to simple chemical “building blocks,” and the REVEAL™ computational platform, which uses evolution’s lessons to inform selection of chemical scaffolds and guide drug design for non-classical drug targets. [company press release, Dec 20, 16]

Startup Revolution Medicines (Redwood City, CA; no SBIR, 12 employees) ... will use a $45 million Series A round to tear apart complex natural chemicals and reassemble those building blocks as safe, effective and potentially life-changing drugs. isn't yet disclosing its timeline for getting one of its drugs into early-stage human clinical trials but said it initially will focus on treatments for fungal infections. ... came across the technology after discovering a paper from University of Illinois chemistry professor Dr. Martin Burke about reengineering amphotericin B. The powerful antifungal compound is found in nature and used in products such as Gilead Sciences Inc.'s AmBisome. The problem with amphotericin B is that many doctors are afraid to use it because of potential liver damage. Burke found that his lab's technology could dial out amphotericin B's toxic side effects while retaining its ability to defeat fungal infections. [Ron Leuty, San Francisco Business Times, Feb 4, 15]

Revterra (Houston, TX)

Revterra (Houston, TX; $200K SBIR), which develops kinetic battery technology, announced raising $6 million in Series A financing ... developing kinetic energy storage products that use flywheels suspended by novel magnetic technology, which the company says significantly amplifies performance [Chris Mathews, Houston Inno, Jul 19, 22]

ReWalk Robotics (Israel)

ReWalk Robotics down 28% [Oct 27, 16]

ReWalk Robotics down 12% [Oct 26, 16]

ReWalk Robotics, the leading global exoskeleton developer and manufacturer announced a collaboration with Harvard University’s Wyss Institute for Biologically Inspired Engineering for the licensing of Intellectual Property (IP), and development of concepts and designs of lightweight exoskeleton system technologies for lower limb disabilities. This exclusive licensing and collaboration agreement will focus on the development of “soft suit” systems for the treatment of stroke, Multiple Sclerosis (MS), mobility limitations for the elderly and other medical applications. [company press release, May 17, 16]

ReWalk Robotics down 10% [Mar 15,16]

ReWalk Robotics down 13% [Mar 1,16]

ReWalk Robotics down 11% [Feb 25, 16]

ReWalk Robotics up 10% [Feb 22, 16]

ReWalk Robotics up 15% [Feb 16, 16]

ReWalk Robotics down 10% [Jan 15, 16]

ReWalk Robotics down 11% [Jan 6, 16]

ReWalk Robotics down 10% [Dec 28, 15]

ReWalk Robotics up 16% [Dec 23, 15]

Rewalk Robotics up 23% [Dec 18, 15]

Rewalk Robotics (Israel and Massachusetts) up 83% [Dec 17, 15] the leading global exoskeleton developer and manufacturer, announced today that the U.S. Department of Veterans Affairs has issued a national policy for the evaluation, training and procurement of ReWalk Personal exoskeleton systems for all qualifying veterans across the United States. The VA policy, which is exclusive to ReWalk Robotics exoskeleton systems, is the first national coverage policy in the United States for qualifying individuals who have suffered spinal cord injury. [company press release]

Rewalk Robotics up 21% [May 22,15]

ReWalk Robotics up 12% [Oct 27, 14]

Rewalk Robotics down 16% [Sep 18, 14]

ReWalk Robotics (Israel) up 45% [Sep 15, 14] from its IPO price.

ReWalk Robotics (Israel, formerly Argo Medical Technologies Ltd.), an innovative medical device company that designs, develops and markets wearable robotic exoskeletons for individuals with spinal cord injury, today announced its [IPO pricing at $31M] [company press release, Sep 12, 14] shares were up 133% Sep 12

Rexahn Pharmaceuticals (Rockville, MD)

Rexahn Pharmaceuticals (Rockville, MD; no SBIR) sold common stock to institutional investors, generating gross proceeds of $5 million.... developing drugs for cancer, nervous system disorders and sexual dysfunction. [Washington Business Journal, Oct 26, 09] Shares trade under a buck.

Rex Computing (San Francisco, CA)

At his startup, Rex Computing (San Francisco, CA; no SBIR, founded 2013), 19-year old Thomas Sohmers is working on an alternative way to architect chips that he says will use a 20th of the power that Intel’s use. ...He dropped out and started Rex in 2013 after receiving a $100,000 grant awarded by investor Peter Thiel to encourage people to start companies instead of finishing their education. ... recently received $1.25 million in funding from Founders Fund, a venture capital firm cofounded by Thiel. ... aiming to get prototype chips to its partners next year, and to start selling final versions by mid-2017. Rex’s chips use less power because they don’t have a block of circuitry that’s standard on chips from Intel and other companies. [Tom Simonite, technologyreview.com, July 21, 2015] Are there any SBIR managers who would have bet on a high school dropout? Most Recent Funding $1.3M Seed on July 21,2015. [crunchbase.com] Sohmers was working with embedded computing systems for military applications at MIT at age 13 [theplatform.net, Mar 12, 2015] Would SBIR slow down a hot tech that the government wanted yesterday? Not if the government wanted it hard enough; the proposal would simply instantly graduate to mainline funding with a phone call from a contracting officer to start work. The authority for that usually resides only two levels above the tech officer.

RF Code (Austin, TX)

RF Code (Austin, TX; no SBIR) got $13M VC part of which pays for moving from AZ to TX where it will make RFID devices to track people and stuff. [Austin American-Statesman, Jul 19] The Navy had an SBIR RFID poster child a decade ago in Savi Technology which Lockheed-Martin bought for $400M.

RFMicron (Austin, TX)

RFMicron (Austin, TX; no SBIR, founded 2006) reported raising $2.1 million of a planned $2.5 million financing. ... develops radio frequency identifier, or RFID, microchips for item-level tracking applications. ... also a two-time Texas Emerging Technology Fund grant recipient. RFMicron collected a $675,000 in ETF funding in 2009 and $250,000 in 2008. ... CEO Shahriar Rokhsaz previously worked on the technical staff of Xilinx after it acquired in 2000 another one of his previous companies, RocketChips (Minneapolis, MN; no SBIR). [Christopher Calnan, Austin Business Journal, Sep 10, 14]

RFS Pharma (Tucker, GA)

RFS Pharma (now a subsidiary of CoCrystal, Tucker, GA; no SBIR, founded 2004) raised $5M in December. [David Allison, Atlanta Business Chronicle, Dec 30, 14] to develop new drugs for the treatment of hepatitis infections as well as emerging viruses. ... in-licensed anti-hepatitis technology from Emory University in 2013. In addition to its own pipeline, RFS Pharma is actively seeking promising new drugs for in-licensing. [company website]

RFS Pharma (Tucker, GA; no SBIR) closed on a merger with [biotech] Cocrystal Pharma (Bothell, WA; no SBIR). Both develop novel antiviral therapeutics for human diseases. ... combined company plans to have a pipeline of products targeting hepatitis, influenza, rhinovirus, dengue fever and norovirus [Ellie Hensley, Atlanta Business Chronicle, Nov 25, 14]

RF Surgical (Bellevue, WA)

Medtronic PLC (now legally Irish) keeps buying, and announced the acquisition of technology [by RF Surgical Systems (Carlsbad, CA; no SBIR, 60 employees) to prevent sponges, gauze and towels from being left inside patients after surgery. [Christopher Snowbeck, Minneapolis Star Tribune, Jul 13, 15]

RF Surgical (Bellevue, WA; no SBIR) which has an R&D facility in San Diego, raised $12 million from venture investors. ... developing technology to make sure surgical sponges and intstruments aren’t left inside patients, plans to use the money to do more R&D on its technology and build up its sales and marketing. [Bruce Bigelow, xconomy.com, Sep 15, 11]

Rgenix (New York, NY)

Rgenix (NYC, NY; no SBIR) a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing [that] will support clinical development of Rgenix’s lead drug candidates, RGX-104 and RGX-202, as well as further development of its therapeutics pipeline. [company press release, Jun 15, 16]

Rgenix (New York, NY; no SBIR), a biotech spun out of New York’s Rockefeller University by three brothers, has reeled in a $33 million Series B financing as it preps its top drug candidate, a cancer immunotherapy agent, to enter clinical trials. The drug, known as RGX-104, was once shelved at GlaxoSmithKline because of side effects. [Alex Lash, xconomy.com, Jun 15, 16]

>Rgenta Therapeutics (Cambridge, MA)

Rgenta Therapeutics (Cambridge,MA; $400K Phase 1 SBIR), focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets, raised $4M in equity in a $38M funding round, per an SEC filing. [Rowan Walrath, BostInno, Apr 2, 21]

Rgenta Therapeutics (Cambridge, MA; no SBIR) a new biotechnology company focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets, announced that it closed a $20 Million seed investment [to] rapidly advance our lead RNA-targeting programs into preclinical studies and expand our portfolio to pursue high-value RNA targets in a range of therapeutic areas. [company press release, Apr 2, 20]

Rhaeos (Evanston, IL)

Rhaeos (Evanston, IL; $1.2M SBIR) raised $2.2M in a seed round. .... has raised more than $8M in total funding since it was founded in 2018. [Jim Dallke, ChicagoInno, Dec 28, 21]

Rhenium Alloys (Elyria, OH)

Balls - An 11th Form of Rhenium. Rhenium Alloys (Elyria, OH) which sells ten forms of rhenium got a BMDO Phase 2 SBIR for an 11th form: micro-spheres. The immediate use for BMDO is coating small rocket nozzles that have to pass really hot gas. There may be a little puffery going on as the company invites present orders for the balls that BMDO says it is only nursing into existence as a prototype. It's the company's first Phase 2. Neither the abstract nor Rhenium's website hint at the economic value of the spheres beyond cost-insensitive military rockets.

Rheostat Therapeutics (Cambridge, MA)

Rheostat Therapeutics (Cambridge, MA; no SBIR) reeled in a $23 million series A round to develop treatments for neurodegenerative and rare diseases by targeting autophagy, the cell’s garbage disposal. .... It’s not the only company looking to exploit autophagy—in May, Casma Therapeutics (Cambridge, MA; no SBIR) launched with $58.5 million to develop a product engine that will identify and validate targets that induce autophagy at various stages of the process and connect them to various diseases. [Amirah Al Idrus, Fierce Biotech, Nov 26, 18]

Rheumco

Navidea Biopharmaceuticals (Dublin, OH; no SBIR) took a first step toward developing radioactive drugs to treat disease instead of just detect it with the formation of a joint venture with an early stage pharmaceutical company [Rheumco LLC (no SBIR,a startup backed by private equity firm )] focused on arthritis. ... seeking new uses for its compound that attaches to a specific receptor on macrophages, a type of white blood cell. That’s what attaches to lymph nodes in Lymphoseek, and in the new venture targets the errant immune cells that attack joints in debilitating rheumatoid arthritis. [Carrie Ghose. Columbus Business First, Jul 11, 14]

Rheos Medicines (Cambridge, MA)

Rheos Medicines (Cambridge, MA; no SBIR, founded 2017) was launched with $60 million in Series A financing backed by Third Rock Ventures, LLC. Rheos is pioneering immunometabolism as a novel approach to tune metabolic pathways in immune cells to treat disease. The company will translate recent breakthroughs in the understanding of immune cell metabolism to develop precision medicines for immune-mediated diseases. [company press release, Mar 22, 18]

Rhevision

Ben Choi, one of the In-Q-Tel guys, told us yesterday he's just made an investment into Rhevision Technology, which is making a miniature zoom lens for cameras. Its Website is still under construction, but the company says modestly that the lens module is "going to rock the entire camera-phone industry." [Siliconbeat.com, May 5]

Rho (Chapel Hill, NC)

Rho (Chapel Hill, NC; $2M SBIR) a drug research company, received a $38.9 million contract from NIH ... provide biostatistical, data management and safety services to the Immune Tolerance Network ... founded in 1984 by two UNC-Chapel Hill researchers. The company now employs about 350 [Raleigh News & Observer, Sep 5, 08]

Rhythmia Medical (Burlington, MA)

Boston Scientific said that it has agreed to buy Rhythmia Medical (Burlington, MA; two SBIRs) developer of software used in medical procedures, for an upfront payment of $90 million and as much as $175 million in additional milestone payments if Rhythmia meets regulatory, commercial and sales targets over the next five years. [Robert Weisman, Boston Globe, Oct 8, 12]

Rhythmia Medical (Burlington, MA; at least $200K SBIR) has taken in $2.7 million in an equity round [says an SEC filing] ... had raised $12 million since its founding in 2004 [Mass High Tech, Mar 19, 10]

Rhythm (also Rhythm Pharmaceuticals (Boston, MA)

Rhythm Pharmaceuticals (Boston, MA; no SBIR), focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced positive topline results from two pivotal, Phase 3 clinical trials evaluating setmelanotide, the company’s melanocortin-4 receptor (MC4R) agonist, for the treatment of pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency obesities. [company press relase, Aug 7, 19]

Rhythm Pharma down 16% [Oct 6, 17]

Rhythm Pharma up 76% [Oct 5, 17] after IPO; focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. [company website]

Rhythm Pharmaceuticals (Boston, MA; no SBIR) filed [SEC] form regarding its [IPO]. No pricing details were provided in the filing, but the offering is valued up to $115 million, although this number is usually just a placeholder. [247wallst.com, Sep 6, 17]

A year after Rhythm (Boston, MA; no SBIR) funneled a stomach drug into a subsidiary and sold it to Allergan for $200 million, the company—developing a different drug for rare forms of obesity—has filed for an IPO. ... Rhythm was formed in 2008 by licensing two peptide drug prospects from Paris-based Ipsen. In 2013, those two drugs diverged onto separate paths. Rhythm formed one company,Motus Therapeutics (Boston, MA; no SBIR) , around relamoralin, a drug for diabetic gastroparesis that was later acquired by Allergan. The second company kept the Rhythm name and has been advancing a drug called setmelanotide, an injectable peptide drug that is meant to boost the activity of a protein called melanocortin 4 receptor, or MC4, which plays a key role in weight and appetite regulation [Ben Fidler, xconomy.com, Sep 6, 17]

Rhythm (Boston, MA; no SBIR) biotech developing drugs for rare, life-threatening metabolic disorders, has raised $41 million [mezzanine round] from a group of crossover investors, a signal that an initial public offering could be on the way. .... to push testing of its drug, setmelanotide, into Phase 3 clinical trials for two different metabolic diseases: pro-opiomelanocortin (POMC) deficiency obesity, and leptin receptor (LEPR) deficiency obesity. [David Holley, xconomy.com, Feb 16, 17]

In further evidence that the biotech IPO boom is over, Rhythm Pharmaceuticals (no SBIR) withdrew its plans for an $86 million public offering. ... Just last week, Rhythm announced a $40 million deal to sell an option to buy a significant portion of the business to drug giant Actavis. Rhythm Health, its subsidiary developing a gastrointestinal-disorder drug called relamorelin, expects to start a Phase 2b trial in patients with diabetic gastroparesis early next year, and after the results are reported, Activis can choose to buy the subsidiary for an unannounced sum. [Don Seiffert, Boston Business Journal, Nov 3, 14]

Rhythm Pharmaceuticals (Boston, MA; no SBIR, founded 2008) filed a [ IPO] registration statement, the 15th life sciences-related company in Massachusetts to file an IPO this year. ... is developing peptide therapeutics for the treatment of obesity, diabetes, gastroparesis and other gastrointestinal functional disorders — filed plans with the SEC on Wednesday to raise up to $86 million in the IPO [Patricia Resende, Boston Business Journal, Aug 28, 14]

Rhythm, (Boston, MA; no SBIR) developing peptide therapeutics to treat such metabolic diseases as obesity and diabetes, said it has raised $8 million from Pfizer Venture Intestments, the venture capital arm of the drug company Pfizer .... completes a $33 million Series B financing. [Boston Globe, Nov 28, 12]

Rhythm (Boston, MA; no SBIR) biotechnology company focused on diabetes and obesity, announced that it has raised $25 million in a Series B financing round. ... brings the total capital raised to $65 million. ... said it will use the proceeds to continue advancing its small-peptide therapeutics for metabolic diseases through Phase 2 clinical trials. [Chris Reidy, Boston Globe, Jun 13, 12]

Rhythm Pharmaceuticals (Boston, MA; no SBIR), a virtual life sciences company making peptide-based drugs to treat conditions such as obesity and diabetes, has launched with a $21 million Series A round ... has licensed intellectual property from French pharmaceutical Ipsen SA [Mass High Tech, Mar 15, 10]

Ribometrix (Durham, NC)

Ribometrix (Durham, NC, $700K SBIR for its one employee) announced a strategic collaboration with Genentech, a member of the Roche Group, to discover and develop novel RNA-targeted small molecule therapeutics against several targets. ... Genentech will pay $25 million upfront, and in return will receive exclusive rights to several predefined targets including an exclusive global license for the development and commercialization of molecules under this collaboration. Ribometrix will also be eligible to receive potential milestone payments exceeding $1 billion as well as tiered royalties on future global net sales of products that result from the collaboration. [company press release, Jan 6, 21]

Vertex Pharmaceuticals and RNA therapeutics developer Ribometrix (Durham, NC; $500K SBIR) announced that the companies have entered into a strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The collaboration will combine Ribometrix’s proprietary discovery platform for identifying and optimizing small molecule therapeutics that modulate RNA function by targeting three-dimensional (3D) RNA structures with Vertex’s scientific, clinical and regulatory capabilities for up to three therapeutic programs, including one ongoing discovery program from Ribometrix. [joint companies press release, Sep 30, 19]

Ribometrix (Durham, NC; $700K SBIR, founded 2014) developing small molecule therapeutics that directly target RNA to treat human diseases, announced that it has completed a $30 million Series A financing to advance its discovery platform and internal pipeline of novel small molecule drugs that directly modulate RNA activity, as well as expand its team and business development activity. [company press release, Nov 13, 18] prior funding $7M [crunchbase.com]

RiboNova (Wynnewood,PA)

BioAdvance, the operator of a $50 million early stage life sciences fund that work with health-care entrepreneurs in the mid-Atlantic region, invested $2.9 million in companies and technologies targeting human health during fiscal 2016. Among the winners were:

Genome Profiling (Newark, DE; no SBIR) $100,000 to discover novel epigenetic biomarkers based on its proprietary, genome-wide methylation profiling platform to improve how to treat, diagnose, and predict chronic and life-threatening disease;
Mebias Discovery (Philadelphia, PA; no SBIR) $800,000 to launch its platform for identifying biased ligands for next generation GPCR drugs;
Enzium (Philadelphia,PA; no SBIR) $140,000 to develop its proprietary protease assay technology for use in measuring drug levels of the new direct oral anticoagulants in patients;
Hsiri Therapeutics (King of Prussia, PA; no SBIR) $70,000 to develop novel siderophore-based antibiotics for hard-to-treat bacteria;
RiboNova (Wynnewood, PA; no SBIR) $175,000 to develop small molecules against novel defective transfer RNA anti-cancer targets and to pursue a clinical trial in mitochondrial diseases.

[John George, Philadelphia Business Journal, Aug 5, 2016]

Ribon Therapeutics (Lexington, MA)

Ribon Therapeutics (Lexington, MA; no SBIR) a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions, today announced the closing of a $65 million Series B financing [to] advance lead programs from the company’s growing pipeline into clinical testing, including small molecule monoPARP inhibitors. [company press release, Jan 4, 19] prior funding $30M [crunchbase.com]

Rib-X Pharmaceuticals (New Haven, CT)

RXi Pharma down 14% [Mar 19, 18]

Rib-X Pharmaceuticals (New Haven, CT; $1.1M SBIR) biotech company with 40 employees, announced it closed on $18.7 million in venture capital and private equity financing, the first phase in $67.5 million planned sales of preferred stock. ... has received about $200 million from investors over the last dozen years . [Mara Lee, Hartford Courant, Nov 29, 12]

Rib-X Pharmaceuticals has become the nation's first company to get special benefits under a bill to promote more antibiotics development, .... received "Qualified Infectious Disease Product" designation under the Generating Antibiotic Incentives Now (GAIN) Act for Delafloxacin, for certain skin ailments and bacterial pneumonia, and for Radezolid, a treatment for "superbugs" such as MRSA. Benefits include an extra five years of marketing exclusivity and eligibility for fast-track approval by [FDA]. .... founded in 2001 by Thomas Steitz, professor of molecular biophysics and biochemistry at Yale University and the 2009 winner of the Nobel Prize for chemistry [Hartford Courant, Oct 10, 12]

Rib-X Pharma going IPO tomorrow to raise about $70M with Deutsche Bank as lead. will be highly speculative and any reward will be years in the making. ... has also received a letter from its independent financial auditing firm expressing doubts about whether Rib-X will be financially able to continue its business. Additionally, in its S1, Rib-X states that the cash from the IPO is still not enough to complete a phase 3 trial of Delafloxacin. [seekingalpha.com, May 7]

Rib-X Pharmaceuticals scored a $3 million milestone payment from French biotech giant Sanofi related to a license for the New Haven, Conn.-based company’s antibiotics to fight superbugs. .... To date, Rib-X has taken in $22 million through four milestone payments, and it could receive as much as $740 million from the [July 2011] deal. [Michelle Lang, Mass High Tech, Feb 7, 12]

Rib-X Pharmaceuticals (New Haven, CT; $1.1M SBIR) drug development firm co-founded by Yale Nobel laureate, intends to raise as much as $80 million in an[IPO] ... with 43 employees, is developing several antibiotics, notably Delafloxacin, which is in clinical trials and is intended for the treatment of "acute bacterial skin and skin structure infections," primarily in hospitals. [Dan Haar, Hartford Courant, Nov 29, 11]

Rib-X Pharmaceuticals (New Haven, CT; $1.1M SBIR) has taken in $5.5 million of a planned $22 million offering combining debt, warrants and options [Michelle Lang, Mass High Tech, Jan 28, 11]

Rib-X Pharmaceuticals (New Haven, CT; $1.1M SBIR), an antibiotics company has taken in a $20 million financing ... to help bring its delafloxacin antibiotic drug to a Phase 2b study this year [Michelle Lang, Mass High Tech, Jan 11, 11]

Rib-X Pharmaceuticals (New Haven, CT; $1M SBIR) antibiotics company raised $5.5 million of a planned $15 million offering of debt and warrants, according to [SEC] filing ... founded in 2001 by Yale University colleagues Peter Moore, William Jorgensen and Thomas Steitz, winner of a portion of the 2009 Nobel Prize in Chemistry for his work describing the structure and function of the ribosome. ... On its website, Rib-X notes that it has raised more than $123 million in three [VC] rounds. [Michelle Lang, Mass High Tech, Jun 11, 10]

Rib-X Pharmaceuticals (New Haven, CT; $1M SBIR) co-founder and Yale University professor Thomas Steitz has won a share of the 2009 Nobel Prize in Chemistry for his work describing the structure and function of the ribosome, according to the school. Steitz, a professor of molecular biophysics, biochemistry and chemistry, will share the $1 million prize [three ways] [Mass High Tech, Oct 7, 09]

Rice Technology (Milwaukee, WI)

“NASA iTech is an innovation incubator that brings together the right people to the right place and time, giving entrepreneurs an opportunity to present their technologies as a future commercial market product solution for both Earth and NASA,” said Kira Blackwell, program executive for the Space Technology Mission Directorate at NASA Headquarters. Blackwell, also said the top 18 companies that have previously participated in NASA iTech have reported raising more than $50 million in private investments over the last 12 months. The top ten competitors for the grand prize: BioVirtua (San Francisco, CA; no SBIR) Humanizing Telehealth in Four Dimensions; FGC Plasma Solutions (Argonne, IL; no SBIR) Novel Fuel Injectors to Enable Clean, Compact Propulsion ; Germfalcon (Los Angeles, CA; no SBIR) Germicidal UVC Emitting Robot for Commercial Aircraft; H2 Energy Now (Boalsburg,PA; no SBIR) New Technology for H2 Generation from Water in Space by Use of Electromagnetic Waves; Hyperloop Tansportation Technologies (Los Angeles, CA; no SBIR, 500-1000 employees) Augmented Voyage; iFirst Medical Technologies (Honolulu, HI; no SBIR, founded 2016) The iFirst Analyzer: Handheld Laboratory-grade Diagnostics Platform for Extreme Environments; Million Concepts (Lemont, PA; no SBIR) The Arisian Lens: A Novel Solution for Low-cost, Lightweight Microscopy; New Frontier Aerospace (Livermore, CA; no SBIR, founded 2015) Affordable, Powered Recovery for Small Launch Vehicles; Rice Technology (Milwaukee, WI; no SBIR) Smart Real-Time Multipurpose Sensor - Dissolved and Suspended Solids, Bacteria, Phosphorus and Viruses; Somatic Labs (Phoenix, AZ; no SBIR, founded 2015) Tactile Interfaces for Augmented Reality to Enhance Communication.

Ridgeback BioTherapeutics (Miami. FL)

Jump ahead to next phase. As a result of their August 9, 2019 review, the DSMB recommended that the study be stopped and that all future patients be randomized to receive either REGN-EB3 [from Regeneron] or mAb114 [from Ridgeback BioTherapeutics (Miami. FL, no SBIR, founded 2015)] in what is being considered an extension phase of the study. This recommendation was based on the fact that an early stopping criterion in the protocol had been met. The preliminary results in 499 study participants indicated that those individuals receiving REGN-EB3 or mAb114 had a greater chance of survival compared to those participants in the other two arms. [Ridgeback press release, Aug 12, 19]

Ridgetop Group (Tucson, AZ)

The rest of DOE,'s Phase II list also shows a preference for SBIR experience: Euclid Labs (Solon, OH; $18M SBIR since 2004, all DOE including one $10M award), four new Phase IIs; Radiabeam Technologies (Santa Monica, CA, $10M SBIR since 2005 SBIR) three awards; Tech-x (Boulder, CO; something over $50M SBIR since 1994) three new awards Muons (Batavia, IL; $13M since 2002 SBIR, all DOE) three awards; Far-Tech (San Diego, CA;$9+M SBIR since 2003) two awards; Ridgetop Group (Tucson, AZ; $10M SBIR since 2002) two awards; Calabazas Creek Research (San Mateo, CA; $26M since 1994) two awards; Niowave (Lansing, MI; $5M since 2007 SBIR) two awards; Mesa Photonics (Santa Fe, NM; $0.8M since 2008 SBIR) two awards; Green Mountain Radio Research ( Colchester, VT; $5.7M SBIR) two awards. Of 104 awards, 33 went to multiple winners who already had collected $378M SBIR from the federal government. Is DOE over-emphasizing contractor competence at the expense of companies and technologies with brighter futures? No one knows becasue Congress shows little interest in the question, and the agency has a bias toward making itself smarter.

Rigel Pharmaceuticals (South San Francisco, CA)

AstraZeneca Plc will not seek approval for an experimental rheumatoid arthritis treatment from Rigel Pharmaceuticals (South San Francisco, CA; no SBIR, 150 employees) Bloomberg reports. AstraZeneca will take a $140 million charge following the decision and return rights to the drug, called fostamatinib, [San Francisco Business Times, Jun 4, 13]

Rigetti Computing (Berkeley, CA)

Rigetti Computing (Berkeley, CA; no SBIR, 15 employees) refrigerators that use liquid helium to cool experimental computer chips to a fraction of a degree from absolute zero. The two-year-old company is trying to build the hardware needed to power a quantum computer, which could trounce any conventional machine by tapping into quantum mechanics. The company aims to produce a prototype chip by the end of 2017 that is significantly more complex than those built by other groups working on fully programmable quantum computers. The following generation of chips should be able to accelerate some kinds of machine learning and run highly accurate chemistry simulations that might unlock new kinds of industrial processes, says Chad Rigetti, the startup’s founder and CEO. ... has so far raised $5 million [Tom Simonite, technologyreview.com, Feb 8, 16]

RightEye (Bethesda, MD)

RightEye (Bethesda, MD; no SBIR) first released its eye-tracking product, which can gauge concussions and detect ADD in children, in January. The company raised the [$2.1M] cash from select investors in anticipation of a large Series A round of funding. The aim is to put it toward new retail outlets. One major league baseball team and the military currently use RightEye. [Chris Bing, dcinno.streetwise.co, Mar 28, 16]

RightHand Robotics (Somerville,MA)

RightHand Robotics (Somerville, MA; $1M SBIR) announces that it has secured $66 million in a Series C financing led by top growth investors [company press release, Feb 23, 22]

RightHand Robotics (Somerville, MA; no SBIR) raised $7.8 million from investors, according to an SEC filing. The Harvard University spinout previously raised about $3.3 million. [Jeff Engel, xconomy.com, Mar 21, 17]

Rinat Pharma (South San Francisco, CA)

With Exelixis (no SBIR)and Renovis (South San Francisco, CA; $500K SBIR) already under his belt, the longtime Bay Area biotech entrepreneur's newest venture, Labrys Biologics (no SBIR), has acquired a Phase II-ready experimental migraine treatment from Pfizer and snagged $31 million in a Series A financing round. ... Labrys' new drug, called RN-307, was discovered and developed by South San Francisco's Rinat Pharmaceuticals (South San Francisco, CA; no SBIR) which Pfizer bought in 2006 [Ron Leuty, San Francisco Business Times, Jan 3,13]

Rinovum Women’s Health (Pittsburgh, PA)

Rinovum Women’s Health LLC, (Pittsburgh, PA; no SBIR, founded 2009) Pimaker of conception devices for home use, last week closed on $6 million to complete a $9 million Series C round. [Patty Tascarella,Pittsburgh Business Times, Aug 5, 15]

Rio Grande Neurosciences (Santa Fe, NM)

Rio Grande Neurosciences (Santa Fe, NM; no SBIR), the leading provider of non-invasive brain stimulation (NIBS) electroceuticals ™ , announced the completion of its acquisition of Cervel Neurotech (Redwood City, CA; no SBIR)’s multi-coil Transcranial Magnetic Stimulation (rTMS) technology. [Rio Grande press release, Oct 20, 16] Rio Grande also signed a cooperate research and development agreement (CRADA) with AFRL [Tristan Navera, Dayton Business Journal, Oct 25, 16] CRADA's give the company access to certain government R&D, but no funding.

RipCode (Austin TX)

RipCode (Austin TX; no SBIR) unveils today a powerful but compact box that takes up a small slot in a computer data center but does the video processing work of 10 to 20 servers. [Kirk Ladendorf, Austin American-Statesman, Sep 17]

Ritter Pharmaceuticals (Los Angeles, CA)

Ritter Pharmaceuticals (Los Angeles, CA; no SBIR), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), announced the closing of private placement of Series B convertible preferred stock and warrants [for] gross proceeds of a$6.0 million [company press release, Nov 6, 18]

River Vision Development (New York, NY)

A bid by a group of investors to transform a stalled cancer drug into an eye disease treatment has paid off. Horizon Pharma (Ireland) [down 35% May 8, 17] acquired River Vision Development Y; SBIR) formed to develop a therapy for an eye condition called Graves’ ophthalmopathy. .... paying $145 million in cash up front for River Vision and its drug teprotumumab, an antibody in mid-stage testing for GO. [Ben Fidler, xconomy.com, May 8, 17]

Rive Technology (Cambridge, MA)

Rive Technology (Cambridge, MA; no SBIR) announced the closing of a $25 million round of financing. ... seeks to commercialize catalyst technology for petroleum refining. Rive's proprietary technology, invented at the Massachusetts Institute of Technology, makes traditional zeolite refining catalysts more accessible to hydrocarbon molecules [Boston Globe, Dec 14, 10]

In an effort to make gasoline production cleaner and more efficient, Rive Technology (Cambridge, MA; no SBIR) is developing a catalyst that can help turn a greater percentage of crude petroleum into gasoline and other usable products. ... could increase the proportion of petroleum processed by as much as 7 to 9 percent. ... Javier Martinez, a cofounder of Rive and now a professor at the University of Alicante, in Spain, came up with a way to control the size of the openings while working as a postdoctoral fellow at MIT's Nanostructured Materials Research Laboratory. [Neil Savage, MIT Tech Review, Jul 10, 09] has raised $22 million in venture capital [company website]

RJA Dispersions

Aldevon (Fargo, ND; no SBIR), maker of DNA and protein products is putting a research and sales operation in [Wisconsin] .... founded by two ND State U graduates, has more than 70 employees, and provides products and services to pharmaceutical companies and diagnostic test-makers. ... also welcomed to Wisconsin: RJA Dispersions (no SBIR), VitalMedix (no SBIR) and Rapid Diagnostek (no SBIR), from Minnesota; Flex Biomedical (one SBIR) and Exact Sciences (no SBIR), from Massachusetts; NanoMedex ($1M SBIR), from Florida; and Inviragen ($2M SBIR) from Colorado. Biotechnology is the fastest-growing segment of the Wisconsin economy, with an annualized growth rate of nearly 7%, [Gov] Doyle said in a statement. The sector has 400 companies in the state with 34,000 employees.

R.L. Phillips (Carlsbad, CA)

Information security firm R.L. Phillips (Carlsbad, CA; no SBIR) is being bought by a Michigan firm for $2.2M. Phillips, founded in 1998 by James Pietrocini and Rebecca Phillips, generated about $5.3 M in annual revenue. It has about 30 employees and serves customers that include the Navy, the Marine Corps and the NSA. [San Diego Union Tribune, Sep 6]

RMH Sciences (Philadelphia,PA)

BioAdvance, operator of the Biotechnology Greenhouse Corp. of Southeastern Pennsylvania, said it made commitments of $2.4 million to seven new life science companies: RMH Sciences (Philadelphia, PA; no SBIR) which is developing antibacterial agents for the treatment of resistant gram negative and gram positive infections; Ossianix (no SBIR), which is developing single domain antibodies based on the shark VNAR structure to treat immunological, inflammatory, musculoskeletal, neurologic, and other disorders; Merganser Biotech (Newtown Square, PA; no SBIR) which is developing hepcidin peptides for the treatment of hemoglobinopathies such as sickle cell anemia and diseases of iron overload; Anakim Biologics (Exton, PA; no SBIR) which is developing efficiencies and improvements in biologics manufacturing; Enzium (Philadelphia, PA; no SBIR) which is developing highly sensitive biosensor methodologies for the testing of proteases and other enzymes; Imiplex (Newtown, PA; two SBIRs) which is developing the TriPol platform, engineered from proteins, designed to provide a flexible system for constructing diverse nanostructures; Cool-Bio (Wayne, PA; no SBIR) which is developing platelet-inhibiting technology geared specifically to activation during the cooling process of cardiac bypass. [John George, Philadelphia Business Journal, Jun 20, 12]

RNAimmune Gaithersburg, MD

RNAimmune, a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced execution of definitive agreements for a seed round financing of $10 million. RNAimmune is a spin- off entity from Sirnaomics (Gaithersburg; $1.2M SBIR), a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases. [company press release, Apr 21, 21]

RNAimmune (Gaithersburg, MD; no SBIR) raised $2.35M in a seed round [to] advance the company’s Covid-19 vaccine program and cancer vaccine programs, RNAimmune spun out of local biopharmaceutical company Sirnaomics ($1.2M SBIR), which develops antifibrosis and anticancer RNAi therapeutics — a process that shuts down disease-causing genes using what’s called RNA interference technology. [DCInno, Aug 25, 20]

RoadBotics (Pittsburgh, PA)

French tire manufacturer Michelin announced that it has acquired RoadBotics (Pittsburgh, PA; one SBIR) that specializes in the analysis of road infrastructure images it captures with smartphones. The companies did not disclose the financial terms [Nate Doughty, Pittsburgh Inno, July 12, 2022]

Robb Surgical Devices (Buffalo, NY)

Robb Surgical Devices (Buffalo, NY; no SBIR) which has secured the rights to manufacture a novel, patented, laparoscopic sponge, will locate in UB's Center of Excellence in Life Sciences and Bioinformatics, creating 15 new jobs and investing $1.87 million. ... admitted to the Start-Up NY tax breaks program through the University at Buffalo, according to an announcement from state Gov [Dan Miner, Buffalo Business First, Oct 21, 14]

Robopsy (Cambridge,MA)

After several years of development, startup Robopsy (Cambridge, MA; no SBIR) is entering the home stretch in its quest to get to market with its disposable robotic diagnosis devices. ... technology was jointly developed by experts at Massachusetts General Hospital and MIT. Since Robopsy first launched several years ago, the system has gone through two prototypes, explained co-founder Rajiv Gupta, MGH laboratory director for the department of radiology [Marc Songini, Mass High Tech, May 1, 09]

Robotic FX

Robotic FX will be dissolved and certain of its residual assets will be retained by iRobot, according to the company. [Founder and ex-iRobot employee] Ahed has been prohibited from participating in competitive activities in the robotics industry for five years. [Mass High Tech, Dec 24]

A federal judge in Boston has issued an injunction against a Chicago-area robot maker accused of stealing trade secrets from iRobot [Boston Globe, Nov 3, 07] Defendant Robotic FX was not reported as railing against "activist un-elected judges."

Robotic Research (Clarksburg, MD)

Robotic Research (Clarksburg, MD; $23M SBIR) secured its first outside investment in a $228 million Series A funding round, company executives said ... develops comprehensive autonomous driving technology that can be deployed on commercial, bus and logistics vehicles. [company press release, Dec 10, 21]

Robotic Research (Clarksburg, MD; $21M SBIR) a leading provider of autonomy and robotic technologies to government and commercial customers, announced receipt of a $16.5 million order for its warfighter localization sensor units, also known as WarLoc®, the U.S. Army Product Manager Sets, Kits Outfits and Tools (PM SKOT) to support forward-deployed U.S. military personnel. [company press release, Dec 19, 19]

Robotics VISION Technologies (Silver Spring, MD)

Robotics VISION Technologies (Silver Spring, MD; no SBIR) closed its first funding round at $10.5M. develops a suite of robots who are able to "see," or have vision capabilities, primarily for manufacturing companies. [Sam Sabin, DCInno, Mar 13, 18]

Robotic Technology (Potomac, MD)

The Energetically Autonomous Tactical Robot is known, of course, by its acronym: EATR. It is the brainchild of Robotic Technology (Potomac, MD; $900K SBIR) .... could, for instance, forage for biofuel while an [Army] unit on a long-endurance mission rested. It could then be used to recharge their electrical devices, carry some of their equipment or even transport the soldiers. ... Robert Finkelstein, Robotic Technology’s president, estimates that about 68 kilograms (150 pounds) of vegetation would provide enough electricity for the machine to travel around 160km (100 miles). [The Economist, Jun 12, 10]

Rocket Lab (Frederick, CO)

Rocket Lab (Long Beach, CA; one SBIR) will design, produce and deliver 18 satellites to a U.S. government agency under a contract valued at approximately $515 million, SpaceNews reported Saturday. [Jane Edwards, govconwire, Dec 27, 2023]

Rocket Lab USA (Frederick, CO; one SBIR)up 23% [Dec 22, 2023] no press release

Rocket Lab (Frederick, CO; one SBIR) will help NASA send four small satellites to low-Earth orbit for a storm observation initiative via twoElectron launch missions under the Venture-class Acquisition of Dedicated and Rideshare contract vehicle. Rocket Lab is one of the 13 companies holding spots on the five-year, $300 million VADR indefinite-delivery/indefinite-quantity contract awarded in January to provide Federal Aviation Administration-licensed payload launch services to the space agency. [Naomi Cooper. govconwire.com, November 28, 2022[

Rocket Pharmaceuticals (NYC, NY)

Two months after [Inotek Pharmaceuticals (Lexington, MA; $24M SBIR)] shares cratered following the second conclusive failure of its lead glaucoma drug — scuttling its share price — the biotech has become a reverse merger shell for a gene therapy, [Rocket Pharmaceuticals ; no SBIR, raised about $25 million in May 2017 ) developing treatments for a variety of rare blood diseases. [John Carroll, endpts.com, Sep 12, 17]

Rockwell Medical (Wixom, MI)

3D Robotics (Berkeley, CA; no SBIR) the drone maker that began life in Tijuana and San Diego, has been consolidating its operations after stumbling in its bid to go head-to-head against China’s DJI, the world’s biggest maker of consumer drones. .. is closing its San Diego facility, with three years still remaining on its lease [Bruce Bigelow, xconomy.com, Mar 24, 16]

Rockwell Medical (Wixom, MI; no SBIR) biopharma startup targeting end-stage renal and chronic kidney diseases, has received approval from the China Food and Drug Administration for the submission of its lead product. ... the first step in getting Triferic to market in China. Triferic is Rockwell’s proprietary iron replacement and hemoglobin maintenance drug for treating anemia in dialysis patients. [Sarah Schmid, xconomy.com, Mar 24. 16]

Rocky Research (Boulder City, NV)

Rocky's Cooler. A refrigerator with no compressor would come from the sorption system of Rocky Research (Boulder City, NV), says Design News, (Nov 4, 96). BMDO SBIR's support was matched in part by investment from Igloo Products during which the technology was the basis for a new FMC Corp factory in Arkansas. Look for ever more portable coolers with the Igloo label if and when Rocky can raise the ever rising capital needed by a maturing technology. BMDO's invitation of matching the early capital brought in Igloo's first investment but government's role ends there (unless you believe in programs like ATP which let companies avoid the discipline of the marketplace and appeal, instead, to the technology preferences of government experts).

Rodeo Therapeutics ((Seattle, WA)

Rodeo Therapeutics (Seattle, WA; no SBIR), founded 2017), developing small-molecule therapies aimed at promoting regeneration and repair of different types of tissue, raised more than $4.2 million in equity funding has raised more than $13.3 million in outside funding since launching. [Jeff Buchanan, xconomy.com, Apr 2, 19]

Rodin Therapeutics (Cambridge, MA)

Alkermes (Ireland, formerly Massachussetts, $3.5M SBIR) is putting down nearly $1 billion to buy out CNS biotech Rodin Therapeutics (Cambridge, MA; $200K SBIR) [ developing a set of brain-penetrant small-molecule drugs designed to boost pathways that play a key role in synaptic function, all the while attempting to lower key safety concerns. Rodin gets $100 million upfront, with $850 million wedded in biobucks and an extra $20 million in added R&D cash. [Ben Adams, Fierce Biotech, Nov 18, 19]

Rodin Therapeutics (Cambridge, MA; no SBIR), a biotechnology company discovering and developing novel therapeutics to boost synaptic resilience, announced today significant progress in advancing the company’s strategic vision, including the completion of a $27 million financing round [company press release, Sep 18,17] $13M Series A in 2014

Rodin (Cambridge, MA, no SBIR) startup trying to develop drugs for the cognitive impairment associated with tough neurological diseases like Alzheimer’s and Parkinson’s, closed a $27 million round this morning from backers including founding investor Atlas Venture, Google’s venture arm [Ben Fidler, xconomy.com, Sep 15, 17]

Johnson & Johnson Innovation said it has formed alliances with six Massachusetts-based life science and research companies to further innovation in pharmaceuticals, medical devices and diagnostic and consumer healthcare. .... • Minerva Neurosciences (Cambridge, MA; no SBIR)– Partnering with Janssen Pharmaceutica N.V., Johnson & Johnson Innovation and the Janssen neuroscience therapeutic area, Minerva has begun a program that will focus on the treatment of patients with primary and secondary insomnia and potentially treating other related neuropsychiatric disorders. • Rodin Therapeutics (Cambridge, MA; no SBIR)- With initial investment from Johnson & Johnson Development Corporation, Rodin’s will work in collaboration with Johnson & Johnson Innovation in studying the inheritable changes in gene activity for the treatment of cognitive disorders, including Alzheimer’s disease. • Energesis Pharmaceuticals (Cambridge, MA; no SBIR) - Janssen Pharmaceuticals Inc. and Johnson & Johnson Innovation have established a collaboration with biotechnology company Energesis to identify biological compounds that stimulate the formation of brown fat for use in treating metabolic diseases. The company’s approach is a novel strategy, leveraging recent scientific insights in BAT biology to increase the body’s ability to burn stored fat and lower insulin resistance. • Navitor Pharmaceuticals (Cambridge, MA; no SBIR) - Johnson & Johnson Development Corporation has made an equity investment in Navitor, which will work in collaboration with Johnson & Johnson Innovation to develop highly-specific modulators to regulate a cell’s response to nutrient availability, including cell growth and function. • Ascelegen Therapeutics (Cambridge, MA; no SBIR)– With an equity investment from Johnson & Johnson Development Corporation, and in collaboration with Johnson & Johnson Innovation, Ascelegen is working on developing novel therapies for cardiovascular diseases, including heart failure. Ascelegen’s work builds on research conducted at the Harvard Stem Cell Institute and Brigham and Women's Hospital. • Padlock Therapeutics (Cambridge, MA; no SBIR) – With an investment from Johnson & Johnson Development Corporation, and in collaboration with Johnson & Johnson Innovation, Padlock is developing new therapies targeting a protein that mediates how protein conversions lead to rheumatoid arthritis and how it drives inflammation and immune complex formation in active autoimmune disease. [Boston Business Journal, Jun 19, 14]

Johnson & Johnson cuts the ribbon on its Boston Innovation Center, the latest step in a broad initiative by the drug giant to help drive biotech innovation in certain life sciences hotspots around the globe—and strike deals t to fatten up its pipeline. Within the past three months, J&J has opened similar innovation centers in London and Menlo Park, CA, and plans to christen a fourth in Shanghai ..... announcing partnerships with a research center (Icahn School of Medicine at Mount Sinai in New York), two local startup biotech companies (Rodin Therapeutics (Cambridge, MA; no SBIR) and Vedanta Biosciences (Boston, MA; no SBIR)), and a non-profit organization (LabCentral), showing the breadth of exactly what it hopes to achieve. [Ben Fidler, xconomy.com, Jun 27]

Roka Bioscience

Roka Bioscience up16% [Nov 29, 16] after financial report and 1:10 reverse split a month ago

RoosterBio (Frederick, MD)

Rooster Bio (Frederick, MD; $200K SBIR, founded 2012) raises $22M [Baltimore Busiess Journal, Aug 21, 19] prior funding $22M [crunchbase.com]

RoosterBio (Frederick, MD; $200K SBIR, founded 2012), disrupting the market by radically simplifying human mesenchymal stem/stromal cell (hMSC) biomanufacturing, announced it has raised in excess of $15 million in an initial Series B financing [to] to expand the biotech startup's team and bolster R&D for its cell and gene therapy solutions. [company press release, Aug 6, 19] prior funding $6M [crunchbase.com]

A four-organization biotech group led by nonprofit BioBridge Global (San Antonio, TX) has been awarded a $7.8 million contract from the (Army's) Medical Technology Enterprise Consortium (MTEC). The funds will enable the development of large-scale manufacturing capabilities for clinical-grade stem cells for research and therapeutic use. BBG led a group including the U.S. Army Institute of Surgical Research (USAISR) Coagulation and Blood Research, StemBioSys (San Antonio, TX; no SBIR), and RoosterBio (Frederick, MD; no SBIR) in submitting the proposal for funding. [BBG press release, Oct 3, 16]

RootPath (Cambridge,MA)

RootPath (Cambridge,MA; no SBIR) that develops personalized T cell therapy platform to bridge precision medicine and cancer immunotherapy, announced a $7 million seed funding round [Srividya Kalyanaraman, Boston Inno, September 5, 2018]

Rosina Food Products (Cheektowaga, NY)

Rosina Food Products (Cheektowaga, NY; no SBIR, founded 1963) has been approved for $1.5 million in state funds for renovations, equipment upgrades and to relocate its R&D function back to Western New York. [David Bertola, Buffalo Business First, Oct 17, 14] Interstate bribery contest?

Ross Valve (Troy, NY)

Never too old for a new thing. Ross Valve (Troy, NY; no SBIR, founded 1879), [manufactures cast-iron and cast-bronze waste and water valves] , will debut a new pressurizing and flow measurement technology in May that executives say give the company an edge in the global marketplace. .... By using industrial computer controls that are about half the size of an iPad [Krystle S. Morey, Albany Business Review, Mar 31, 14]

Rotation Medical (Plymouth, MN)

Smith & Nephew plc (England), the global medical technology business, announces that it has entered into a definitive agreement to acquire Rotation Medical (Plymouth,MN; no SBIR), a developer of a novel tissue regeneration technology for shoulder rotator cuff repair, for an initial cash consideration of $125 million and up to $85 million over the next five years, contingent on financial performance. [Smith&Nephew press release, Oct 23, 17]

Rotation Medical (Plymouth, MN; SBIR), a developer of treatments for rotator cuff disease, raised $8 million. [Patrick Kennedy, Minneapolis Star Tribune, Oct 14, 16]

Rotator-cuff fixer Rotation Medical (Plymouth, MN; no SBIR, founded 2009) raised $8 million in a new round of financing, according to [SEC] filing ... The company’s Rotation Medical Rotator Cuff Repair System treats rotator cuff disease with it’s a unique implant that helps the body grow new tendon-like tissue. The product secured approval from the U.S. Food and Drug Administration in 2014. In the new filing, Rotation Medical declined to disclose its revenue. The company has a solid track record of attracting investors. In July 2014, the company announced that it had raised $27.2 million in Series B financing to support the commercial launch [Burt Gilyard, Twin Cities Business, Aug 10, 16]

Rotation Medical (Plymouth, MN; no SBIR) has raised $27.2 million to fund the launch of its medical technology for repairing small rotator-cuff tears. .... has developed a collagen scaffold that is attached to shoulder tendons using a set of disposable instruments. .... received regulatory approval earlier this year. .... total amount of venture capital raised by Rotation to about $47 million. [Katharine Grayson, Minneapolis / St. Paul Business Journal, Jul 1, 14]

Med-tech startup Rotation Medical (Plymouth, MN; no SBIR) which has developed an implant for treating rotator cuff disease, has raised about $5.5 million through the sale of debt, according to a regulatory filing. ... spun out of venture-backed med-tech incubator Denali Medical (Blaine, MN; no SBIR). ... founded in 2009, raised $10 million in 2011 and received regulatory approval to market its technology in January.[Katherine Grayson, Minneapolis / St Paul Business Journal, Jun 5, 13]

RotoMetrics (Eureka, MO)

RotoMetrics (Eureka, MO; one SBIR in CA) global provider of precision rotary tooling and accessories, has been acquired by private equity firm Sentinel Capital Partners. Terms of the deal were not disclosed. .... had been owned by Morgenthaler Private Equity. ... While under the ownership of Morgenthaler, RotoMetrics invested in equipment, expanding its manufacturing presence in Europe and Asia, and realigning its global organizational structure. [Joe Dwyer, St. Louis Business Journal, Nov 26, 14]

RoverMed BioSciences (St. Cloud, MN)

bioscience startup RoverMed BioSciences (St. Cloud, MN; no SBIR) [raised] more than $1 million in new investment. Gopher Angels, a Minnesota-based angel investor network, led the round. ... the leading nanocapsule technology capable of cell specific delivery of biologic drugs directly to the nucleus of disease cells to deliver precision-targeted treatments for challenging diseases. [company press release, Aug 24, 17]

Rowbot Systems (Minneapolis, MN)

Rowbot Systems (Minneapolis, MN; no SBIR) start-up, showed off a prototype robot in several fields last fall that could motor between corn rows to add nitrogen fertilizer in midsummer when corn plants need it the most and heavy machinery isn’t an option. .... Precision agriculture has gone from largely experimental to mainstream since the mid-1990s, and more technology is on the horizon: narrow robots that chug down corn rows to zap weeds or squirt fertilizer and drones that hover above cropland taking pictures of insect infestations. [Tom Meersman, Minneapolis Star Tribune, May 15, 14]

Royole (Fremont,CA)

In 2014, Royole (Fremont, CA; no SBIR, founded 2015, funding $200M, 500 employees) unveiled a full-color, flexible, touch-enabled computer display only 0.01 millimeters thick, the result of years of work on Liu’s part. ... In early May 2016, in fact, Royole announced a partnership with China Mobile, the largest telecommunications company in China. The deal will include virtual reality and cinematic wearable devices, and smart home appliances. [Richard Procter, San Francisco Business Times, May 27, 16]

startup Royole (Fremont, CA; no SBIR, founded 2012, 100 employees (80 in China)) says it has created what appears to be the world's thinnest, full-color, flexible, touch-enabled computer display. The bendable and rollable film has a thickness of 0.01 millimeters, or less than one fifth the diameter of the human hair, Royole says. .... CEO Zihong "Bill" Liu said that his company has successfully integrated its novel displays with a smartphone. The technology is ready for production and could be in gadgets as early as next year, he added. ... The market research company IDTechEx, has predicted that the market for plastic and flexible AMOLED displays will rise to $16 billion by 2020, with flexible displays then accounting for about half, up from virtually nothing today. [Patrick Hoge, San Francisco Business Times, Dec 17, 14] backed by several VC funds, says oled-info.com.

RQx Pharmaceuticals (San Diego, CA)

RQx Pharmaceuticals (San Diego, CA; no SBIR) said it signed a drug discovery partnership with Genentech, the Roche subsidiary, that could result eventually in $111 million in milestone payments. RQx was founded two years ago with about $3.5 million in venture funding by a sole investor, San Diego-based Avalon Ventures, to advance a promising discovery involving the antibiotic arylomycin. [Bruce Bigelow, xconomy.com, Feb 15, 13]

RRE Solar (TX)

Rubicon Tech (Bensonville, IL)

Rubicon Technologies (Franklin Park, IL; $5.2M SBIR) down 39% [Aug 16, 2022]

Rubicon Technology (Bensenville IL; $5.2M SBIR) up 65% [Jul 5, 22] announcing that it has entered into a definitive Stock Purchase and Sale Agreement with Janel Corporation, pursuant to which Janel will commence a cash tender offer to purchase up to 45% of the outstanding shares of Rubicon’s common stock on a fully-diluted basis at a price of $20 per share. [pulse2.com]

Rubicon Tech up 10% [Nov 7, 14]

Rubicon Tech (Bensenville, IL; one SBIR) down 10% [Oct 9, 14]

Rubicon Tech down 16% [May 2, 14]

Rubicon Tech up 15% [Apr 1, 14]

Rubicon Tech (Bensenville IL, one SBIR) up 14% [Feb 20, 14]

Rubicon Tech up 10% [Nov 5, 13]

Rubicon Technology (Bensenville, IL; one SBIR) up 15% [Sep 18, 13] founded 2000, IPO 2007.

Rubicon Tech (Franklin Park, IL; one SBIR) up 12% [Jul 30, 13]

Rubicon Technology (Franklin Park, IL; one SBIR) up 14% [Apr 8, 13]

Rubicon Technology (Bensenville, IL; one SBIR) down 12% [Feb 7, 13]

Rubicon Tech (Bensonville, IL; one SBIR) down 13%% [Aug 3, 12]

Rubigo Therapeutics (St Paul,MN)

Investors thought the technology was promising, but wouldn’t give them any money. “There are almost no venture capital investors left that will look at drug delivery [technologies],” [Rubigo Therapeutics(St Paul, MN; no SBIR) CEO] Nickels said .... began diving into research about fishes’ olfactory senses. They modified their [skin] patch so it could be applied to a fishing lure and began testing it .... So far, the feedback has been positive, and the company is ramping up manufacturing [Katharine Grayson, Minneaapolis / St Paul Business Journal, Dec 21, 12] ll

Rubitection (Pittsburgh, PA)

Rubitection (Pittsburgh, PA; no SBIR) on the [crowdfunding] website Indiegogo, is looking to raise $250,000 [to] continue to develop a medical device that can detect early signs of pressure ulcers. [Malia Spencer, Pittsburgh Business Times, Jan 28, 13]

Rubius Therapeutics (Cambridge, MA)

Rubius Therapeutics down 20% [Mar 26, 21]

Rubius Therapeutics (Cambridge, MA; no SBIR) up 84% [Mar 15, 21], a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics(TM), announced initial clinical, pharmacodynamic and tumor trafficking data from its ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors. [COMPANY PRESS RELEASE, Mar 15, 21]

Rubius Thera up 19% [Nov 13, 18]

Rubius Therapeutics (Cambridge, MA; no SBIR, founded 2013), a preclinical biotech developing novel therapies based on red blood cells, raised $241 million by [IPO]. [nasdaq.com, Jul 19, 18] creating RCTs™ as a new class of medicines. Leading applications include programs in cancer, enzyme deficiency diseases and the induction of tolerance to treat autoimmune disease. total funding $245M [crunchbase.com]

Rubius Therapeutics (Cambridge, MA; no SBIR, founded 2014), a biotechnology company pioneering the creation of a new class of extraordinarily active, ready-to-use and life-changing cellular therapies, announced the successful completion of $100 million crossover financing. In just under nine months, the Company has now raised over $220 million..... has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics™ (RCT™) products, which have the potential to provide transformational clinical benefits to a wide range of patients across multiple therapeutic areas. [company press release, Mar 1, 18]

venture dollars are dousing life-science startups this week. The latest biotech is Rubius Therapeutics (Cambrdge, MA; no SBIR, founded 2015), that announced a $100 million “crossover” round including investors that back both private and publicly traded companies, Rubius has now raised $220 million from founding backer Flagship Pioneering and others in nine months. ... Rubius engineers human red blood cells into tiny vehicles that carry disease-fighting proteins into a patient. [Ben Fidler, xconomy.com, Mar 1, 18]

Flagship Ventures put $25 million into its latest startup, Rubius Therapeutics (Cambridge, MA; no SBIR) that aims to transform blood cells into tiny drug delivery pods. [Ben Fidler, xconomy.com, Dec 11, 15]

RubrYc Therapeutics (San Ramon, CA)

RubrYc Therapeutics (San Ramon, CA; no SBIR, founded 2017) announced the closing of $10 millionas the startup presses ahead in its efforts to discover new antibody drugs. ... says it has completed its spinoff from HealthTell, a company that has developed tests for analyzing the immune system’s response to disease. ... says it has exclusive rights to libraries of chemicals developed by HealthTell. .... says it will use the funding to build its platform for discovering antibody drugs and seek drug discovery partnerships with biotech companies. ... also plans to develop its own molecules. [Frank Vinluan, xconomy.com, Apr 12, 18]

Rules-Based Medicine (Austin TX)

BioPhysical (Austin, TX; $1.1M SBIR, founded 1982, 53 employees) raised $4.1 million of a $5 million round of funding that it will use to pay for an office expansion in Houston and Austin in 2015. ... has yet to turn a profit [Chad Swiatecki, Austin Business Journal, Nov 14, 14] manages and markets biomarker-based health assessments direct to consumers and corporations ... provides the most comprehensive blood-based assessments of an individual's health. ... history: 1982 Inland Labs (no SBIR) is founded; 1995 Luminex ($1.1M SBIR) is formed from Inland Labs; 2002 Rules Based Medicine (no SBIR) is formed from Inland Labs; 2005 Biophysical forms from Rules Based Medicine. [company website]

Rules-Based Medicine (Austin, TX; $2M SBIR) filed to raise $90 million in a public stock offering in 2010 ... founded in 2002, has developed technology for tests that identify biomarkers that can signal whether a patient has a particular disease or disorder and how well drugs are working. [Austin American Statesman, Dec 24, 09]

Rules-Based Medicine (Austin TX; one SBIR) got a $1.1M Phase I/Phase II "Fast-Track" SBIR from the National Cancer Institute for the development of 50 new quantitative, multiplexed immunoassays for cancer-related proteins . It calls itself the world’s leading multiplexed biomarker testing company [company press release]

Rushford Hypersonic

NanoReturn. Will any of this stuff translate into an economic windfall for Minnesota? So far, the U has licensed nanotechnology to three companies, two of them local, with mixed results. Nanocopoeia (St. Paul , MN; $1M SBIR) is trying to divest its original medical device coating business to focus on pharmaceuticals. Rushford Hypersonic (no SBIR) next month will open the world's first hypersonic plasma particle disposition plant in southeastern Minnesota. Innovalight, (Austin, TX to St. Paul, MN to Sunnyvale, CA; $900K SBIR in TX), which originally focused on light bulbs, is now making solar cells. ... The U's uneven experience with nanoscience mirrors corporate America's teasing and often frustrating flirtation with a technology that's failed, so far, to match hype with reality. Despite millions of dollars in government research money and venture capital, making big bucks off nanotechnology remains an elusive dream. [Thomas Lee, Minneapolis Star Tribune, Jun 28, 09] Nanostuff, GaAs, CVD diamond, SiC substrates, and such, are the kind of futures that SBIR should invest in until economic barriers show that it has only a long term possible future. Then it should be turned over to long term investors with long green, not slogged away in a small high tech nursery program. SBIR's goal should be economic visibility for a technology, not long term development a few bucks at a time in life-style companies.

Ruud Lighting

Researchers in Wisconsin over the next two years will strive to bring down the cost to produce energy-saving LED lights, under a pair of federal projects awarded funding Tuesday. Eaton Corp. has been awarded $2.4 million to develop a new manufacturing process to streamline the design of LED light fixtures. The Department of Energy awarded the funds, which will be matched dollar-for-dollar by Eaton and the other four recipients of $10.1 million in funding. The two-year research projects aim to bring down the cost of manufacturing light-emitting diodes, or LEDs. Cree, that bought Ruud Lighting and BetaLED of Sturtevant in 2011, was awarded $2.3 million. [Thomas Content, Milwaukee Journal Sentinel, Jun 4, 13]

RxFunction (Minneapolis, MN)

RxFunction startup (embedded with the Sister Kenny Research Center, Minneapolis, MN) that has developed a high-tech shoe insert called the Walkasin has landed a $1 million [SBIR] grant that it will use to conduct clinical trials. [The device] can detect whether a person is about to lose his or her balance and fall. [Katharine Grayson, Minneapolis / St Paul Business Journal, May 30, 13]

RXi Pharmaceuticals (Worcester, MA)

RXi Pharma up 42% [Mar 14, 18]

RXi Pharma down 15% [Mar 13, 18]

RXi Pharma (Worcester, MA; $600K SBIR, market cap $8M) up 27% [Mar 9, 18]

RXi Pharmaceuticals will split into two publicly traded companies. The first, called Galena Biopharma, will focus on developing targeted cancer therapies and will be headquartered in Portland, Ore. RXi will be spun off later this year and will continue to work on RNAi-based therapeutics --> [Arlene Weintraub, Boston Globe, Sep 26, 11]

RXi Pharmaceuticals (Worcester, MA; $600K SBIR) made a public stock and warrants offering that could bring about $12 million ... announced at the end of March that it planned to spend about $7.2 million in a stock deal to acquire Apthera Inc., an Arizona biotechnology company developing cancer therapeutics. At the beginning of March, RXI raised $8.1 million through a public stock offering [Michelle Lang, Mass High Tech, Apr 15, 11]

RXi Pharmaceuticals (Worcester, MA; no SBIR) is raising $8.1 million through a public stock offering ... In September 2010, RXi teamed up with EyeGate Pharmaceuticals (Waltham, MA; no SBIR) to collaborate on an effort to deliver RNAi therapeutics to the eye to treat retinal disorders. [Mass High Tech, Mar 1, 11]

RXi Pharmaceuticals (Worcester, MA; no SBIR) won an Advanced Technology $600K [NIH]grant [for] pre-clinical development of RNAi therapeutics. ... founded in 2006 by University of Massachusetts researcher [Nobel laureate] Craig Mello [Michelle Lang, Mass High Tech, Jul 13, 10]

Rxmedic (Raleigh, NC)

RxMedic (Raleigh, NC; no SBIR) a 3-year-old maker of robotic helpers for pharmacies is under a new owner that could boost sales for the local company’s automated pill sorting system. RxMedic was acquired last month by the JMSmith< Corp., a health care company in Spartanburg, S.C., that specializes in pharmacy support services. [John Murawski, Raleigh News & Observer, Jun 11, 10]

Rypos (Holliston, MA)

Rypos (Holliston, MA; no SBIR) makers of filter technology for reducing diesel vehicle emissions, has taken in $3.15 million of a planned $3.5 million Series B funding round, according to federal documents. ... founded in 1997 and spent almost eight years developing its technology, not recording any revenue from sales until 2007. The company’s filters range in price from $4,000 for a truck filter to more than $100,000 for a filter attached to a large generator. Rypos primarily targets transport refrigeration units and diesel generators, and the bulk of the company’s sales come from California, officials have said. [Rodney Brown, Mass High Tech, Mar 22, 11]